Clinical trial NCT01332331
Conditions: Hypertension, Pulmonary
Keywords: pulmonary arterial hypertension pediatric
Sponsor: GlaxoSmithKline
Start date: 2011-01-04; Completion date: 2013-11-12
Enrollment: 41 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
A 6-month (24-week), randomized, open label evaluation of the safety, tolerability, and efficacy of a high and low dose ambrisentan (adjusted for body weight) treatment group in subjects aged 8 years up to 18 years with pulmonary arterial hypertension (PAH). An additional objective is to determine the ambrisentan population pharmacokinetics in the paediatric population. The study will include a screening/baseline period and a treatment period. The treatment period will be 24 weeks or until the subject's clinical condition deteriorates to the point that alternative/additional treatment is necessary. Patients who participate in the study and in whom continued treatment with ambrisentan is desired will be eligible to enrol into a long term follow-up study. The primary comparison will be the safety and tolerability of the two ambrisentan dose groups (Low vs. High) in the paediatric PAH population The secondary comparison will be the change from baseline for the efficacy parameters between the two treatment groups.

Detailed description:
Pulmonary arterial hypertension (PAH) is a rare, progressive, highly debilitating disease characterized by vascular obstruction and the variable presence of vasoconstriction, leading to increased pulmonary vascular resistance and right-sided heart failure. If left untreated, PAH ultimately leads to right ventricular failure and death; adult subjects have a median survival of 2.8 years without treatment. Epidemiological estimates vary but prevalence in Europe is thought to be of the order of 15 cases per million. Large scale epidemiology studies of PAH in children have not been conducted and there is no or limited outcome data in pediatric PAH patients. A register in France (1995-1996) estimates the prevalence in children is as low as 3.7 cases per million. In a national, comprehensive country wide survey of the epidemiology of idiopathic PAH (IPAH) management and survival in the United Kingdom (UK) the incidence was 0.48 cases per million children per year and the prevalence was 2.1 cases per million children.

Ambrisentan (VOLIBRIS™ tablets) is an endothelin receptor antagonist (ERA) marketed in the European Union (EU) and some other countries by GlaxoSmithKline (GSK) and in the United States as LETAIRIS® by Gilead Sciences Inc. Ambrisentan is indicated for the treatment of adult patients with PAH to improve exercise capacity, decrease the symptoms of PAH, and delay clinical worsening.

The primary purpose of this paediatric study is to provide clinically relevant information on the safety and pharmacokinetic profile of ambrisentan in children with the most common causes of PAH in this age group. The design of the study is also intended to provide information to guide dose selection and supportive efficacy data in this age group. Despite the fact that none of the currently available adult treatments are licensed for use in children \<12 yrs, (with the exception of bosentan which was recently approved for use in paediatric population from 2 years of age) they are widely used off label. This study will provide useful prescribing information to the medical community for treating this orphan disease in children in this environment of rapidly changing medical practice.

This study is part of a Paediatric Investigational Plan (PIP; EMEA-000434-PIP01-08) agreed with the European Medicines Agency's Paediatric Committee (PDCO).

Arms: arm 1: body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg arm 2: body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
Interventions: intervention 1: Ambrisentan - low dose intervention 2: Ambrisentan - high dose
Intervention descriptions: intervention 1: body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg intervention 2: body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg

Protocol documents:
Prot_001.pdf: 
RM2010/00053/03 
CONFIDENTIAL 
 
The GlaxoSmithKline group of companies 
 
AMB112529 
 
1 
 
Division: Worldwide Development 
Retention Category: GRS019 
Information Type: Protocol Amendment 
 
Title: 
A randomized, open label study comparing safety and efficacy 
parameters for a high and a low dose of ambrisentan (adjusted 
for body weight) for the treatment of pulmonary arterial 
hypertension in paediatric patients aged 8 years up to 18 years. 
Compound Number: GSK1325760 
Effective Date: 
02-FEB-2011 
Protocol Amendment Number:  03 
Description: 
A 6-month (24-week), randomized, open label evaluation of the safety, tolerability, and 
efficacy of a high and low dose ambrisentan (adjusted for body weight) treatment group 
in subjects aged 8 years up to 18 years with pulmonary arterial hypertension (PAH).  An 
additional objective is to determine the ambrisentan population pharmacokinetics in the 
paediatric population.  The study will include a screening/baseline period and a treatment 
period.  The treatment period will be 24 weeks or until the subject’s clinical condition 
deteriorates to the point that alternative/additional treatment is necessary.  Patients who 
participate in the study and in whom continued treatment with ambrisentan is desired will 
be eligible to enrol into a long term follow-up study.  The primary comparison will be the 
safety and tolerability of the two ambrisentan dose groups (Low vs. High) in the 
paediatric PAH population  The secondary comparison will be the change from baseline 
for the efficacy parameters between the two treatment groups. 
 
Subject: Pulmonary Arterial Hypertension 
Author: 
 
 
 
 
 
 
 
Copyright 2011 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised copying or use of this information is prohibited 
PPD


RM2010/00053/03 
CONFIDENTIAL 
 
The GlaxoSmithKline group of companies 
 
AMB112529 
 
2 
 
Revision Chronology: 
 
 
RM2010/00053/00 
2010-MAY-07 
Original 
RM2010/00053/01 
2010-JUN-09 
Amendment No.: 01 
Clarify the inclusion criteria that 
existing drug treatment for PAH would 
continue unchanged throughout the 
study. 
Clarify that two forms of contraception 
is required only for female subjects of 
child bearing potential who are 
sexually active 
Expand the eligibility for the 
continuation study to all patients who 
participate in this study and in whom 
continued treatment with ambrisentan 
is desired. 
Specify that patients will be given a 
diary card to collect information about 
dosing and days missed from school. 
Remove references to “brain natriuretic 
peptide” and clarify that it is N-
Terminal pro-B-type Natriuretic 
Peptide that is being assessed. 
Add more specific references for the 
Tanner development criteria. 
Change the wording of the questions 
regarding days missed from school to 
make it clear that the total number of 
days  missed includes the days missed 
because of PAH and that the days 
missed because of PAH are due to 
symptoms of PAH and do not include 
clinic visits. 
Remove the requirement for an 
unblinded person to enter compliance 
data into InForm. 
Allow the investigator to be unblinded 
to treatment for an individual patient 
once that patient has completed the 
study. 


RM2010/00053/03 
CONFIDENTIAL 
 
The GlaxoSmithKline group of companies 
 
AMB112529 
 
3 
 
RM2010/00053/02 
2010-OCT-26 
Amendment No.: 02 
To clarify that it is hepatitis B surface 
antigen, and not hepatitis B surface 
antibody, that is being assessed as part 
of the exclusion criteria. 
Add the US IND number to the 
Sponsor Information Page and clarify 
that the medical monitor and Serious 
Adverse Events contact are the same 
person. 
RM2010/00053/03 
2011-FEB-02 
Amendment No.: 03 
Add oestrogen to the laboratory tests 
being performed on female subjects at 
all times that pubertal development 
assessments are performed. 
Remove testosterone from the 
laboratory tests being performed on 
female subjects at all times that the 
pubertal development assessments are 
performed. 
Change the storage requirements for 
the study medication to store below 
30°C. 
 


P P D


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
5 
 
SPONSOR INFORMATION PAGE 
Clinical Study Identifier:   AMB112529 
 
GlaxoSmithKline 
Iron Bridge Road  
Stockley Park West, Uxbridge, Middlesex, UB11 1BU, UK 
Telephone:  
  
In some countries, the clinical trial sponsor may be the local GlaxoSmithKline affiliate 
company (or designee).  Where applicable, the details of the Sponsor and contact person 
will be provided to the relevant regulatory authority as part of the clinical trial 
submission. 
Sponsor Medical Monitor and Serious Adverse Events (SAE) Contact Information: 
 
 FRCS 
Clinical Development Physician 
MDC Clinical Metabolic EU 
GlaxoSminthKline  
Stockley Park 
Sponsor Serious Adverse Events (SAE) Contact Information:  
Regulatory Agency Identifying Number(s):  EudraCT 2010-019547-19 
 
 
 
 
 
 
US IND 64,915 
 
PPD
PPD


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
6 
 
INVESTIGATOR AGREEMENT PAGE 
For protocol AMB112529 
I confirm agreement to conduct the study in compliance with the protocol, as amended by 
this protocol amendment. 
I acknowledge that I am responsible for overall study conduct. I agree to personally 
conduct or supervise the described clinical study. 
I agree to ensure that all associates, colleagues and employees assisting in the conduct of 
the study are informed about their obligations. Mechanisms are in place to ensure that site 
staff receives the appropriate information throughout the study.  
Investigator Name:  _____________________________ 
 
 
 
 
Investigator Signature 
 
Date 
 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
7 
 
TABLE OF CONTENTS 
PAGE 
LIST OF ABBREVIATIONS ............................................................................................. 10 
PROTOCOL SUMMARY ................................................................................................. 12 
1. 
INTRODUCTION ..................................................................................................... 15 
1.1. 
Background .................................................................................................. 15 
1.2. 
Rationale ...................................................................................................... 16 
2. 
OBJECTIVE(S) ........................................................................................................ 17 
2.1. 
Primary ......................................................................................................... 17 
2.1.1. 
Safety ............................................................................................ 17 
2.1.2. 
Secondary ..................................................................................... 17 
2.1.2.1. 
Pharmcokinetics: ......................................................... 17 
2.1.2.2. 
Efficacy ........................................................................ 18 
2.1.2.3. 
Exploratory .................................................................. 18 
2.1.2.4. 
Other ........................................................................... 18 
3. 
INVESTIGATIONAL PLAN ...................................................................................... 18 
3.1. 
Study Design ................................................................................................ 18 
3.2. 
Discussion of Design .................................................................................... 19 
4. 
SUBJECT SELECTION AND WITHDRAWAL CRITERIA ....................................... 20 
4.1. 
Number of Subjects ...................................................................................... 20 
4.2. 
Inclusion Criteria .......................................................................................... 20 
4.3. 
Exclusion Criteria ......................................................................................... 21 
4.4. 
Withdrawal Criteria ....................................................................................... 22 
5. 
STUDY TREATMENTS ........................................................................................... 23 
5.1. 
Investigational Product and Reference Therapy .......................................... 23 
5.2. 
Treatment Assignment ................................................................................. 24 
5.3. 
Blinding ........................................................................................................ 24 
5.4. 
Product Accountability .................................................................................. 25 
5.5. 
Treatment Compliance ................................................................................. 25 
5.6. 
Concomitant Medications and Non-Drug Therapies .................................... 25 
5.6.1. 
Permitted Medications and Non-Drug Therapies .......................... 25 
5.6.2. 
Prohibited Medications and Non-Drug Therapies ......................... 25 
5.7. 
Treatment after the End of the Study ........................................................... 26 
5.8. 
Treatment of Investigational Product Overdose ........................................... 26 
6. 
STUDY ASSESSMENTS AND PROCEDURES ...................................................... 26 
6.1. 
Critical Baseline Assessments ..................................................................... 29 
6.2. 
Safety ........................................................................................................... 29 
6.2.1. 
Physical examination .................................................................... 29 
6.2.2. 
Electrocardiogram / Echocardiogram ............................................ 29 
6.2.3. 
Vital Signs, Body Weight and Height ............................................ 29 
6.2.4. 
Pubertal Development Assessment .............................................. 30 
6.2.5. 
Clinical Laboratory Tests .............................................................. 30 
6.2.5.1. 
Safety Tests ................................................................ 30 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
8 
 
6.2.5.2. 
Pharmacogenetics and NT-Pro BNP ........................... 30 
6.2.6. 
Liver chemistry stopping and followup criteria .............................. 31 
6.2.7. 
Adverse Events ............................................................................. 33 
6.2.7.1. 
Definition of an AE ....................................................... 33 
6.2.7.2. 
Definition of a SAE ...................................................... 34 
6.2.8. 
Laboratory and Other Safety Assessment Abnormalities 
Reported as AEs and SAEs .......................................................... 36 
6.2.9. 
Pregnancy ..................................................................................... 36 
6.2.10. 
Time Period and Frequency of Detecting AEs and SAEs ............. 36 
6.2.11. 
Prompt Reporting of Serious Adverse Events and Other 
Events to GSK .............................................................................. 37 
6.2.11.1.  Regulatory reporting requirements for SAEs ............... 38 
6.3. 
Pharmacokinetics ......................................................................................... 38 
6.4. 
Efficacy ......................................................................................................... 39 
6.4.1. 
Change from baseline in the 6 minute walking distance 
(6MWD) test. ................................................................................. 39 
6.4.2. 
Time to worsening of PAH ............................................................ 39 
6.4.3. 
Change from baseline (Week 0) in Subject Global 
Assessment to Week 24. .............................................................. 39 
6.4.4. 
Change from baseline in WHO functional class to Week 
24. ................................................................................................. 39 
6.4.5. 
Change from baseline plasma N-terminal pro-B type 
natriuretic peptide (NT-Pro BNP) at Week 24 ............................... 40 
6.4.6. 
Change from baseline in major prognostic factors to Week 
24. ................................................................................................. 40 
6.4.7. 
Change from baseline in cardiopulmonary hemodynamics 
at Week 24 .................................................................................... 40 
6.5. 
Health Outcomes.......................................................................................... 40 
6.6. 
Pharmacogenetics........................................................................................ 41 
7. 
DATA MANAGEMENT ............................................................................................. 41 
8. 
DATA ANALYSIS AND STATISTICAL CONSIDERATIONS ................................... 41 
8.1. 
Study Objectives .......................................................................................... 41 
8.2. 
Study Design Considerations ....................................................................... 42 
8.2.1. 
Sample Size Assumptions ............................................................ 42 
8.2.2. 
Sample Size Sensitivity ................................................................. 42 
8.2.3. 
Sample Size Re-estimation ........................................................... 42 
8.3. 
Data Analysis Considerations ...................................................................... 42 
8.3.1. 
Analysis Populations ..................................................................... 42 
8.3.2. 
Analysis Data Sets ........................................................................ 42 
8.3.3. 
Treatment Comparisons ............................................................... 43 
8.3.3.1. 
Primary Comparisons of Interest ................................. 43 
8.3.3.2. 
Secondary Comparisons of Interest ............................ 43 
8.3.3.3. 
Exploratory Comparisons of Interest ........................... 44 
8.3.3.4. 
Other Comparisons of Interest .................................... 44 
8.3.4. 
Interim Analysis ............................................................................. 44 
8.3.5. 
Key Elements of Analysis Plan ..................................................... 44 
8.3.5.1. 
Safety Analyses ........................................................... 44 
8.3.5.2. 
Pharmacokinetic Analyses .......................................... 44 
8.3.5.3. 
Pharmacokinetic/Pharmacodynamic Analyses ........... 45 
8.3.5.4. 
Efficacy Analyses ........................................................ 45 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
9 
 
8.3.5.5. 
Health Outcomes Analyses ......................................... 46 
8.3.5.6. 
Pharmacogenetic Analyses ......................................... 47 
8.3.5.7. 
Novel Biomarker(s) Analyses ...................................... 47 
8.3.5.7.1. 
RNA Transcriptome Analysis .................. 47 
8.3.5.7.2. 
RNA Expression Analysis of a 
Subset of RNA Species ........................... 47 
9. 
STUDY CONDUCT CONSIDERATIONS ................................................................. 47 
9.1. 
Posting of Information on Clinicaltrials.gov .................................................. 47 
9.2. 
Regulatory and Ethical Considerations, Including the Informed 
Consent Process .......................................................................................... 47 
9.3. 
Quality Control (Study Monitoring) ............................................................... 48 
9.4. 
Quality Assurance ........................................................................................ 48 
9.5. 
Study and Site Closure................................................................................. 49 
9.6. 
Records Retention........................................................................................ 49 
9.7. 
Provision of Study Results to Investigators, Posting to the Clinical 
Trials Register and Publication ..................................................................... 50 
9.8. 
Independent Data Monitoring Committee (IDMC) ........................................ 50 
10.  REFERENCES ........................................................................................................ 51 
11.  APPENDICES .......................................................................................................... 53 
11.1. 
Appendix 1: Cardiopulmonary Hemodynamic Sub-study ............................. 53 
11.2. 
Appendix 2: List of Highly Effective Methods for Avoidance of 
Pregnancy in Women of Childbearing Potential ........................................... 54 
11.3. 
Appendix 3: Pharmacogenetic Research ..................................................... 55 
11.4. 
Appendix 4: Country Specific Requirements ................................................ 60 
11.5. 
Appendix 5: Protocol Amendment 01 ........................................................... 61 
11.6. 
Appendix 6: Protocol Amendment 02 ........................................................... 70 
11.7. 
Appendix 7: Protocol Amendment 03 ........................................................... 72 
 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
10 
 
LIST OF ABBREVIATIONS 
6MWD 
6 minute walking distance test 
ACE 
Angiotensin-converting enzymes 
AE 
Adverse Event 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
BMI 
Body mass index 
BSA 
Body surface area 
BUN 
Blood urea nitrogen 
CCBs 
Calcium Channel Blockers 
cGMP 
Cyclic guanosine monophosphate  
CHD 
Congenital heart defects 
COPD 
Congestive obstructive pulmonary disease 
CPK 
Creatine phosphokinase 
CTD 
Connective tissue disease 
ECG 
Electrocardiogram 
eCRF 
Electronic Case Report Form 
ERA 
Endothelin receptor antagonist  
ET 
endothelin 
EU 
European Union 
FDA 
Food and Drug Administration 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practice 
GGT 
gamma glutamyl transferase 
GGT 
gamma glutamyl transferase 
GSK 
GlaxoSmithKline 
IDMC 
Independent Data Monitoring Committee 
IEC 
Independent Ethics Committee 
INR 
International Normalized Ratio 
IPAH 
Idiopathic Pulmonary Arterial Hypertension 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 
IVRS 
Central interactive voice recognition system 
IVRS 
Interactive Voice Response System 
kg 
kilogram 
LDH 
Lactate dehydrogenase 
LEVDP 
Left ventricular end diastolic pressure 
LFT 
Liver function test 
LH 
Luteinizing hormone  
m 
meter 
MCH 
mean corpuscular haemoglobin 
MCHC 
mean corpuscular haemoglobin concentration 
MCV 
mean corpuscular volume 
MedDRA 
Medical Dictionary for Regulatory Activities 
mg  
milligram 
mPAP 
mean pulmonary arterial pressure 
MSDS 
Material Safety Data Sheet 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
11 
 
NT-Pro BNP 
N-Terminal pro-B-type Natriuretic Peptide 
PAH 
Pulmonary Arterial Hypertension  
PAH-CTD 
pulmonary arterial hypertension associated with connective 
tissue disease 
PCWP 
Pulmonary capillary wedge pressure 
PDCO 
EMA Paediatric Committee 
PDE-5 
Phosphodiesterase type 5 
PGx 
Pharmacogenetic 
PIP 
Paediatric Investigational Plan 
Pk 
pharmacokinetic 
PVR 
Pulmonary vascular resistance 
RA 
Right atrial 
RHC 
Right heart catheterisation 
RV 
Right ventricle  
RVF 
Right ventricular failure 
SAE 
Serious Adverse Event 
SEM 
Standard error of the mean 
SHBG 
Sex hormone binding globulin 
SPC 
Summary of Product Characteristics 
SPM 
Study Procedures Manual 
TAPSE 
Tricuspid annular plane systolic excursion 
TRAX 
Tracleer excellence database 
TRJ 
Tricuspid regurgitant jet 
ULN 
Upper limit of normal 
V/Q 
Ventilation/perfusion 
WHO 
World Health Organization 
 
Trademark Information 
Trademarks of the GlaxoSmithKline 
group of companies 
 
Trademarks not owned by the 
GlaxoSmithKline group of companies 
FLOLAN 
 
Adcirca 
VOLIBRIS 
 
C RIBA 
 
 
Letairis 
 
 
NONMEM 
 
 
Remodulin 
 
 
Revatio 
 
 
Thelin 
 
 
Tracleer 
 
 
Ventavis 
 
 
Viagra 
 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
12 
 
PROTOCOL SUMMARY 
Rationale 
Pulmonary arterial hypertension (PAH) is a rare, progressive, highly debilitating disease  
characterized by vascular obstruction and the variable presence of vasoconstriction, 
leading to increased pulmonary vascular resistance and right-sided heart failure 
[Moledina, 2010; Newman, 2004].  If left untreated, PAH ultimately leads to right 
ventricular failure and death; adult subjects have a median survival of 2.8 years without 
treatment [Krum, 2000].  Epidemiological estimates vary but prevalence in Europe is 
thought to be of the order of 15 cases per million [Humbert, 2006].  Large scale 
epidemiology studies of PAH in children have not been conducted and there is no or 
limited outcome data in pediatric PAH patients.  A register in France (1995-1996) 
estimates the prevalence in children is as low as 3.7 cases per million [Fraisse, 2010].  In 
a national, comprehensive country wide survey of the epidemiology of idiopathic PAH 
(IPAH) management and survival in the United Kingdom (UK) the incidence was 0.48 
cases per million children per year and the prevalence was 2.1 cases per million children 
[Moledina, 2010]. 
Ambrisentan (VOLIBRIS™ tablets) is an endothelin receptor antagonist (ERA) marketed 
in the European Union (EU) and some other countries by GlaxoSmithKline (GSK) and in 
the United States as Letairis by Gilead Sciences Inc.  Ambrisentan is indicated for the 
treatment of adult patients with PAH to improve exercise capacity, decrease the 
symptoms of PAH, and delay clinical worsening. 
The primary purpose of this paediatric study is to provide clinically relevant information 
on the safety and pharmacokinetic profile of ambrisentan in children with the most 
common causes of PAH in this age group.  The design of the study is also intended to 
provide information to guide dose selection and supportive efficacy data in this age 
group.  Despite the fact that none of the currently available adult treatments are licensed 
for use in children <12 yrs, (with the exception of bosentan which was recently approved 
for use in paediatric population from 2 years of age) they are widely used off label.  This 
study will provide useful prescribing information to the medical community for treating 
this orphan disease in children in this environment of rapidly changing medical practice.  
This study is part of a Paediatric Investigational Plan (PIP; EMEA-000434-PIP01-08) 
agreed with the European Medicines Agency’s Paediatric Committee (PDCO). 
Objective(s) 
The primary objective of this study is to evaluate the safety and tolerability of 
ambrisentan in the paediatric (aged 8 years up to 18 years) PAH population.  Other 
objectives are to obtain supportive efficacy data (change from baseline in efficacy 
parameters) on the paediatric use of ambrisentan in PAH and to determine the 
ambrisentan population pharmacokinetics in the paediatric population.  Because patient 
recruitment is limited by the low prevalence of the disease in children, powered clinical 
hypotheses testing cannot be performed. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
13 
 
Study Design 
A 6-month (24-week), randomized, open label evaluation of the safety, tolerability, and 
efficacy of a high and low dose ambrisentan (adjusted for body weight) treatment group 
in 66 subjects (33 per treatment group) aged 8 years up to 18 years with PAH.  The study 
will include a screening/baseline period and a treatment period.  The treatment period 
will be 24 weeks or until the subject’s clinical condition deteriorates to the point that 
alternative/additional treatment is necessary.  Patients who participate in this study and in 
whom continued treatment with ambrisentan is desired will be eligible to enrol into a 
long term follow-up study.  The primary comparison will be the safety and tolerability of 
the two ambrisentan dose groups (Low vs. High) in the paediatric PAH population  The 
secondary comparison will be the change from baseline of the efficacy parameters 
between the two treatment groups.  Because patient recruitment is limited by the low 
prevalence of the disease in children, powered clinical hypotheses testing cannot be 
performed.  Sixty-six (66) subjects were chosen on the predicted recruitment rate based 
on historic data so that the study can be completed in a reasonable time frame (2 years) 
for it to be useful and informative to the medical community.  A 10% drop out rate will 
leave 60 evaluable subjects. 
Study Endpoints/Assessments 
Primary 
The safety and tolerability of ambrisentan in the paediatric PAH population (see Safety): 
Safety 
• 
Adverse Events. 
• 
Serious Adverse Events. 
• 
Clinical laboratory parameters. 
• 
Physical examination (Including  height, weight, body mass index / body surface 
area, oxygen saturation, jugular venous pressure, liver size, and presence of 
peripheral oedema and/or ascites.) 
• 
Vital Signs. 
• 
Pubertal development (change from baseline in endocrinology assessments at Weeks 
12 and 24). 
Secondary 
Pharmcokinetics: 
• 
Population pharmacokinetic assessment based on one plasma sample per subject at 
Weeks 4 (trough), 8 (0.5 to 4 hours post-dose), 12 (trough), 16 (0.5 to 4 hours post-
dose), 20 (4 to 22 hours post-dose), and 24 (trough). 
• 
Pharmacokinetic/pharmacodynamic modelling. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
14 
 
Efficacy 
• 
The change from baseline in the 6 minute walking distance (6MWD) test evaluated 
after 24 weeks of therapy. 
• 
Mean changes from baseline in the 6MWD test at Weeks 4, 8, 12, 16, and 20. 
• 
The time to clinical worsening of PAH. 
• 
The change from baseline in Subject Global Assessment to Week 24 using the SF-10 
health survey for children. 
• 
The change from baseline in WHO functional class to Week 24. 
• 
Change from baseline in plasma N-Terminal pro-B-type Natriuretic Peptide (NT-Pro 
BNP) concentration at Week 24. 
Exploratory 
• 
The change from baseline in major prognostic factors based on echocardiogram: 
pericardial effusion, right atrial (RA) pressure, tricuspid annular plane systolic 
excursion (TAPSE), eccentricity index (systolic and diastolic), and right ventricular 
(RV) pressure by tricuspid regurgitant jet (TRJ) velocity to Week 24. 
Other 
• 
Change from baseline in cardiopulmonary hemodynamics at Week 24 (a sub-study in 
subjects enrolled at centres where the collection of hemodynamic data is considered 
part of the standard of care); see Appendix 1. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
15 
 
1. 
INTRODUCTION 
1.1. 
Background 
Pulmonary arterial hypertension (PAH) is a group of diseases characterised by a 
progressive increase of pulmonary vascular resistance (PVR) leading to right ventricular 
failure (RVF) and premature death. A recent meta-analysis estimates survival for 
untreated idiopathic PAH (IPAH) in adults to be only 79% at 1 year and 66% at 2 years 
[McLaughlin, 2006].  In the UK, survival in treated children with IPAH at 1, 3 and 5 
years was 89%, 84%, and 75% respectively; whilst transplant free survival was 89%, 
76%, and 57% respectively [Moledina, 2010]. 
Detailed, consensus, evidence-based guidelines for the treatment of PAH have been 
published [Badesch, 2004; Galiè, 2009].  Pharmacological approaches are divided into 
those that are supportive or background treatment (aimed at alleviating vasoconstriction, 
breathlessness, and thromboembolic complications) and those (such as endothelium 
receptor antagonist [ERAs]) that target the underlying pathophysiology.  
Diuretics and anticoagulants have been widely used in the management of PAH, yet 
response varies [Humbert, 2004].  Calcium channel blockers (CCBs) have shown 
improved survival in vasoreactive IPAH patients, yet the relatively low incidence of 
vasoreactivity make CCBs useful only in a minority of the population with PAH 
[Humbert, 2004; Rich, 1992]. 
The pathophysiologic mechanisms which underpin the disease spectrum of PAH involve 
pulmonary vascular dysfunction, which produces an imbalance in vasoactive substances 
as well as proliferation signals that lead to structural remodelling and pulmonary 
vasoconstriction.  Although its role is not fully understood, endothelin (ET) is considered 
to be an important mediator of pathology in PAH.  Almost all components of the 
endothelin system are upregulated in PAH [Giaid, 1993; Galiè, 2004].  There appears to 
be a significant correlation between serum endothelin 1 (ET-1) levels and disease 
severity, reflected by elevations in PVR, mean pulmonary artery pressure (mPAP) and 
right atrial pressure [Nootens, 1995].  Endothelin-1 (ET-1) receptor antagonists are a 
targeted pharmacological approach that limit both the vasoconstrictor and proliferative 
action of endothelin [Dingemanse, 2004], and in this way ameliorate the clinical 
manifestations of the disease.  
Three signalling pathways involved in the pathogenesis of PAH have been targeted for 
therapeutic intervention [Humbert, 2004]: the cAMP-dependent prostacyclin (PGI2) 
pathway, the cGMP-dependent nitric oxide (NO) pathway, and the 
phospholipase-C-dependent endothelin pathway.  These pathways are targeted by the 
following classes of PAH medicines: prostanoids (FLOLAN™ [epoprostenol], Ventavis 
[iloprost] and Remodulin [terprostinil]); phosphodiesterase type-5 (PDE-5) inhibitors 
(Revatio [EU]/Viagra [sildenafil] and Adcirca [tadalafil])); and ERAs (VOLIBRIS 
[EU]/Letairis [US] (ambrisentan), Tracleer [bosentan] and Thelin [sitaxentan]). 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
16 
 
There is evidence that prostanoid therapies are effective in children, but in common to 
their use in adults, the pharmacokinetic properties of these drugs and routes of 
administration (e.g., intravenous, subcutaneous injection, and multiple inhalations) 
present substantial challenges to their successful use in a pediatric population. 
The clinical profile of ambrisentan (an ERA selective for the ETA receptor) in adults is 
that it has an efficacy profile broadly comparable with other targeted oral treatments, but 
that it has potentially important advantages.  Ambrisentan has been associated with a 
favourable liver safety profile and a low risk of drug-drug interactions.  It is noted that 
data from the TRAX1 database indicates that the risk of elevated aminotransferases with 
bosentan is lower in children than adults [Beghetti, 2008].  Nevertheless the liver safety 
profile of ambrisentan in adults has been favourable and if replicated in children would 
provide a clinically useful option.  Children, like adults with PAH, commonly require 
many concomitant medications.  The low risk of drug-drug interactions and convenient 
once a day dosing associated with ambrisentan may provide a therapeutic option that 
simplifies treatment in this complex disease. 
1.2. 
Rationale 
Pulmonary arterial hypertension (PAH) is a rare, progressive, highly debilitating disease 
characterized by vascular obstruction and the variable presence of vasoconstriction, 
leading to increased pulmonary vascular resistance and right-sided heart failure 
[Moledina, 2010; Newman, 2004].  If left untreated, PAH ultimately leads to right 
ventricular failure and death; adult subjects have a median survival of 2.8 years without 
treatment [Krum, 2000].  Epidemiological estimates vary but prevalence in Europe is 
thought to be of the order of 15 cases per million [Humbert, 2006].  Large scale 
epidemiology studies of PAH in children have not been conducted and there is no or 
limited outcome data in paediatric PAH patients.  A register in France (1995-1996) 
estimates the prevalence in children is as low as 3.7 cases per million [Fraisse, 2010].  In 
a national, comprehensive country wide survey of the epidemiology of idiopathic PAH 
(IPAH) management and survival in the United Kingdom (UK) the incidence was 0.48 
cases per million children per year and the prevalence was 2.1 cases per million children 
[Moledina, 2010].  
Ambrisentan (VOLIBRIS tablets) is an endothelin receptor antagonist (ERA) marketed in 
the European Union (EU) and some other countries by GlaxoSmithKline (GSK) and in 
the United States as Letairis by Gilead Sciences Inc.  Ambrisentan is indicated for the 
treatment of adult patients with PAH to improve exercise capacity, decrease the 
symptoms of PAH, and delay clinical worsening. 
The primary purpose of this paediatric study is to provide clinically relevant information 
on the safety and pharmacokinetic profile of ambrisentan in children with the most 
common causes of PAH in this age group.  The design of the study is also intended to 
                                                 
1  TRAX - the Tracleer Excellence database is a non-interventional, prospective, internet-based surveillance 
system initiated by the manufacturer in cooperation with Regulatory agencies to collect potential safety 
signals associated with bosentan use including adverse events, elevations of liver aminotransferase 
levels, other abnormal laboratory values, deaths, and hospitalisation [Segal, 2005]. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
17 
 
provide information to guide dose selection and supportive efficacy data in this age 
group.  Despite the fact that none of the currently available adult treatments are licensed 
for use in children <12 yrs, (with the exception of bosentan which was recently approved 
for use in paediatric population from 2 years of age) they are widely used off label.  This 
study will provide useful prescribing information to the medical community for treating 
this orphan disease in children in this environment of rapidly changing medical practice.  
This study is part of a Paediatric Investigational Plan (PIP; EMEA-000434-PIP01-08) 
agreed with the European Medicines Agency’s Paediatric Committee (PDCO).  
2. 
OBJECTIVE(S) 
The primary objective of this study is to evaluate the safety and tolerability of 
ambrisentan in the paediatric (aged 8 years up to 18 years) PAH population.  Other 
objectives are to obtain supportive efficacy data (change from baseline in efficacy 
parameters) on the paediatric use of ambrisentan in PAH and to determine the 
ambrisentan population pharmacokinetics in the paediatric population.  Because patient 
recruitment is limited by the low prevalence of the disease in children, powered clinical 
hypotheses testing cannot be performed. 
2.1. 
Primary 
The primary objective is the safety and tolerability of ambrisentan in the paediatric PAH 
population (see Safety). 
2.1.1. 
Safety 
• 
Adverse Events. 
• 
Serious Adverse Events. 
• 
Clinical laboratory parameters. 
• 
Physical examination (Including  height, weight, body mass index / body surface 
area, oxygen saturation, jugular venous pressure, liver size, and presence of 
peripheral oedema and/or ascites.) 
• 
Vital Signs. 
• 
Pubertal development (change from baseline in endocrinology assessments at Weeks 
12 and 24). 
2.1.2. 
Secondary 
2.1.2.1. 
Pharmcokinetics: 
• 
Population pharmacokinetic assessment based on one plasma sample per subject at 
Weeks 4 (trough), 8 (0.5 to 4 hours post-dose), 12 (trough), 16 (0.5 to 4 hours post-
dose), 20 (4 to 22 hours post-dose), and 24 (trough). 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
18 
 
• 
Pharmacokinetic/pharmacodynamic modelling. 
2.1.2.2. 
Efficacy 
• 
The change from baseline in the 6 minute walking distance (6MWD) test evaluated 
after 24 weeks of therapy. 
• 
Mean changes from baseline in the 6MWD test at Weeks 4, 8, 12, 16, and 20. 
• 
The time to clinical worsening of PAH. 
• 
The change from baseline in Subject Global Assessment to Week 24 using the SF-10 
health survey for children. 
• 
The change from baseline in WHO functional class to Week 24. 
• 
Change from baseline in N-terminal pro-B-type natriuretic peptide (NT-Pro BNP) 
concentration at Week 24. 
2.1.2.3. 
Exploratory 
• 
The change from baseline in major prognostic factors based on echocardiograms: 
pericardial effusion, right atrial (RA) pressure, tricuspid annular plane systolic 
excursion (TAPSE), eccentricity index (systolic and diastolic), and right ventricular 
(RV) pressure by tricuspid regurgitant jet (TRJ) velocity to Week 24. 
2.1.2.4. 
Other 
• 
Change from baseline in cardiopulmonary hemodynamics at Week 24 (a sub-study in 
subjects enrolled at centres where the collection of hemodynamic data is considered 
part of the standard of care); see Appendix 1. 
3. 
INVESTIGATIONAL PLAN 
3.1. 
Study Design 
A 6-month (24-week), randomized, open label evaluation of the safety, tolerability, and 
efficacy of a high and low dose ambrisentan (adjusted for body weight) in 66 subjects (33 
per treatment group) aged 8 years up to 18 years with PAH.  The study will include a 
screening/baseline period and a treatment period.  The treatment period will be 24 weeks 
or until the subject’s clinical condition deteriorates to the point that alternative/additional 
treatment is necessary.  Subjects who participate in the study will be eligible to enrol into 
a long term follow-up study.  The primary comparison will be the safety and tolerability 
of the two ambrisentan dose groups (Low vs. High) in the paediatric PAH population.  
The secondary comparison will be the change from baseline of the efficacy parameters 
between the two treatment groups.  Because subject recruitment is limited by the low 
prevalence of the disease in children, powered clinical hypotheses testing cannot be 
performed.  Sixty-six (66) subjects were chosen on the predicted recruitment rate based 
on historic data so that the study can be completed in a reasonable time frame (2 years) 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
19 
 
for it to be useful and informative to the medical community.  A 10% drop out rate will 
leave 60 evaluable subjects. 
Supplementary study conduct information not mandated to be present in this protocol is 
provided in the accompanying Study Procedures Manual (SPM).  The SPM will provide 
the site personnel with administrative and detailed technical information on study 
conduct. 
3.2. 
Discussion of Design 
PAH is a serious and rapidly progressive disease in children.  Despite the fact that none 
of the currently available adult treatments are licensed for use in children <12 yrs, (with 
the exception of bosentan which was recently approved for use in paediatric population 
from 2 years of age) they are widely used off label.  In this context it is not considered 
appropriate to have a placebo control.  This has been confirmed by discussion with expert 
clinicians in the treatment of PAH in children.  The lack of robust data in children for the 
currently available treatments also means that there is little consistency regarding 
treatment selection.  As a result there is no international consensus on what represents 
current standard of care.  This makes a study comparing ambrisentan with ‘standard of 
care’ impractical across the number of sites required to conduct a study in children. 
Recruitment into studies in children with PAH has been difficult and slow as evidenced 
by the 4 years the sildenafil study took to recruit [ClinicalTrials.gov identifier: 
NCT00159913].  A study with this duration of recruitment may be confounded by 
changes in routine management.  This GSK study will be more tightly controlled in that it 
proposes to include patients with IPAH, PAH associated with connective tissue disease, 
and cases of sustained PAH following intracardiac repair.  PAH associated with 
congenital heart disease, which is more common, will not be included because of the 
wide variation in causation and complexity.  GSK has therefore based the size of the 
proposed study (in 8 up to 18 year-olds) on what is considered to be a feasible number of 
patients to recruit within a reasonable timeframe (18 months to 2 years).  The estimate is 
based on the number of incident cases reported by a panel of clinical PAH experts at their 
centres.  All patients will receive ambrisentan.  On this basis the estimated sample size is 
60 evaluable subjects.  It is not possible to power the study for inferential analyses of 
between-group differences. 
This is an open label study since there is no feasible method of blinding the study.  All 
subjects will be randomised to one of two dose groups of ambrisentan.  The risks and 
inconveniences associated with blinding the study as to dose outweigh any benefit of 
conducting the study in a blinded fashion.  All patients will be receiving ambrisentan and, 
although the dose group assignment could be blinded the unsuitability of the resulting 
dosage form precludes blinding.  The 2.5 mg, 5 mg, and 10 mg ambrisentan tablets differ 
in size and colour.  Over-encapsulating the tablets so that all dose strengths appear the 
same would create a dosage form that would be more difficult for the younger children to 
swallow.  Using all 2.5 mg tablets (with matching placebo) to disguise the dose would 
require every subject to take four tablets at each dose (which would be very difficult for 
the younger children) and could lead to an unacceptable risk of patients receiving the 
wrong dose (i.e., the wrong mix of active and placebo tablets). 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
20 
 
However, to minimise bias, a person who is not involved in subject assessments will be 
designated at each investigation site to dispense the investigational product and to 
perform the subsequent compliance checks (i.e., pill counts).  Subjects and their parents 
or legal guardian will be asked not to comment on the treatment (e.g., no. of tablets 
taken) with the individual making the assessments.  Therefore, the individual making the 
subjects assessments would be unbiased. 
4. 
SUBJECT SELECTION AND WITHDRAWAL CRITERIA 
4.1. 
Number of Subjects 
Approximately 80 subjects will enter the study to achieve 66 randomized subjects (33 per 
treatment group).  It is anticipated that approximately 60 randomized subjects will 
complete the study and/or provide some evaluable data for the primary endpoint.   
4.2. 
Inclusion Criteria 
Subjects eligible for enrolment in the study must meet all of the following criteria: 
1. Male or female at least 8 years of age and not yet 18 years of age at the time of 
randomization. 
2. A current diagnosis of PAH (WHO Group 1) with WHO class II or III symptoms in 
one of the following categories: 
• 
Idiopathic 
• 
Heritable [familial] 
• 
Secondary to connective tissue disease (e.g., limited scleroderma, diffuse 
scleroderma, mixed connective tissue disease (CTD), systemic lupus 
erythematosus, or overlap syndrome). 
• 
Persistent PAH despite surgical repair (at least 6 months prior to the screening 
visit) of atrial septal defects, ventricular septal defects, atrio-ventricular septal 
defects, and persistent patent ductus. 
3. Have met the following hemodynamic criteria for subjects with right heart 
catheterization (RHC) when performed as part of the diagnosis or routine care (see 
Appendix 1): 
• 
mean pulmonary arterial pressure (mPAP) of ≥25 mmHg 
• 
pulmonary vascular resistance (PVR) of ≥240 dyne⋅sec/cm5 
• 
left ventricular end diastolic pressure (LEVDP) or pulmonary capillary wedge 
pressure (PCWP) of ≤15 mmHg. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
21 
 
4. Subjects must either be treatment naïve, have discontinued treatment with another 
ERA (e.g., bosentan) at least 1 month previously because of elevated liver function 
tests (LFTs), or have been on a stable dose of drug therapy for PAH (e.g., sildenafil 
or prostacyclin) for at least one month prior to the Screening Visit.  The baseline 
drug therapy for PAH, if any, should not change from the Screening Visit until the 
end of all Treatment Period assessments. 
5. Subjects who discontinued ERA treatment due to elevated LFTs, must have LFTs of 
<3 x Upper Limit of Normal (ULN). 
6. A female is eligible to participate in this study, as assessed by the investigator, if she 
is of: 
a. 
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); 
or, 
b. Child-bearing potential - has a negative pregnancy test and is not lactating at the 
Screening and Baseline/Randomisation Visits and, if sexually active, agrees to use 2 
reliable methods of contraception from the Screening Visit until study completion 
and for at least 30 days following the last dose of study drug (reliable methods of 
contraception are listed in Appendix 2). 
7. Subject or subject’s legal guardian is able and willing to give written informed 
consent.  As part of the consent, female subjects of childbearing potential will be 
informed of the risk of teratogenicity and will need to be counselled in a 
developmentally appropriate manner on the importance of pregnancy prevention; and 
male subjects will need to be informed of potential risk of testicular tubular atrophy 
and aspermia. 
Complete information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the investigational product that may impact subject 
eligibility is provided in the Investigators Brochure and product label. 
French subjects: In France, a subject will be eligible for inclusion in this study only if 
either affiliated to or a beneficiary of a social security category. 
4.3. 
Exclusion Criteria 
Subjects meeting any of the following criteria must not be enrolled in the study: 
1. Subjects currently taking an ERA. 
2. Subjects currently taking cyclosporine A. 
3. Subjects whose body weight is less than 20 Kg. 
4. Subjects who have not tolerated PAH therapy due to adverse effects which may be 
related to their mechanism of action (e.g., prostanoids, ERA, PDE-5 inhibitors) with 
the exception of liver abnormalities for those subjects who were receiving another 
ERA. 
5. Female subjects who are pregnant or breastfeeding. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
22 
 
6. Subjects with diagnosis of active hepatitis (hepatitis B surface antigen and hepatitis 
C antibody), or clinically significant hepatic enzyme elevation (i.e., ALT, AST or AP 
>3xULN) at Screening. 
7. Subjects with severe renal impairment (creatinine clearance <30 mL/min) at 
Screening. 
8. Subject has clinically significant fluid retention in the opinion of the investigator. 
9. Subject has clinically significant anaemia in the opinion of the investigator. 
10. Subject has a known hypersensitivity to the study drug, the metabolites, or 
formulation excipients. 
11. Subjects who have participated in another trial or have taken another investigational 
product during the previous 30 days. 
12. Alcohol abuse, illicit drug use within 1 year. 
13. Any concurrent condition or concurrent use of medication that would affect subject 
safety in the opinion of the investigator. 
4.4. 
Withdrawal Criteria 
Subjects who do not tolerate treatment or whose baseline drug therapy for PAH (i.e., 
PDE-5 or prostanoid) is changed will be withdrawn from the study.  Treatment for 
subjects withdrawn from the study will be implemented at the Investigator’s discretion 
and PAH guidelines. 
Subjects whose clinical condition deteriorates to the point that additional drug treatment 
is indicated (including increasing the baseline doses of targeted PAH therapy) prior to 
Week 24 will be considered as having completed the study at that point. 
The Independent Data Monitoring Committee (IDMC) may stop the study at any time if 
they consider that the potential risks outweigh the potential benefits (based on review of 
safety [adverse experiences] and exposure [plasma concentration] data after 20 subjects 
have completed Week 12 of the study and again after 40 subjects have completed 
Week 12). 
A subject may also be discontinued prior to completion of the study for the following 
reasons: 
• 
Liver chemistry values exceeding the threshold criteria (as outlined in Section 6.2.6). 
• 
Adverse event which in the opinion of the investigator requires withdrawal. 
• 
Pregnancy. 
• 
Consent withdrawn. 
• 
Lost to follow-up. 
• 
Protocol violation. 
• 
Termination of study by sponsor. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
23 
 
• 
Investigator’s discretion (document reason in eCRF). 
5. 
STUDY TREATMENTS 
5.1. 
Investigational Product and Reference Therapy 
The sponsor will provide commercially available ambrisentan 5 mg, and 10 mg tablets, as 
well as 2.5 mg tablets of equivalent quality.  For centres in Japan, one or more 2.5 mg 
tablets will be used to achieve the appropriate dose.  Subjects will be dosed orally (tablet 
must be swallowed whole) once daily for 24 weeks after randomization to either a high 
dose or a low dose group as shown below.  Within each body weight group, subjects will 
start at the lower dose for that group and then, at Week 2 those randomized to the high 
dose group will receive the higher dose. 
Body Weight 
Low Dose 
High Dose 
≥ 50 kg 
5 mg 
10 mg 
≥ 35 kg and < 50 kg 
5 mg 
7.5 mg 
≥ 20 kg and <35 kg 
2.5 mg 
5 mg 
 
The 7.5 mg dose will consist of one 2.5 mg tablet and one 5 mg tablet (three 2.5 mg 
tablets in Japan).   
The contents of the label will be in accordance with all applicable regulatory 
requirements. 
Under normal conditions of handling and administration, investigational product is not 
expected to pose significant safety risks to site staff.  A Material Safety Data Sheet 
(MSDS) describing the occupational hazards and recommended handling precautions will 
be provided to site staff if required by local laws or will otherwise be available from GSK 
upon request. 
Investigational product must be stored in a secure area under the appropriate physical 
conditions for the product.  The Investigator, the hospital pharmacist, or other personnel 
allowed to store and dispense the investigational products will be responsible for ensuring 
that the investigational product used in the study will be securely maintained as specified 
by the Sponsor and in accordance with applicable regulatory requirements. 
Study medication will be stored in secure (locked) areas at a temperature below30°C and 
dispensed according to the protocol under the supervision of the Investigator or his/her 
designee.  Investigational product must be dispensed or administered only to subjects 
enrolled in the study and in accordance with the protocol.  Subjects will be instructed to 
keep dispensed treatment in a secure place, out of reach of children, and at room 
temperature.   
Subjects will be instructed to return unused medication to the Investigator.  Any unused 
product will be returned by the Investigator to GSK or destroyed at the site based on local 
regulations. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
24 
 
5.2. 
Treatment Assignment 
All subjects who meet the inclusion and exclusion criteria will be randomized to one of 
two dose groups (Low dose or High dose, based on body weight, see Section 5.1) of 
ambrisentan according to a computer-generated randomisation schedule.  To ensure 
balance with respect to the number of patients assigned to each treatment group, the 
allocation schedule will be generated in blocks.  Each subject will be assigned to a pack 
number according to the predefined randomisation list.  A central Interactive Voice 
Response System (IVRS) will be used for treatment assignment. 
Once a randomisation number has been assigned, the patient will be considered as 
definitely included and the number will not be re-assigned.  The assigned study treatment 
should be initiated as soon as possible after randomisation.  
Randomization will be stratified by the age groups 8 years up to 11 years and 12 years up 
to 18 years and by aetiology of PAH as follows: 
• 
idiopathic; 
• 
heritable [familial]; 
• 
secondary to connective tissue disease; and  
• 
persistent despite surgical repair of atrial septal defects, ventricular septal 
defects, atrio-ventricular septal defects, and persistent patent ductus.  
Subjects will be assigned to study treatment in accordance with the randomization 
schedule. 
5.3. 
Blinding 
This is an open label study.  It is not feasible to blind the study in the classical sense; 
however, to minimise bias, a person who is not involved in subject assessments will be 
designated at each investigation site to dispense the investigational product and to 
perform the subsequent compliance checks (i.e., pill counts).  Subjects and their parents 
or legal guardian will be asked not to comment on the treatment (e.g., no. of tablets 
taken) with the individual making the assessments.  Therefore, the individual making the 
subjects assessments would be unbiased. 
After each subject has completed the study, the randomised treatment will be unblinded 
to the investigators to allow for informed dose adjustments and follow-up treatment as 
may be necessary 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
25 
 
5.4. 
Product Accountability 
In accordance with local regulatory requirements, the investigator, designated site staff, 
or head of the medical institution (where applicable) must document the amount of GSK 
investigational product dispensed and/or administered to study subjects, the amount 
returned by study subjects, and the amount received from and returned to GSK, when 
applicable.  Product accountability records must be maintained throughout the course of 
the study. 
5.5. 
Treatment Compliance 
Compliance will be assessed by the investigator or designee as specified in the Time and 
Events Table, (Table 1), and recorded in the eCRF.  Compliance is calculated based on 
the number of tablets dispensed and the number of tablets returned, and the days between 
the date dispensed and the date returned.  Compliance should be assessed for each child 
resistant blister pack to ensure an accurate assessment.  The range of compliance at the 
appropriate visits will be recorded on the eCRF. 
5.6. 
Concomitant Medications and Non-Drug Therapies 
5.6.1. 
Permitted Medications and Non-Drug Therapies 
Standard medical treatment(s) being taken by the subject upon study entry may be 
maintained throughout the study. 
Subjects taking PAH specific medications (i.e., prostanoids [treprostinil, epoprostinol, 
iloprost ], vasodilators [e.g., Angiotensin-converting enzymes [ACE] inhibitors, Calcium 
Channel blockers, nitric oxide] or Cyclic guanosine monophosphate (cGMP) inhibitors –
specific phosphodiesterase type 5 [PDE-5; e.g., slidenafil, tadalafil]) have to have stable 
PAH therapy for 1 month before screening and the therapy has to be maintained 
throughout the study treatment period. 
If a subjects targeted PAH background therapy (i.e., PDE-5 or prostanoid) is changed or 
discontinued due to tolerability issues, the subject should be withdrawn from the study. 
Subjects may begin oral contraceptive therapy as per the prescribing information. 
5.6.2. 
Prohibited Medications and Non-Drug Therapies 
During the study, patients may not receive: 
• 
Endothelin receptor antagonists other than ambrisentan (e.g., bosentan, sitaxentan). 
• 
Cyclosporine A. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
26 
 
5.7. 
Treatment after the End of the Study 
Patients who participate in the study and in whom continued treatment with ambrisentan 
is desired will be eligible to enrol into a long term follow-up study. 
5.8. 
Treatment of Investigational Product Overdose 
There is no experience in PAH patients of ambrisentan at daily doses greater than 10 mg.  
In healthy volunteers, single doses of 50 mg and 100 mg (5 to 10 times the maximum 
recommended dose) were associated with headache, flushing, dizziness, nausea, and 
nasal congestion. 
Due to the mechanism of action, an overdose of ambrisentan could potentially result in 
hypotension.  In case of pronounced hypotension, active cardiac support may be required.  
No specific antidote is available. 
6. 
STUDY ASSESSMENTS AND PROCEDURES 
The following measurements and evaluations will be conducted during the trial.  Please 
refer to the Time and Events Table (Table 1) for additional details on the timing of the 
assessments.  Every effort must be made to adhere to the protocol defined visit schedule.  
The data collection tool for this study will be GSK defined eCRFs.  In all cases, subject 
initials will not be collected nor transmitted to GSK.  Subject data necessary for analysis 
and reporting will be entered/transmitted into a validated database or data system.  
Clinical data management will be performed in accordance with applicable GSK 
standards and data cleaning procedures.   


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
27 
 
Table 1 
Time and Events Table 
Procedure 
Screening/ 
Baseline1 
Treatment 
Early 
Withdrawal 
End of 
Therapy 
Follow-
up2 
 
Max. 2 Wks  
Wk 2 
±2 days 
Wk 4 
±7 days 
Wk 8 
±7 days 
Wk 12 
±7 days 
Wk 16 
±7 days 
Wk 20 
±7 days 
 
Week 
24 
 
Written informed consent and assent 
X 
 
 
 
 
 
 
 
 
 
Subject Demography 
X 
 
 
 
 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
 
 
 
 
Disease History 
X 
 
 
 
 
 
 
 
 
 
Therapy History 
X 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion Criteria 
X 
 
 
 
 
 
 
 
 
 
Adverse Events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serious Adverse Events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Clinical Chemistry3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Haematology4 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical Examination 
X 
 
 
 
X 
 
 
X 
X 
X 
Vital Signs5 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
12-lead ECG 
X 
 
 
 
X 
 
 
X 
X 
X 
Concomitant Medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
6 Minute Walk Distance6 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
WHO Functional Class 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
Health Outcome Assessments7  
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
Echocardiogram 
X 
 
 
 
X 
 
 
X 
X 
X 
Plasma NT-Pro BNP concentration 
X 
 
 
 
X 
 
 
X 
X 
 
Plasma Sample for Population 
Pharmacokinetic assessment8 
 
 
X 
X 
X 
X 
X 
X 
X 
 
Hemodynamic assessment9 
X 
 
 
 
 
 
 
X 
X 
 
PGx Sampling 
 
 
X 
 
 
 
 
 
 
 
Pregnancy Test10 
U 
 
U 
U 
U 
U 
U 
U 
U 
U 
Pubertal Development Assessment11 
X 
 
 
 
X 
 
 
X 
X 
 
HBsAg and hepatitis C antibody12 
X 
 
 
 
 
 
 
 
 
 
Dispense Investigational Product13 
X 
X 
X 
X 
X 
X 
X 
 
 
 
Assess Investigational Product 
Compliance 
 
X 
X 
X 
X 
X 
X 
X 
X 
 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
28 
 
Table 1 
Time and Events Table (Continued) 
1. 2 weeks maximum between screening and baseline (randomization) visit; Note: screening and baseline can be the same day if local labs available to confirm eligibility.  Central 
lab blood draw must also be done at this visit. 
2. Only for subjects who are not participating in the long term follow-up study; within 4 to 6 weeks after last dose of investigational drug 
3. Includes sodium, magnesium, potassium, calcium, glucose, chloride, bicarbonate (CO2,) phosphorus-inorganic, creatinine, total protein, albumin, ALT (SGPT), AST (SGOT), 
GGT, LDH, total bilirubin, creatine phosphokinase (CPK), blood urea nitrogen (BUN), uric acid, and alkaline phosphatase 
4. Includes platelet count, RBC count, reticulocyte count, hematocrit, hemoglobin, RBC indices (mean corpuscular volume [MCV], mean corpuscular haemoglobin [MCH], and mean 
corpuscular haemoglobin concentration [MCHC]), WBC count, automated WBC differential (neutrophils-total, lymphocytes, monocytes, eosinophils, basophils) 
5. Includes height, weight, supine blood pressure, and heart rate 
6. Subjects with a 20% decrease in 6MWD will need to return in 1 week to repeat the test, to confirm PAH deterioration. 
7. SF 10 and a record of school days scheduled and missed.  Two diary cards will be given to the subject at Baseline, and one diary card will be given to the subject at Weeks 4, 8, 
12, 16, 20 and 24 on which to record the number of school days scheduled, the number missed for any reason, and the number missed because of symptoms of PAH.  One 
baseline diary card will be completed and returned during the visit.  The other baseline diary card should be returned at the Week 4 visit.  All other diary cards will be returned at 
the next visit.  Data from all diary cards will be transcribed into the eCRF. 
8. One plasma sample per visit. A diary card will be given to the subject at Baseline to record date and time of study medication dosing 2 days prior to and 1 day prior to the Week 4 
visit and at Weeks 4, 8, 12, and 20 to record date and time of study medication dosing 2 days prior to and 1 day prior to the next visit.  At Week 16, a diary card will be given to the 
subject to record the date and time of study medication dosing 2 days prior to, 1 day prior to and on the day of the Week 20 visit.  The diary card given out at Baseline should be 
returned at the Week 4 visit.  All other diary cards will be returned at the next visit.  The dates and times of study medication dosing will be transcribed into the eCRF.  Subjects will 
have the option to receive a reminder SMS message on the days they should complete the diary card and to remind them of their next visit date. 
9. Sub-study - Heart rate, mean blood pressure (systolic, diastolic), mean pulmonary artery (PA) pressure (systolic, diastolic), mean right atrium (RA) pressure, left ventricular end 
diastolic pressure (LEVDP) or pulmonary capillary wedge pressure (PCWP), cardiac output, cardiac index (calculated value), arterial oxygen saturation and mixed venous oxygen 
saturation.  Record method used to calculate cardiac output measurement (if Fick’s principle was used it must be stated if oxygen consumptions is measured or assumed).  
10. Monthly pregnancy test for females of childbearing potential for the duration of the study:  U = urine. 
11. Pubertal development in male and female subjects will be assessed using Tanner criteria.  In male subjects, testicular volume will be assessed using Prader’s orchidometer, and 
blood samples will be obtained to measure follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, sex hormone binding globulin (SHBG) and inhibin B levels.  
In female subjects, blood samples will be obtained to measure FSH, LH, oestrogen, SHBG and inhibin B levels. 
12. Hepatitis B surface antigen and hepatitis C antibody (if hepatitis C antibody positive, a hepatitis C RIBA immunoblot assay should be reflexively performed on the same sample to 
confirm the result). 
13. Within each body weight group, subjects will start at the lower dose for that group and then, at Week 2 those randomized to the high dose group will receive the higher dose. 
 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
29 
 
6.1. 
Critical Baseline Assessments 
Review historical diagnostic tests, such as Right Heart Catheter (RHC); chest X-ray; 
echocardiogram; ventilation/perfusion scan, computed axial tomography (CT) or spiral 
CT, and pulmonary arteriogram (if applicable), to ensure that none of the exclusion 
criteria for PAH aetiology are met. 
Historic hemodynamic data (e.g., mPAP, RAP, PVR, and cardiac index) based on the 
most recent RHC prior to starting this study will be collected. 
Therapy history including PAH treatment and ERA discontinued due to elevated LFTs. 
6.2. 
Safety 
6.2.1. 
Physical examination 
Physical examination at Baseline and Weeks 12 and 24 (including height, weight, body 
mass index [BMI] / body surface area [BSA], oxygen saturation, jugular venous pressure, 
liver size, and presence of peripheral oedema and/or ascites) and pubertal development 
(see Section 6.2.4).   
Note: BMI and BSA to be calculated centrally using height and weight collected in the 
eCRF. 
6.2.2. 
Electrocardiogram / Echocardiogram 
A 12-lead ECG will be performed at Baseline and at Weeks 12 and 24 (or early 
withdrawal), and Follow-up.  Any changes since Baseline felt to be significant in the 
medical and scientific judgement of the investigator are to be recorded as AEs or SAEs in 
the eCRF. 
An echocardiogram will be performed at Baseline and at Weeks 12 and 24 (or early 
withdrawal), and Follow-up (if applicable).  An echocardiogram (the results of which are 
considered exploratory in this study) will also be performed if there is PAH deterioration 
or if there is a change in PAH therapy. 
6.2.3. 
Vital Signs, Body Weight and Height 
Vital signs (including heart rate and supine blood pressure), height, and weight will be 
collected at each clinic visit. 
All measures of blood pressure will be performed using standard sphygmomanometry.  If 
possible, the same sphygmomanometer and arm should be used.  Procedural details are 
provided in the study procedures manual. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
30 
 
6.2.4. 
Pubertal Development Assessment 
Pubertal development in male and female subjects will be assessed at baseline, Week 12, 
and Week 24 or early termination using Tanner criteria [Marshall, 1969; Marshall, 1970; 
Cameron, 2004].  In male subjects, testicular volume will be assessed by Prader’s 
orchidometer.  These assessments will be performed by a paediatric endocrinologist or 
another individual with comparable experience employing the Tanner criteria and 
Prader’s orchidometer.  Preferably, the same assessor will evaluate an individual subject 
at each assessment time. 
In addition, follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone 
(in male subjects only), oestrogen (in female subjects only), sex hormone binding 
globulin (SHBG), and inhibin B levels will be assessed at baseline, Week 12, and Week 
24 or early withdrawal.  
6.2.5. 
Clinical Laboratory Tests 
Central labs (Quest Diagnostics) will be used for all laboratory assessments.  However, 
results from local labs can be used if more readily available to confirm eligibility criteria 
at the Screening visit. 
6.2.5.1. Safety Tests 
The following tests are required at each clinic visits (including early withdrawal or end of 
therapy visits, and Follow-up visit [if applicable]). 
• 
Chemistry:  serum alanine aminotransferase (ALT/SGPT), aspartate 
aminotransferase (AST/SGOT), alkaline phosphatase, gamma glutamyl transferase 
(GGT), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), total bilirubin, 
creatinine, sodium, magnesium, potassium, chloride, bicarbonate (CO2), 
phosphorus-inorganic, calcium, blood urea nitrogen (BUN), uric acid, glucose, total 
protein, and albumin. 
• 
Haematology:  haemoglobin, hematocrit, red cell count, red cell indices (mean 
corpuscular volume [MCV], mean corpuscular haemoglobin [MCH], and mean 
corpuscular haemoglobin concentration [MCHC]), white blood cell count (total and 
differential), reticulocyte count, and platelet count. 
• 
Pregnancy:  Urine pregnancy test at screening/baseline and end of treatment or early 
withdrawal visit and monthly urine pregnancy test for female subjects of child 
bearing potential. 
6.2.5.2. Pharmacogenetics and NT-Pro BNP 
• 
Blood samples for NT-Pro BNP concentration will be collected at 
screening/baseline, Week 12, early withdrawal or Week 24 (end of therapy) visits, 
and Follow-up visit (if applicable).  Assays for plasma concentrations will be 
performed in the central laboratory. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
31 
 
• 
The first PK sample (at Week 4) will also be used for pharmacogenetics. 
Collection, processing, labelling, and shipping of the NT-pro BNP and pharmacogenetic 
samples to central laboratory are detailed in the SPM. 
6.2.6. 
Liver chemistry stopping and followup criteria 
Phase II liver chemistry stopping and follow up criteria have been designed to assure 
subject safety and evaluate liver event aetiology. 
Phase II liver chemistry stopping criteria 1-5 are defined below: 
1. ALT ≥ 3xULN and bilirubin ≥ 2xULN (>35% direct bilirubin) (or ALT ≥ 3xULN 
and International Normalized Ratio [INR]>1.5, if INR measured). 
NOTE: if serum bilirubin fractionation is not immediately available, study drug should be 
discontinued if ALT ≥ 3xULN and bilirubin ≥ 2xULN. Serum bilirubin fractionation 
should be performed if testing is available. If testing is unavailable, record presence of 
detectable urinary bilirubin on dipstick, indicating direct bilirubin elevations and 
suggesting liver injury. 
2. ALT ≥ 5xULN. 
3. ALT ≥ 3xULN if associated with the appearance or worsening of symptoms of 
hepatitis or hypersensitivity such as fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash or eosinophilia. 
4. ALT ≥ 3xULN persists for ≥4 weeks 
5. ALT ≥ 3xULN and cannot be monitored weekly for 4 weeks. 
When any of the liver chemistry stopping criteria 1-5 is met, do the following: 
• 
Immediately withdraw investigational product  
• 
Report the event to GSK within 24 hours of learning its occurrence 
• 
Complete the liver event CRF and SAE data collection tool if the event also meets 
the criteria for an SAE. All events of ALT ≥ 3xULN and bilirubin ≥ 2xULN (>35% 
direct bilirubin) (or ALT ≥ 3xULN and INR>1.5, if INR measured; INR 
measurement is not required and the threshold value stated will not apply to patients 
receiving anticoagulants), termed ‘Hy’s Law’, must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis). 
NOTE: if serum bilirubin fractionation is not immediately available, study drug should be 
discontinued if ALT ≥ 3xULN and bilirubin ≥ 2xULN. Serum bilirubin fractionation 
should be performed if testing is available. If testing is unavailable, record presence of 
detectable urinary bilirubin on dipstick, indicating direct bilirubin elevations and 
suggesting liver injury. 
• 
Complete the liver imaging and/or liver biopsy CRFs if these tests are performed 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
32 
 
• 
Perform liver event follow up assessments, and monitor the subject until liver 
chemistries resolve, stabilize, or return to baseline values as described below.  
• 
Withdraw the subject from the study (unless further safety follow up is required) 
after completion of the liver chemistry monitoring as described below. 
• 
Do not re-challenge with investigational product. 
In addition, for criterion 1:  
• 
Make every reasonable attempt to have subjects return to clinic within 24 hours for 
repeat liver chemistries, liver event follow up assessments (see below), and close 
monitoring 
• 
A specialist or hepatology consultation is recommended. 
• 
Monitor subjects twice weekly until liver chemistries (ALT, AST, alkaline 
phosphatase, bilirubin) resolve, stabilize or return to within baseline values. 
For criteria 2, 3, 4, and 5: 
• 
Make every reasonable attempt to have subjects return to clinic within 24-72 hrs for 
repeat liver chemistries and liver event follow up assessments (see below) 
• 
Monitor subjects weekly until liver chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) resolve, stabilize or return to within baseline values; criterion 5 subjects 
should be monitored as frequently as possible. 
Subjects with ALT ≥3xULN but <5xULN and bilirubin <2xULN, without hepatitis 
symptoms or rash, and who can be monitored weekly for 4 weeks 
• 
Notify the GSK medical monitor within 24 hours of learning of the abnormality to 
discuss subject safety.  
• 
Can continue investigational product [this can be deleted for single-dose studies] 
• 
Must return weekly for repeat liver chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilize or return to within baseline  
• 
If at any time these subjects meet the liver chemistry stopping criteria, proceed as 
described above 
• 
If, after 4 weeks of monitoring, ALT <3xULN and bilirubin <2xULN, monitor 
subjects twice monthly until liver chemistries normalize or return to within baseline 
values.  
For criteria 1-5, make every attempt to carry out the liver event follow up assessments 
described below: 
• 
Viral hepatitis serology including: 
• 
Hepatitis A IgM antibody; 
• 
Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM);  


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
33 
 
• 
Hepatitis C RNA;  
• 
Cytomegalovirus IgM antibody;   
• 
Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);   
• 
Hepatitis E IgM antibody (if subject resides outside the US or Canada, or has 
travelled outside US or Canada in past 3 months); 
• 
Blood sample for pharmacokinetic (PK) analysis, obtained within 24 hours of last 
dose.  Record the date/time of the PK blood sample draw and the date/time of the last 
dose of investigational product prior to blood sample draw on the eCRF.  If the date 
or time of the last dose is unclear, provide the subject’s best approximation.  If the 
date/time of the last dose cannot be approximated OR a PK sample cannot be 
collected in the time period indicated above, do not obtain a PK sample.  Instructions 
for sample handling and shipping are in the SPM.  
• 
Serum creatine phosphokinase (CPK) and lactate dehydrogenase (LDH). 
• 
Fractionate bilirubin, if total bilirubin≥2xULN. 
• 
Obtain complete blood count with differential to assess eosinophilia. 
• 
Record the appearance or worsening of clinical symptoms of hepatitis, or 
hypersensitivity, such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever rash or eosinophilia as relevant on the AE report form. 
• 
Record use of concomitant medications, acetaminophen, herbal remedies, other over 
the counter medications, or putative hepatotoxins, on the concomitant medications 
report form. 
• 
Record alcohol use on the liver event alcohol intake case report form 
The following are required for subjects with ALT ≥3xULN and bilirubin ≥2xULN (>35% 
direct) but are optional for other abnormal liver chemistries: 
• 
Anti-nuclear antibody, anti-smooth muscle antibody, and Type 1 anti-liver kidney 
microsomal antibodies. 
• 
Liver imaging (ultrasound, magnetic resonance, or computerized tomography) to 
evaluate liver disease. 
6.2.7. 
Adverse Events 
The investigator or site staff will be responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE. 
6.2.7.1. 
Definition of an AE 
Any untoward medical occurrence in a patient or clinical investigation subject, 
temporally associated with the use of a medicinal product, whether or not considered 
related to the medicinal product. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
34 
 
Note:  An AE can therefore be any unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a medicinal product.  For marketed medicinal products, this 
also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. 
Events meeting the definition of an AE include: 
• 
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition 
• 
New conditions detected or diagnosed after investigational product administration 
even though it may have been present prior to the start of the study 
• 
Signs, symptoms, or the clinical sequelae of a suspected interaction 
• 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concomitant medication (overdose per se will not be 
reported as an AE/SAE). 
“Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE.  However, the signs and symptoms and/or clinical sequelae 
resulting from lack of efficacy will be reported if they fulfil the definition of an AE or 
SAE.   
Events that do not meet the definition of an AE include: 
• 
Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that 
leads to the procedure is an AE 
• 
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital) 
• 
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen 
• 
The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition. 
6.2.7.2. 
Definition of a SAE 
A serious adverse event is any untoward medical occurrence that, at any dose: 
a. 
Results in death 
b. Is life-threatening 
NOTE:  The term 'life-threatening' in the definition of 'serious' refers to an event in 
which the subject was at risk of death at the time of the event.  It does not refer to an 
event, which hypothetically might have caused death, if it were more severe. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
35 
 
c. 
Requires hospitalization or prolongation of existing hospitalization 
NOTE:  In general, hospitalization signifies that the subject has been detained 
(usually involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician’s 
office or out-patient setting.  Complications that occur during hospitalization are 
AEs.  If a complication prolongs hospitalization or fulfils any other serious criteria, 
the event is serious.  When in doubt as to whether “hospitalization” occurred or was 
necessary, the AE should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE. 
d. Results in disability/incapacity, or 
NOTE:  The term disability means a substantial disruption of a person’s ability to 
conduct normal life functions.  This definition is not intended to include experiences 
of relatively minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhoea, influenza, and accidental trauma (e.g. sprained ankle) which 
may interfere or prevent everyday life functions but do not constitute a substantial 
disruption. 
e. 
Is a congenital anomaly/birth defect 
f. 
Medical or scientific judgement should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize 
the subject or may require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition.  These should also be considered 
serious.  Examples of such events are invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse. 
g. All events of possible drug-induced liver injury with hyperbilirubinaemia defined as 
ALT ≥ 3xULN and bilirubin ≥ 2xULN (>35% direct) (or ALT ≥ 3xULN and 
INR>1.5, if INR measured) termed ‘Hy’s Law’ events (INR measurement is not 
required and the threshold value stated will not apply to patients receiving 
anticoagulants). 
NOTE: bilirubin fractionation is performed if testing is available. If testing is 
unavailable, record the presence of detectable urinary bilirubin on dipstick indicating 
direct bilirubin elevations and suggesting liver injury. If testing is unavailable and a 
subject meets the criterion of total bilirubin ≥ 2xULN, then the event is still reported 
as an SAE. If INR is obtained, include values on the SAE form. INR elevations >1.5 
suggest severe liver injury. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
36 
 
6.2.8. 
Laboratory and Other Safety Assessment Abnormalities 
Reported as AEs and SAEs 
Any abnormal laboratory test results (haematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g., ECGs, radiological scans, vital signs measurements), 
including those that worsen from baseline, and felt to be clinically significant in the 
medical and scientific judgement of the investigator are to be recorded as AEs or SAEs. 
However, any clinically significant safety assessments that are associated with the 
underlying disease, unless judged by the investigator to be more severe than expected for 
the subject’s condition, are not to be reported as AEs or SAEs. 
6.2.9. 
Pregnancy 
Subjects who become pregnant during the study must discontinue study drug 
immediately.  The Investigator should counsel the subject regarding the possible effects 
of prior study drug exposure on the foetus (See SmPC and USPI) and the need to inform 
the study site of the outcome of the pregnancy.  Subjects should be instructed to notify 
the Investigator if they become pregnant at any time during the study, or if they become 
pregnant within 30 days of last study drug dose. 
Any pregnancy that occurs during study participation must be reported using a clinical 
trial pregnancy form.  To ensure subject safety, each pregnancy must be reported to GSK 
within 2 weeks of learning of its occurrence.  The pregnancy must be followed up to 
determine outcome (including premature termination) and status of mother and child.  
Pregnancy complications and elective terminations for medical reasons must be reported 
as an AE or SAE.  Spontaneous abortions must be reported as an SAE. 
Any SAE occurring in association with a pregnancy brought to the investigator’s 
attention after the subject has completed the study and considered by the investigator as 
possibly related to the investigational product, must be promptly reported to GSK. 
6.2.10. 
Time Period and Frequency of Detecting AEs and SAEs 
The investigator or site staff is responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE. 
AEs will be collected from the start of investigational product and until 30 days after the 
last dose of investigational product.  
SAEs will be collected over the same time period as stated above for AEs.  However, any 
SAEs assessed as related to study participation (e.g., investigational product, protocol-
mandated procedures, invasive tests, or change in existing therapy) or related to a GSK 
concomitant medication, will be recorded from the time a subject consents to participate 
in the study up to and including any follow up contact. All SAEs will be reported to GSK 
within 24 hours, as indicated in Section 6.2.11.  


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
37 
 
6.2.11. 
Prompt Reporting of Serious Adverse Events and Other Events 
to GSK 
SAEs, pregnancies, and liver function abnormalities meeting pre-defined criteria will be 
reported promptly by the investigator to GSK as described in the following table once the 
investigator determines that the event meets the protocol definition for that event. 
 
Initial Reports 
Follow-up Information on a 
Previous Report 
Type of Event 
Time Frame 
Documents 
Time Frame 
Documents 
All SAEs 
24 hours 
“SAE” data 
collection tool 
24 hours 
Updated “SAE” 
data collection tool
Pregnancy 
2 Weeks 
Pregnancy 
Notification Form 
2 Weeks 
Pregnancy Follow 
up Form 
Liver chemistry 
abnormalities Phase 
II: 
 
 
 
 
ALT≥3xULN and 
Bilirubin≥2xULN 
(>35% direct) (or 
ALT≥3xULN and 
INR>1.5, if INR 
measured)*** 
24 hours* 
SAE data 
collection tool. 
**Liver Event 
Case Report Form 
(CRF) and liver 
imaging and/or 
biopsy CRFs if 
applicable  
24 hours 
Updated SAE data
collection tool. 
**Updated Liver 
Event CRF 
ALT≥5xULN; 
ALT≥3xULN with 
hepatitis or rash or 
3xULN ≥4 weeks 
24 hours* 
**Liver Event CRF 
24 hours 
**Updated Liver 
Event CRF 
ALT≥3xULN and 
<5xULN and biliribin 
<2xULN 
24 hours* 
**Liver Event CRF 
does not need 
completing unless 
elevations persist  
for 4 weeks or 
subject cannot be 
monitored weekly 
for 4 weeks 
 
 
*GSK to be notified at onset of liver chemistry elevations to discuss subject safety. 
** Liver event documents should be completed as soon as possible. 
*** INR measurement is not required; if measured, the threshold value stated will not apply to patients receiving 
anticoagulants. 
 
The method of detecting, recording, evaluating and follow-up of AEs and SAEs plus 
procedures for completing and transmitting SAE reports to GSK are provided in the 
SPM.  Procedures for post-study AEs/SAEs are provided in the SPM. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
38 
 
Procedures for documenting, transmitting and follow-up of medical device incidents 
along with the regulatory reporting requirements for medical devices are provided in the 
SPM. 
6.2.11.1. 
Regulatory reporting requirements for SAEs 
Prompt notification of SAEs by the investigator to GSK is essential so that legal 
obligations and ethical responsibilities towards the safety of subjects are met. 
GSK has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a product under clinical investigation.  GSK will 
comply with country specific regulatory requirements relating to safety reporting to the 
regulatory authority, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators. 
Investigator safety reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory requirements and GSK policy and are forwarded 
to investigators as necessary. 
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safety information (e.g., summary or listing of SAEs) from GSK will file it with 
the IB and will notify the IRB/IEC, if appropriate according to local requirements. 
6.3. 
Pharmacokinetics 
Blood samples for pharmacokinetic analysis of ambrisentan will be collected at the time 
points indicated in Table 2.  The actual date and time of each blood sample collection 
will be recorded in the GSK-defined eCRF.  The exact time of dosing on the day of the 
visit, 1 day prior to the visit and 2 days prior to the visit will be recorded in the eCRF by 
having the subject return a patient diary card on which this information is recorded. 
Table 2 
Pharmacokinetic Sampling 
 
Treatment 
Sample Collection Timepoint1 
Week 4 
Week 8 
Week 12 
Week 16 
Week 20 
Week 24 
Pre-dose 
 (Trough concentration) 
X2 
 
X2 
 
 
X2 
0.5-4 hours after dose  
(Absorption phase) 
 
X 
 
X 
 
 
4-22 hours after dose 
(Elimination phase) 
 
 
 
 
X 
 
1. If the subject is withdrawn early, a blood sample for PK should be collected prior to discharge, if possible. 
2. Subjects should be reminded to not take their study medication until after the PK sample is drawn. 
 
Plasma analysis will be performed under the management of Worldwide Bioanalysis, 
DMPK, GSK.  Plasma samples will be analyzed for ambrisentan only.  The main 
circulating metabolite of ambrisentan, 4-hydroxymethyl ambrisentan, represents 
approximately 4% of parent AUC in plasma and the binding affinity of this metabolite is 
approximately 64-fold less than ambrisentan.  Therefore, at concentrations observed in 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
39 
 
the plasma, 4-hydroxymethyl ambrisentan is not expected to contribute to 
pharmacological activity of ambrisentan. 
Details of PK blood sample collection (including volume to be collected), processing, 
storage, and shipping procedures are provided in the Study Procedures Manual (SPM). 
6.4. 
Efficacy 
6.4.1. 
Change from baseline in the 6 minute walking distance (6MWD) 
test. 
The 6MWD will be assessed at Baseline, Weeks 4, 8, 12, 16, 20, and Week 24 or early 
withdrawal, and Follow –up (at Follow-up only for subjects who are not participating in 
the long term follow-up study).  Subjects with a 20% decrease in 6MWD will need to 
return in 1 week to repeat the test, to confirm PAH deterioration. 
6.4.2. 
Time to worsening of PAH 
Time to clinical worsening of PAH is defined as the time from randomization to the first 
occurrence of: 
• 
Death (all cause) or placed on active list for lung transplant; 
• 
Hospitalisation due to PAH deterioration; 
• 
Addition or increased dose of other targeted PAH therapeutic agents (prostanoids, 
PDE-5 inhibitors) and/or atrial septostomy; 
• 
PAH related deterioration identified by: 
• 
increase in WHO functional class;  
• 
deterioration in exercise testing (i.e., 20% decrease in 6MWD on two 
consecutive tests - 1 week apart); 
• 
clinical signs or symptoms of right sided heart failure (i.e., new peripheral 
edema, increase in liver size, ascites, increase in jugular venous pressure, 
pericardial effusion, increased dyspnea).  
6.4.3. 
Change from baseline (Week 0) in Subject Global Assessment to 
Week 24. 
Global assessments will be performed at baseline and Week 24 or early withdrawal, and 
Follow–up (if appropriate). 
6.4.4. 
Change from baseline in WHO functional class to Week 24. 
WHO functional class will be determined at baseline and Weeks 4, 8, 12, 16, 20, and 
Week 24 or early withdrawal, and Follow –up (if appropriate). 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
40 
 
6.4.5. 
Change from baseline plasma N-terminal pro-B type natriuretic 
peptide (NT-Pro BNP) at Week 24 
Blood samples for determination of N-Terminal pro-B-type Natriuretic Peptide plasma 
concentrations will be determined at baseline, Week 12 and Week 24 or early 
withdrawal.  A central lab (Quest Diagnostics) will analyze all samples. 
6.4.6. 
Change from baseline in major prognostic factors to Week 24. 
Echocardiograms will be performed at baseline and Weeks 12 and 24 or early 
withdrawal.  Prognostic factors included pericardial effusion, RA pressure, tricuspid 
annular plane systolic excursion (TAPSE), eccentricity index (systolic and diastolic), and 
right ventricular (RV) pressure by tricuspid regurgitant jet (TRJ) velocity.  These 
evaluations were considered exploratory in this study.  
6.4.7. 
Change from baseline in cardiopulmonary hemodynamics at 
Week 24 
Cardiopulmonary hemodynamic assessments will be performed at baseline and Week 24 
or early withdrawal in a subgroup of subjects enrolled in centres where the collection of 
hemodynamic data is considered part of the standard of care (see Appendix 1). 
6.5. 
Health Outcomes 
Patient global assessments will be performed at Baseline, Weeks 4, 8, 12, 16, 20, and 
Week 24 or early withdrawal, and Follow-up (if appropriate).  Health outcomes will be 
recorded using the parent-completed Short Form 10 (SF10) Health Survey for children. 
The short-form 10 (SF-10) Health Survey for Children is a 10-item, 4-week recall, 
parent-completed health assessment that measures physical and psychosocial functioning 
for children ages five and over.  Specific domains include Physical Functioning (2 items), 
Role/Social Emotional-Behavioral (1 item), Role/Social Physical (1 item), Bodily Pain (1 
item), General Behavior (1 item), Mental Health (1 item), Self Esteem (2 items), and 
General Health Perceptions (1 item).  This instrument provides a brief, reliable, and 
scientifically valid health status measurement that is easy to administer and interpret. 
In addition to the SF10, specific questions will be asked regarding school days as 
follows: 
1. 
Within the past month, how many days of school were scheduled? (at Baseline 
only) 
 
or 
 
Since your baseline visit, how many days of school were scheduled? (at Week 4 
only) 
 
or 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
41 
 
 
Since your last clinic visit, how many days of school were scheduled? (all other 
assessment times) 
2. 
How many scheduled days of school were missed for any reason? 
3. 
Of these, how many days were missed because of symptoms of pulmonary arterial 
hypertension (PAH)? 
Subjects will record the days of school scheduled and missed on a patient diary card, 
which will be returned to the clinic at the scheduled visits. 
6.6. 
Pharmacogenetics 
Information regarding pharmacogenetic research is included in Appendix 3.  The 
IEC/IRB and, where required, the applicable regulatory agency must approve the PGx 
assessments before these can be conducted at the site.  The approval(s) must be in writing 
and will clearly specify approval of the PGx assessments (i.e., approval of X).  In some 
cases, approval of the PGx assessments can occur after approval is obtained for the rest of 
the study.  If so, then the written approval will clearly indicate approval of the PGx 
assessments is being deferred and the study, except for PGx assessments, can be initiated.  
When PGx assessments will not be approved, then the approval for the rest of the study 
will clearly indicate this and therefore, PGx assessments will not be conducted. 
7. 
DATA MANAGEMENT 
For this study, subject data will be entered into GSK defined electronic case report forms 
(eCRFs), transmitted electronically to GSK, and combined with data provided from other 
sources in a validated data system.   
Management of clinical data will be performed in accordance with applicable GSK 
standards and data cleaning procedures to ensure the integrity of the data, e.g., removing 
errors and inconsistencies in the data.  Adverse events and concomitant medications 
terms will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), 
and an internal validated medication dictionary, GSKDrug.  eCRFs (including queries 
and audit trails) will be retained by GSK, and copies will be sent to the investigator to 
maintain as the investigator copy.  In all cases, subject initials will not be collected or 
transmitted to GSK according to GSK policy. 
8. 
DATA ANALYSIS AND STATISTICAL CONSIDERATIONS 
8.1. 
Study Objectives 
The primary objective of this study is to evaluate the safety and tolerability of 
ambrisentan in the proposed paediatric PAH population.  Secondary objectives are to 
obtain supportive efficacy data (change from baseline in efficacy parameters) on the 
paediatric use of ambrisentan in PAH.  Other objectives are to determine the ambrisentan 
population pharmacokinetics in the paediatric population. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
42 
 
8.2. 
Study Design Considerations 
8.2.1. 
Sample Size Assumptions 
Due to the low prevalence of the disease in children, sample size was based on feasibility 
rather than formal power calculations.  Recruitment of approximately 66 subjects (33 per 
treatment group with no prespecified number in each age group/aetiology stratum) is felt 
to be achievable within a reasonable period of time (~ 2 years) minimizing any impact of 
changing practice on the conduct and interpretation of the study. 
8.2.2. 
Sample Size Sensitivity 
Since the sample size is based on feasibility and no formal hypothesis testing is planned, 
no sample size sensitivity calculations were performed. 
8.2.3. 
Sample Size Re-estimation 
No sample size re-estimation is planned for this study. 
8.3. 
Data Analysis Considerations 
8.3.1. 
Analysis Populations 
The Intention-to-Treat (ITT) Population will consist of all randomized subjects who 
received at least 1 dose of study drug.  For the ITT population, subjects were considered 
as belonging to their randomized treatment group, regardless of the actual dose of 
ambrisentan received.  The ITT population will be used in all efficacy summaries. 
The Safety Population is defined as all randomized subjects who received at least 1 dose 
of study drug.  Subjects were considered as belonging to the treatment group according to 
highest dose received.  The safety population will be used in all safety summaries. 
The Pharmacokinetic Population will consist of all randomized subjects from which a PK 
blood sample is obtained. 
8.3.2. 
Analysis Data Sets 
Analysis datasets will consist of all data collected in the study and evaluated according to 
the populations described in Section 8.3.1. 
PK analysis data will contain all plasma ambrisentan concentrations with appropriate 
corresponding dosing records.  Pharmacokinetic data from this study may be enriched 
with selected adult PK data to establish a structural PK model as described in 
Section 8.3.5.2. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
43 
 
8.3.3. 
Treatment Comparisons 
8.3.3.1. 
Primary Comparisons of Interest 
The primary comparison of interest will be between Low and High dose of Ambrisentan 
in terms of safety and tolerability during the treatment period as follows: 
• 
Adverse Events. 
• 
Serious Adverse Events. 
• 
Clinical laboratory parameters. 
• 
Physical examination (Including  height, weight, body mass index / body surface 
area, oxygen saturation, jugular venous pressure, liver size, and presence of 
peripheral oedema and/or ascites.) 
• 
Vital Signs. 
• 
Pubertal development (change from baseline in endocrinology assessments at Weeks 
12 and 24). 
8.3.3.2. 
Secondary Comparisons of Interest 
Secondary comparisons of interest will be the comparison of the two treatment groups in 
respect to the following: 
Phamacokinetics: 
• 
Population pharmacokinetic assessment based on one plasma sample per subject at 
Weeks 4, 8, 12, 16, 20, and 24. 
• 
Pharmacokinetic/pharmacodynamic modelling. 
Efficacy: 
• 
The change from baseline in 6 minute walking distance (6MWD) test  after 24 weeks 
• 
Mean changes from baseline in the 6MWD test at each Weeks 4, 8, 12, 16, and 20 
• 
Time to clinical worsening of PAH 
• 
The change from baseline in Subject Global Assessment to Week 24. 
• 
The change from baseline in WHO functional class to Week 24. 
• 
Change from baseline in plasma N-Terminal pro-B-type Natriuretic Peptide 
concentration at Week 24. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
44 
 
8.3.3.3. 
Exploratory Comparisons of Interest 
• 
The change from baseline in major prognostic factors based on echocardiograms:  
pericardial effusion, RA pressure, tricuspid annular plane systolic excursion 
(TAPSE), eccentricity index (systolic and diastolic), and right ventricular (RV) 
pressure by tricuspid regurgitant jet (TRJ) velocity to Week 24. 
8.3.3.4. 
Other Comparisons of Interest 
• 
Change from baseline in cardiopulmonary hemodynamics at Week 24 (a sub-study in 
subjects enrolled at centres where the collection of hemodynamic data is considered 
part of the standard of care), see Appendix 1. 
8.3.4. 
Interim Analysis 
There is no interim analysis planned for this study. 
8.3.5. 
Key Elements of Analysis Plan 
8.3.5.1. 
Safety Analyses 
All subjects who received at least one dose of study medication will be assessed for 
clinical safety and tolerability and will be denoted as the Safety population. 
Clinical interpretation will be based upon review of displays of adverse events, laboratory 
values, vital signs, body weight, pubertal development, and concomitant medications.  
Principal considerations in this evaluation of adverse events will be time to onset and 
investigator-reported relationship of either adverse events or laboratory abnormalities to 
study medication.  . For each laboratory test, the number and percentage of subjects with 
values above the reference range will be displayed for each treatment group and overall.  
Appropriate monitoring of safety data will be conducted throughout the conduct of the 
study. 
No formal statistical analysis is planned for safety parameters.  All data will be presented 
descriptively or graphically, by treatment group (Low and High) and overall.  Where data 
are available, it will be summarised by visit. 
8.3.5.2. 
Pharmacokinetic Analyses 
The objective of the pharmacokinetic analysis is to establish a population 
pharmacokinetic model adequate to describe the time-course and variability of plasma 
ambrisentan concentrations following repeat dosing in paediatric PAH patients.  The 
specific objectives are: 
1. To define a suitable structural PK model to characterize the PK of ambrisentan in 
paediatrics following oral administration. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
45 
 
2. To estimate the population pharmacokinetic parameters (e.g., absorption rate 
constant [ka], apparent volume of distribution [V/F] and apparent clearance [CL/F] 
of ambrisentan and their associated variability and precision. 
3. To evaluate the influence of available covariates (e.g., subject demographics, 
physiological factors, patient status, ambrisentan doses and concomitant 
medications) on the population pharmacokinetic parameters and their associated 
variability. 
The paediatric PK data may be enriched with selected adult PK data to establish a 
structural PK model.  PK data will be analyzed using the nonlinear mixed effects 
modeling program (NONMEM).  During each step in the model building process, 
improvements to the model will be assessed by evaluation of the agreement between the 
observed and predicted plasma concentrations, reductions in the range of weighted 
residuals, uniformity of the distribution of the weighted residuals versus the predicted 
concentrations about the line of identity, and increases in the precision of the parameter 
estimates, as well as reduction of the terms for inter-individual variability and random 
residual variability.  Assessment of the log likelihood ratio test will also be conducted as 
a means of assessing improvement in the model. 
Population PK analysis will be the responsibility of the Department of Clinical 
Pharmacology Modeling and Simulation (CPMS), Quantitative Sciences, 
GlaxoSmithKline. 
8.3.5.3. 
Pharmacokinetic/Pharmacodynamic Analyses 
The objective of the pharmacokinetic/pharmacodynamic (PK/PD) analysis is to evaluate 
the potential relationships between ambrisentan dose/exposure versus efficacy and/or 
safety measures in the paediatric patient population. 
PK/PD data will be graphically assessed initially and maybe further analyzed with the use 
of the nonlinear mixed effects modeling program (NONMEM).  Model selection will be 
conducted using the same criteria as described above for the PK analyses. Covariates 
examined during the development of the population PK model will also be evaluated to 
assess their effects on ambrisentan PK/PD. 
Population PK/PD analysis will be the responsibility of the Department of Clinical 
Pharmacology Modeling and Simulation (CPMS), Quantitative Sciences, 
GlaxoSmithKline. 
8.3.5.4. 
Efficacy Analyses 
All subjects from the ITT population will be included in the analysis of efficacy data. 
Given the small sample size, all efficacy data will be summarized descriptively 
(including 95% CI) and graphically.  Data will be summarised by treatment group (Low 
and High) and overall.  In addition, summary analysis of the difference between the Low 
and High dose will be performed. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
46 
 
The summary analysis will include:  
• 
mean change from baseline in the 6MWD after 24 weeks of therapy; 
• 
mean changes from baseline in 6MWD for Weeks 4, 8, 12 16, and 20; 
• 
mean time to clinical worsening of PAH; 
• 
change from baseline in Subject Global Assessment to Week 24; 
• 
change from baseline in WHO functional class to Week 24; 
• 
The change from baseline in major prognostic factors: pericardial effusion, right 
atrial (RA) pressure, tricuspid annular plane systolic excursion (TAPSE), and 
eccentricity index (systolic and diastolic) to Week 24 
• 
change from baseline in cardiopulmonary hemodynamics at Week 24; and  
• 
change from baseline in plasma NT-Pro BNP concentration at Week 24. 
• 
change form baseline in endocrinology assessments in male subjects at Weeks 12 
and 24. 
Time to clinical worsening will be presented graphically by Kaplan-Meier curves.  
Results will include the estimated hazard ratio, and confidence interval.  The hazard 
ratios will express the rate of event occurrence for the high dose ambrisentan group 
relative to the low dose ambrisentan group. 
Exploratory 
• 
The change from baseline in major prognostic factors to Week 24 by 
echocardiogram:  pericardial effusion, right atrial (RA) pressure, tricuspid annular 
plane systolic excursion (TAPSE), eccentricity index (systolic and diastolic), and 
right ventricular (RV) pressure by tricuspid regurgitant jet (TRJ) velocity. 
Other 
• 
Change from baseline in cardiopulmonary hemodynamics at Week 24 (a sub-study in 
subjects enrolled at centres where the collection of hemodynamic data is considered 
part of the standard of care); see Appendix 1. 
8.3.5.5. 
Health Outcomes Analyses 
Two sets of summary scores will be calculated based on responses to each item on the 
SF-10 Health Survey for Children (see Section 6.5): 
• 
Physical Health Summary (PHS-10); and 
• 
Psychosocial Summary (PSS-10). 
The mean change from Baseline in SF10 scores will be calculated at Weeks 4, 8, 12, 16, 
20, and 24. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
47 
 
8.3.5.6. 
Pharmacogenetic Analyses 
8.3.5.7. 
Novel Biomarker(s) Analyses 
The results of these biomarker investigations will be reported separately from the main 
clinical study report.  All endpoints of interest from all comparisons will be descriptively 
and/or graphically summarised as appropriate to the data. 
8.3.5.7.1. RNA Transcriptome Analysis 
RNA transcriptome profile data will first be normalized to enable direct comparison of all 
data sets.  Uninformative data (RNA species in all samples below detectable limits or 
levels unchanged across all samples under comparison) will be removed and multivariate 
statistical analyses will be performed on the remaining data to uncover intrinsic 
differences and similarities in the levels of RNAs between the different samples, and 
groups of samples.  Statistical tools such as Principal Component Analysis, PLS-
Discriminant Analysis, and ANOVA using either standard or customized software will be 
used for the profile analysis to assist identification of patterns/profiles which may 
associate with treatment outcome or PAH and medically related conditions. 
8.3.5.7.2. RNA Expression Analysis of a Subset of RNA Species 
RNA expression profile data are first normalised to enable direct comparison of all data 
sets.  After data reduction to remove uninformative data (RNAs whose levels are below 
levels of detection for all samples, and those whose levels are unchanged across all 
samples) the remaining data will be subject to a series of multivariate statistical analyses 
to uncover intrinsic differences and similarities in the levels of RNAs between the 
different samples.  This will include application of statistical tools such as Principal 
Component Analysis, and ANOVA using standard analysis software as well as software 
packages customised for such profile analysis to assist identification of patterns/profiles 
which may associate with treatment outcome and/or PAH. 
9. 
STUDY CONDUCT CONSIDERATIONS 
9.1. 
Posting of Information on Clinicaltrials.gov 
Study information from this protocol will be posted on clinicaltrials.gov before enrolment 
of subjects begins. 
9.2. 
Regulatory and Ethical Considerations, Including the 
Informed Consent Process 
Prior to initiation of a study site, GSK will obtain approval from the appropriate 
regulatory agency to conduct the study in accordance with applicable country-specific 
regulatory requirements, including those required under a US IND. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
48 
 
The study will be conducted in accordance with all applicable regulatory requirements. 
The study will be conducted in accordance with Good Clinical Practice (GCP), all 
applicable subject privacy requirements, and the ethical principles that are outlined in the 
Declaration of Helsinki 2008, including, but not limited to: 
• 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) review and 
approval of study protocol and any subsequent amendments. 
• 
Subject informed consent. 
• 
Investigator reporting requirements. 
GSK will provide full details of the above procedures, either verbally, in writing, or both. 
Written informed consent must be obtained from each subject prior to participation in the 
study. 
9.3. 
Quality Control (Study Monitoring) 
In accordance with applicable regulations, GCP, and GSK procedures, GSK monitors 
will contact the site prior to the start of the study to review with the site staff the protocol, 
study requirements, and their responsibilities to satisfy regulatory, ethical, and GSK 
requirements.  When reviewing data collection procedures, the discussion will include 
identification, agreement and documentation of data items for which the CRF will serve 
as the source document. 
GSK will monitor the study to ensure that the: 
• 
Data are authentic, accurate, and complete. 
• 
Safety and rights of subjects are being protected. 
• 
Study is conducted in accordance with the currently approved protocol and any other 
study agreements, GCP, and all applicable regulatory requirements. 
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents. 
9.4. 
Quality Assurance 
To ensure compliance with GCP and all applicable regulatory requirements, GSK may 
conduct a quality assurance audit of the site records, and the regulatory agencies may 
conduct a regulatory inspection at any time during or after completion of the study. In the 
event of an audit or inspection, the investigator (and institution) must agree to grant the 
auditor(s) and inspector(s) direct access to all relevant documents and to allocate their 
time and the time of their staff to discuss any findings/relevant issues. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
49 
 
9.5. 
Study and Site Closure 
Upon completion or termination of the study, the GSK monitor will conduct site closure 
activities with the investigator or site staff (as appropriate), in accordance with applicable 
regulations, GCP, and GSK Standard Operating Procedures. 
GSK reserves the right to temporarily suspend or terminate the study at any time for 
reasons including (but not limited to) safety issues, ethical issues, or severe non-
compliance.  If GSK determines that such action is required, GSK will discuss the 
reasons for taking such action with the investigator or head of the medical institution 
(where applicable).  When feasible, GSK will provide advance notice to the investigator 
or head of the medical institution of the impending action. 
If a study is suspended or terminated for safety reasons, GSK will promptly inform all 
investigators, heads of the medical institutions (where applicable),and/or institutions 
conducting the study.  GSK will also promptly inform the relevant regulatory authorities 
of the suspension/termination along with the reasons for such action.  Where required by 
applicable regulations, the investigator or head of the medical institution must inform the 
IRB/IEC promptly and provide the reason(s) for the suspension/termination. 
9.6. 
Records Retention 
Following closure of the study, the investigator or head of the medical institution (where 
applicable) must maintain all site study records (except for those required by local 
regulations to be maintained elsewhere) in a safe and secure location.  The records must 
be easily accessible when needed (e.g., for a GSK audit or regulatory inspection) and 
must be available for review in conjunction with assessment of the facility, supporting 
systems, and relevant site staff. 
Where permitted by local laws/regulations or institutional policy, some or all of the 
records may be maintained in a format other than hard copy (e.g., microfiche, scanned, 
electronic); however, caution must be exercised before such action is taken.  The 
investigator must ensure that all reproductions are legible and are a true and accurate 
copy of the original.  In addition, they must meet accessibility and retrieval standards, 
including regeneration of a hard copy, if required.  The investigator must also ensure that 
an acceptable back-up of the reproductions exists and that there is an acceptable quality 
control procedure in place for creating the reproductions. 
GSK will inform the investigator of the time period for retaining the site records in order 
to comply with all applicable regulatory requirements.  The minimum retention time will 
meet the strictest standard applicable to a particular site, as dictated by local 
laws/regulations, GSK standard operating procedures, and/or institutional requirements. 
The investigator must notify GSK of any changes in the archival arrangements, including, 
but not limited to archival of records at an off-site facility or transfer of ownership of the 
records in the event that the investigator is no longer associated with the site. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
50 
 
9.7. 
Provision of Study Results to Investigators, Posting to the 
Clinical Trials Register and Publication 
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity to review the complete study results at a GSK site or other mutually-
agreeable location. 
GSK will also provide the investigator with the full summary of the study results.  The 
investigator is encouraged to share the summary results with the study subjects, as 
appropriate. 
GSK will provide the investigator with the randomization codes for their site only after 
completion of the full statistical analysis. 
The results summary will be posted to the Clinical Study Register no later than 12 
months after the last subject’s last visit (LSLV) or sooner if required by legal agreement, 
local law or regulation. In addition, a manuscript will be submitted to a peer-reviewed 
journal for publication within 18 months of LSLV. When manuscript publication in a 
peer-reviewed journal is not feasible, further study information will be posted to the GSK 
Clinical Study Register to supplement the results summary.  
9.8. 
Independent Data Monitoring Committee (IDMC) 
An IDMC will be utilized in this study to ensure external objective medical and/or 
statistical review of safety and/or efficacy issues in order to protect the ethical and safety 
interests of subjects and to protect the scientific validity of the study.  The schedule of 
any planned interim analysis and the analysis plan for IDMC review is described in the 
charter, which is available upon request. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
51 
 
10. 
REFERENCES 
Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, 
McLaughlin VV. Medical therapy for pulmonary arterial hypertension: ACCP evidence-
based clinical practice guidelines. Chest. 2004 Jul;126(1 Suppl):35S-62S.  
Beghetti M, Hoeper MM, Kiely DG, Carlesen J, Schwierin B, Segal ES, Humbart M. 
Safety experience with bosentan in 146 children 2-11 years with pulmonary arterial 
hypertension: results from the European post-marketing surveillance program. Pediar 
Res. 2008;64(2):200-4. 
Cameron N.  Measuring maturity.  In: Hauspie R, Cameron N, Molinari L. (eds.) 
Methods in Human Growth Research. Cambridge: Cambridge University Press 2004 
Dingemanse J, van Giersbergen P. Clinical pharmacology of bosentan, a dual endothelin 
receptor antagonist. Clin Pharmacokinet. 2004;43(15):1089-1115.  
Fraisse A, Xavier J, Schliech JM, di Flippo S, Maragnes P, Beghetti M, Gressin V, 
Voisin M, Dauphin C, Clerson, Godart F, Bonnet D. Characteristics and prospective 2-
year follow-up of children with pulmonary arterial hypertension in France. Arch 
Cardiovasc Dis (2010), doi:10.1016/j.acvd.2009.12.001; in press  
Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. 
Cardiovasc Res. 2004;61:227–37.  
Galiè N, Hoeper MM, Humbert M. Torbicki A, Vachiery JL, Barbera JA, Beghetti M, et. 
al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 
2009; 34:1219-1263.  Co-published:  Eur Heart J. 2009; 30:2493-2537. 
Giaid A, Yanagisawa M, Langleben D Michel R, Levy R, Shennib H. Expression of 
endothelin-1 in the lungs of subjects with pulmonary hypertension. N Engl J Med 
1993;328:1732–9. 
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, 
Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun 
A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: 
results from a national registry. Am J Respir Crit Care Med. 2006 1;173(9): 1023-30. 
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension. N Eng J 
Med. 2004;351:1425-36. 
Krum H. New and emerging pharmacologic strategies in the management of chronic 
heart failure. Clin Cardiol 2000; 23(10): 724-730. 
Marshall WA and Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis 
Childh. 1969, 44: 291-303. 
Marshall WA and Tanner JM. Variations in pattern of pubertal changes in boys Arch Dis 
Child. 1970, 45: 13-23. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
52 
 
McLaughlin VV. Survival in subjects with pulmonary arterial hypertension treated with 
first-line bosentan. Eur J Clin Invest. 2006;36(Suppl. 3):10–15.  
Moledina S, Hislop A, Foster H, Schulze-Neick I, Haworth S. Childhood idiopathic 
pulmonary hypertension – A national cohort study. Heart 2010, in press.  
Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JGN, et al., 
Pulmonary Arterial Hypertension: Future Directions: Report of a National Heart, Lung 
and Blood Institute/Office of Rare Diseases Workshop. Circulation 2004; 109(24): 2947-
52. 
Nootens M, Kaufmann E, Rector T, Fisher C, Judd D, Francis G. Neurohormonal 
activation in subjects with right ventricular failure from pulmonary hypertension: relation 
to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995;26:1581–5.  
Rich S and Levy PS. The effect of high doses of calcium-channel blockers on survival in 
primary pulmonary hypertension.  N Eng J Med. 1992; 327(2):76-81.  
Segal E, Valette C, Oster L, Bouley L, Edfjall C, et. al. Risk management strategies in the 
postmarketing period – Safety experience with the US and EU bosentan surveillance 
programmes. Drug Safety.2005;28(11);971-980 
Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al., 
Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl 
S):5S-12S.  
Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term 
response to calcium channel blockers in idiopathic pulmonary arterial hypertension. 
Circulation. 2005;111(23):3105-11 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
53 
 
11. 
APPENDICES 
11.1. 
Appendix 1: Cardiopulmonary Hemodynamic Sub-study 
Hemodynamic assessments will be performed at baseline and Week 24 or early 
withdrawal in a subgroup of subjects enrolled in centres where the collection of 
hemodynamic data is considered part of the standard of care.  A ‘diagnostic catheter’ 
must have been done within 3 months prior to randomization or re-catheterisation, and no 
change in PAH targeted medication since the most recent hemodynamic assessment. 
Hemodynamic assessments will include: 
• 
heart rate; 
• 
mean blood pressure (systolic, diastolic); 
• 
mean pulmonary arterial pressure (PA; systolic, diastolic); 
• 
mean right atrial (RA) pressure; 
• 
left ventricular end diastolic pressure (LEVDP); or 
• 
pulmonary capillary wedge pressure (PCWP); 
• 
cardiac output; 
• 
cardiac index (calculated value); 
• 
arterial and mixed venous oxygen saturation (Record method used to calculate 
cardiac output measurement, if Fick’s principle was used it must be stated if 
oxygen consumptions is measured or assumed). 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
54 
 
11.2. 
Appendix 2: List of Highly Effective Methods for Avoidance 
of Pregnancy in Women of Childbearing Potential 
The following is the all inclusive list of the highly effective methods for avoiding 
pregnancy (i.e., have a failure rate of less than 1% per year).  
• Abstinence [Hatcher, 2004] 
• Combination Oral Contraceptive [Hatcher, 2004] 
• Injectable progestogen [Hatcher, 2004] 
• Implants of levonorgestrel [Hatcher, 2004] 
• Estrogenic vaginal ring [Hatcher, 2004] 
• Percutaneous contraceptive patches [Hatcher, 2004] 
• Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP 
effectiveness criteria as stated in the product label [Hatcher, 2004] 
• Male partner sterilization (vasectomy with documentation of azoospermia) prior 
to the female subject's entry into the study, and this male is the sole partner for 
that subject [Hatcher, 2004]. For this definition, “documented” refers to the 
outcome of the investigator's/designee’s medical examination of the subject or 
review of the subject's medical history for study eligibility, as obtained via a 
verbal interview with the subject or from the subject’s medical records. 
• Double barrier method: condom and an occlusive cap (diaphragm or 
cervical/vault caps) with a vaginal spermicidal agent 
(foam/gel/film/cream/suppository) [Trussell, 2003]  
Nonoxynol-9 is the critical component in most spermicides, and is regarded as an 
acceptable spermicidal agent. Concern has been raised that nonoxynol-9 damages 
the epithelial lining of the vagina, and exposure may facilitate transmission of 
viruses, particularly human immunodeficiency virus (HIV). The World Health 
Organization (WHO) conducted a technical consultation in October 2001 and 
concluded that the increased risk for such transmission was low to minimal 
[Trussell, 2003]. 
References 
Hatcher RA, Trussell J, Stewart F, Nelson AL, Cates W, Guest F, Kowal DD, editors. 
Contraceptive Technology. New York: Ardent Media, 2004: 226. Table 9-2, “% of 
Women Experiencing an Unintended Pregnancy During the First Year of Typical Use 
and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at 
the End of the First Year. United States”, column entitled, “% of Women Experiencing 
an Unintended Pregnancy Within the First Year of Use. Perfect Use”. 
Trussell J. Personal communication WHO/CONRAD Technical consultation on 
nonoxynol-9. WHO, Geneva, 9-10 October 2001. Summary Report. World Health 
Organization, 2003 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
55 
 
11.3. 
Appendix 3: Pharmacogenetic Research 
Pharmacogenetics – Background 
Pharmacogenetics (PGx) is the study of variability in drug response due to hereditary 
factors in different populations.  There is increasing evidence that an individual's genetic 
composition (i.e., genotype) may impact the pharmacokinetics (absorption, distribution, 
metabolism, and elimination), pharmacodynamics (relationship between concentrations 
and pharmacologic effects or the time course of pharmacologic effects) and/or clinical 
outcome (in terms of efficacy and/or safety and tolerability). Some reported examples of 
PGx analysis include: 
Drug 
Disease 
Gene 
Outcome 
Abacavir 
HIV [Hetherington, 2002; 
Mallal, 2002] 
HLA –B*5701 
Individuals with HLA-B*5701 variant 
may be at increased risk for 
experiencing hypersensitivity to 
abacavir. Clinical assays are 
available for HLA-B*5701 but none 
has been validated. HLA-B*5701 
screening would supplement but 
never replace abacavir clinical risk 
management strategies aimed at 
minimising rare but serious 
outcomes associated with abacavir 
hypersensitivity. 
Warfarin 
Cardiovascular  
[Neergard, 2006; 
Wilke, 2005] 
CYP2C9 
Serious adverse events (SAEs) 
experienced by some patients on 
warfarin may be explained by 
variations in the CYP2C9 gene that 
influences the degree of 
anticoagulation achieved.  
Irinotecan 
Cancer  
[FDA News Release, 2005] 
UGT1A1 
Variations in the UGT1A1 gene can 
influence a patient’s ability to break 
down irinotecan, which can lead to 
increased blood levels of the drug 
and a higher risk of side effects. A 
dose of irinotecan that is safe for 
one patient with a particular 
UGT1A1 gene variation, might be 
too high for another patient without 
this variation, raising the risk of 
certain side-effects.  
A genetic blood test (Invader 
UGT1A1 molecular assay) is 
available that can detect variations 
in the gene.     
 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
56 
 
A key component to successful PGx research is the collection of samples during the 
conduct of clinical studies. 
Collection of whole blood samples, even when no a priori hypothesis has been identified, 
may enable PGx analysis to be conducted if at any time it appears that there is a potential 
unexpected or unexplained variation in handling or response to ambrisentan.  
Pharmacogenetic Research Objectives 
The objective of the PGx research (if there is a potential unexpected or unexplained 
variation) is to investigate a possible genetic relationship to handling or response to 
ambrisentan.  If at any time it appears there is potential variability in response in this 
clinical study or in a series of clinical studies with ambrisentan that may be attributable to 
genetic variations of subjects, the following objectives may be investigated:  
• 
Relationship between genetic variants and the pharmacokinetics and/or 
pharmacodynamics of investigational product; 
• 
Relationship between genetic variants and safety and/or tolerability of investigational 
product; and  
• 
Relationship between genetic variants and efficacy of investigational product. 
Study Population 
Any subject who has given informed consent to participate in the clinical study, has met 
all the entry criteria for the clinical study, and receives investigational product may take 
part in the PGx research.  Any subject who has received an allogeneic bone marrow 
transplant must be excluded from the PGx research. 
Subject participation in the PGx research is voluntary and refusal to participate will not 
indicate withdrawal from the clinical study.  Refusal to participate will involve no penalty 
or loss of benefits to which the subject would otherwise be entitled. 
Study Assessments and Procedures 
Blood taken for pharmacokinetics will also be used for the PGx sample.  It is 
recommended that the first PK sample (Week 4) is used to prepare the PGx sample, but 
any of the PK samples can be used.  Full details of sample preparation are provided in the 
SPM. 
The PGx sample is labelled (or “coded”) with a study specific number that can be traced 
or linked back to the subject by the investigator or site staff.  Coded samples do not carry 
personal identifiers (such as name or social security number).  The blood sample is taken 
on a single occasion unless a duplicate sample is required due to inability to utilize the 
original sample.   


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
57 
 
The DNA extracted from the blood sample may be subjected to sample quality control 
analysis.  This analysis will involve the genotyping of several genetic markers to confirm 
the integrity of individual samples.  If inconsistencies are noted in the analysis, then those 
samples may be destroyed. 
The need to conduct PGx analysis may be identified after a study (or a set of studies) of 
ambrisentan has been completed and the study data reviewed. 
In some cases, the samples may not be studied. e.g., no questions are raised about how 
people respond to ambrisentan. 
Samples will be stored securely and may be kept for up to 15 years after the last subject 
completes the study or GSK may destroy the samples sooner.  GSK or those working 
with GSK (for example, other researchers) will use samples collected from the study for 
the purpose stated in this protocol and in the informed consent form.   
Subjects can request their sample to be destroyed at any time. 
Subject Withdrawal from Study 
If a subject who has consented to participate in PGx research and has a sample taken for 
PGx research withdraws from the clinical study for any reason other than lost to follow-
up, the subject will be given the following options: 
• 
The sample is retained for PGx research 
• 
Any PGx sample is destroyed. 
If a subject withdraws consent from the PGx research or requests sample destruction for 
any reason, the investigator must complete the appropriate documentation to request 
sample destruction within the timeframe specified by GSK and maintain the 
documentation in the site study records.  If the sample has already been processed, it will 
be destroyed after all steps are complete. GSK will ensure that any data related to the 
sample will not be analysed. The sample will be destroyed after processing is complete.  
Pharmacogenetics Analyses 
Generally GSK will utilize three approaches to explore genetic variation in drug 
response. 
1. Specific sections of DNA may be selected from areas of the genome (e.g., candidate 
genes) known to encode the drug target, drug metabolizing enzymes, areas 
associated with mechanisms underlying adverse events, and those linked to study 
disease and, thus, linked to drug response.  
The candidate genes that may be investigated in this study include the following: the 
GSK Absorption, Distribution, Metabolism and Excretion genes. These play a central 
role in drug pharmacokinetics and pharmacodynamics. In addition, continuing research 
may identify other enzymes, transporters, proteins or receptors that may be involved in 
response to ambrisentan.  The genes that may code for these proteins may also be studied. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
58 
 
2. By evaluating large numbers of polymorphic markers (e.g., single nucleotide 
polymorphisms or SNPs) throughout the genome, sets of markers may be identified 
that correspond to differential drug response.  
The results of PGx investigations will be reported either as part of the main clinical study 
report or as a separate report. All endpoints of interest from all comparisons will be 
descriptively and/or graphically summarised as appropriate to the data. In all cases, 
appropriate statistical methods will be used to analyse the genetic markers in the context 
of other clinical data. Statistical methods may include, but are not limited to Hardy-
Weinberg Equilibrium testing, Comparison of Demographic and Baseline Characteristics 
by Genotype, Evaluation of Genotypic Effects, Evaluation of Treatment by Genotype and 
Gene-Gene Interaction, Linkage Disequilibrium, Multiple Comparison and Multiplicity 
and/or Power and Sample Size Considerations. Detailed description of the analyses to be 
conducted will be documented in the Pharmacogenetics Reporting and Analysis Plan.   
3. Genome-wide scans involving a large number of polymorphic markers (e.g., single 
nucleotide polymorphisms) located throughout the genome. This approach is often 
employed when potential genetic effects are not well understood. 
Informed Consent 
Subjects who do not wish to participate in the PGx research may still participate in the 
clinical study.  PGx informed consent must be obtained prior to any blood being taken for 
PGx research. 
Provision of Study Results and Confidentiality of Subject’s PGx Data 
GSK may summarize the cumulative PGx research results in the clinical study report. 
In general, GSK does not inform the investigator, subject, or anyone else (e.g., family 
members, study investigators, primary care physicians, insurers, or employers) of the 
PGx research results that are not known to be relevant to the subject’s medical care at the 
time of the study, because the information generated from PGx studies is preliminary in 
nature, and the significance and scientific validity of the results are undetermined at such 
an early stage of research, under any circumstances unless required by law. 
References 
Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, 
Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses 
AD. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. 
Lancet. 2002; 359:1121-2. 
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte 
C, Maxwell D, James I.  Association between presence of HLA-B*5701, HLA-DR7, and 
HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.  
Lancet. 2002; 359:727-32. 
Neergard. Reducing the risk of blood thinners. Associated press, September 2006.  


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
59 
 
U.S. Food and Drug Administration, FDA Clears Genetic Test That Advances 
Personalized Medicine Test Helps Determine Safety of Drug Therapy 22 August 2005, 
http://www.fda.gov/bbs/topics/NEWS/2005/NEW01220.html.    
Wilke RA, Musana AK, Weber WW. Cytochrome P450 gene-based drug prescribing, 
and factors impacting translation into routine clinical practice. Personalized Med 2005; 2: 
213-224.   


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
60 
 
11.4. 
Appendix 4: Country Specific Requirements 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
61 
 
11.5. 
Appendix 5: Protocol Amendment 01 
Statement of Intent 
The intents of this amendment are to clarify procedural issues to insure a better global 
understanding of intent of the protocol and to open the long term extension study to those 
patients who have reached an endpoint in this study prior to week 24 but in whom 
continued treatment with ambrisentan is desirable. 
Amended Sections of the Protocol 
Deletions are noted in Italics 
Insertions are noted in bold face. 
Section 2.1.2.2 Efficacy 
Item 6 
Was: 
• 
Change from baseline in plasma brain natriuretic peptide (NT-Pro BNP) 
concentration at Week 24. 
Is: 
• 
Change from baseline in plasma N-terminal pro-B-type natriuretic peptide (NT-Pro 
BNP) concentration at Week 24. 
Section 3.1 – Study Design 
Was: 
Subjects who complete 24 weeks of treatment will be eligible to enrol into a long term 
follow-up study.   
Is: 
Subjects who participate in this study and in whom continued treatment with 
ambrisentan is desired will be eligible to enrol into a long term follow-up study.   


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
62 
 
Section 3.2 – Discussion of Design 
Last paragraph 
Was: 
However, to minimise bias, a person who is not involved in subject assessments will be 
designated at each investigation site to dispense the investigational product, to perform 
the subsequent compliance checks (i.e., pill counts), and to complete the InForm data 
entry.  Subjects and their parents or legal guardian will be asked not to comment on the 
treatment (e.g., no. of tablets taken) with the individual making the assessments.  
Therefore, the individual making the subjects assessments would be unbiased. 
Is: 
However, to minimise bias, a person who is not involved in subject assessments will be 
designated at each investigation site to dispense the investigational product and to 
perform the subsequent compliance checks (i.e., pill counts).  Subjects and their parents 
or legal guardian will be asked not to comment on the treatment (e.g., no. of tablets 
taken) with the individual making the assessments.  Therefore, the individual making the 
subjects assessments would be unbiased. 
Section 4.2 – Inclusion Criteria 
Item 4 
Was: 
Subjects must either be treatment naïve, have discontinued treatment with another ERA 
(e.g., bosentan) at least 1 month previously because of elevated liver function tests 
(LFTs), or have been on a stable dose of background treatment for PAH (e.g., sildenafil 
or prostacyclin) for at least one month prior to the Screening Visit.  Background 
treatment for PAH, if any, should not change from the Screening Visit until the end of all 
Treatment Period assessments. 
Is: 
Subjects must either be treatment naïve, have discontinued treatment with another ERA 
(e.g., bosentan) at least 1 month previously because of elevated liver function tests 
(LFTs), or have been on a stable dose of drug therapy for PAH (e.g., sildenafil or 
prostacyclin) for at least one month prior to the Screening Visit.  The baseline drug 
therapy for PAH, if any, should not change from the Screening Visit until the end of all 
Treatment Period assessments. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
63 
 
Rationale: 
The intent of the protocol was to ensure that subjects who were still symptomatic despite 
other PAH treatment (excluding another ERA) could enter the study, as long as the 
previous treatment was maintained throughout the study.  Some people interpreted 
“background treatment” to include only supportive therapy such as supplemental oxygen; 
therefore, the protocol is amended to make it clear that it is the baseline drug therapy 
targeted to PAH that is allowed and is not to be changed during the course of the study. 
Item 6 b 
Was: 
Child-bearing potential - has a negative pregnancy test and is not lactating at the 
Screening and Baseline/Randomisation Visits and agrees to use 2 reliable methods of 
contraception from the Screening Visit until study completion and for at least 30 days 
following the last dose of study drug (reliable methods of contraception are listed in 
Appendix 2. 
Is: 
Child-bearing potential - has a negative pregnancy test and is not lactating at the 
Screening and Baseline/Randomisation Visits and, if sexually active, agrees to use 2 
reliable methods of contraception from the Screening Visit until study completion and for 
at least 30 days following the last dose of study drug (reliable methods of contraception 
are listed in Appendix 2). 
Rationale: 
Abstinence is one of the acceptable methods of contraception listed in Appendix 2, and it 
makes no sense to require another form of contraception in subjects who are not sexually 
active. 
Section 4.4 – Withdrawal Criteria 
Was: 
Subjects who do not tolerate treatment or whose background targeted PAH therapy (i.e., 
PDE-5 or prostanoid) is changed will be withdrawn from the study.  Treatment for 
subjects withdrawn from the study will be implemented at the Investigator’s discretion 
and PAH guidelines. 
Subjects whose clinical condition deteriorates to the point that additional treatment is 
indicated prior to Week 24 will be considered as having completed the study at that point. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
64 
 
Is: 
Subjects who do not tolerate treatment or whose baseline drug therapy for PAH (i.e., 
PDE-5 or prostanoid) is changed will be withdrawn from the study.  Treatment for 
subjects withdrawn from the study will be implemented at the Investigator’s discretion 
and PAH guidelines. 
Subjects whose clinical condition deteriorates to the point that additional drug treatment 
is indicated (including increasing the baseline doses of targeted PAH therapy) prior to 
Week 24 will be considered as having completed the study at that point. 
Rationale: 
To clarify that increasing the dose from baseline of targeted PAH therapy meets the 
criteria of “additional drug treatment” and to be consistent with the amended wording in 
Section 4.2 item 4. 
Section 5.3 Blinding 
Was: 
This is an open label study.  It is not feasible to blind the study in the classical sense; 
however, to minimise bias, a person who is not involved in subject assessments will be 
designated at each investigation site to dispense the investigational product, to perform 
the subsequent compliance checks (i.e., pill counts), and to complete the InForm data 
entry.  Subjects and their parents or legal guardian will be asked not to comment on the 
treatment (e.g., no. of tablets taken) with the individual making the assessments.  
Therefore, the individual making the subjects assessments would be unbiased. 
Is: 
This is an open label study.  It is not feasible to blind the study in the classical sense; 
however, to minimise bias, a person who is not involved in subject assessments will be 
designated at each investigation site to dispense the investigational product and to 
perform the subsequent compliance checks (i.e., pill counts).  Subjects and their parents 
or legal guardian will be asked not to comment on the treatment (e.g., no. of tablets 
taken) with the individual making the assessments.  Therefore, the individual making the 
subjects assessments would be unbiased. 
After each subject has completed the study, the randomised treatment will be 
unblinded to the investigators to allow for informed dose adjustments and follow-up 
treatment as may be necessary 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
65 
 
Rationale 
Since the compliance data that are entered into InForm are only categorical estimates of 
the percent compliance, there is no reason for the unblinded person to physically enter 
those data into the system.  It is important that the investigator know which dose the 
patient was receiving to manage the patient’s care properly once the patient has 
completed the study. 
Section 5.7 – Treatment after the End of the Study 
Was 
Patients who complete 24 weeks of treatment will be eligible to enrol into a long term 
follow-up study. 
Is 
Patients who participate in the study and in whom continued treatment with 
ambrisentan is desired will be eligible to enrol into a long term follow-up study. 
Rationale 
Subjects could complete the study prior to week 24 (e.g., if additional PAH treatment or 
if a dose adjustment to their baseline PAH drug therapy is necessary).  In some of these 
patients, it might be desirable to continue treatment with ambrisentan and add or change 
the dose of other targeted PAH treatment.  
Section 6.2.2 – Electrocardiogram / Echocardiogram 
Was: 
A 12-lead ECG will be performed at Baseline and at Weeks 12 and 24 (or early 
withdrawal), and Follow-up.  Any changes since the Screening Visit felt to be significant 
in the medical and scientific judgement of the investigator are to be recorded as AEs or 
SAEs in the eCRF. 
Is: 
A 12-lead ECG will be performed at Baseline and at Weeks 12 and 24 (or early 
withdrawal), and Follow-up.  Any changes since Baseline felt to be significant in the 
medical and scientific judgement of the investigator are to be recorded as AEs or SAEs in 
the eCRF. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
66 
 
Section 6.2.4 – Pubertal Development Assessment 
Was: 
Pubertal development in male and female subjects will be assessed at baseline, Week 12, 
and Week 24 or early termination by a paediatric endocrinologist using Tanner criteria 
[Cameron, 2004].  In male subjects, testicular volume will be assessed by Prader’s 
orchidometer. 
Is: 
Pubertal development in male and female subjects will be assessed at baseline, Week 12, 
and Week 24 or early termination using Tanner criteria [Marshall, 1969; 
Marshall, 1970; Cameron, 2004].  In male subjects, testicular volume will be assessed 
by Prader’s orchidometer.  These assessments will be performed by a paediatric 
endocrinologist or another individual with comparable experience employing the 
Tanner criteria and Prader’s orchidometer.  Preferably, the same assessor will 
evaluate an individual subject at each assessment time. 
Rationale: 
“Paediatric endocrinologist” is not a recognized speciality in all territories.  The intent is 
that the person performing these assessments be someone who is competent and 
experienced with using the Tanner criteria and Prader’s orchidometer.  In some centres, 
the individual who has that experience might not have the title “paediatric 
endocrinologist”. 
Section 6.3 – Pharmacokinetics 
Was 
Blood samples for pharmacokinetic analysis of ambrisentan will be collected at the time 
points indicated in Table 2.  The actual date and time of each blood sample collection 
will be recorded in the GSK-defined eCRF.  The exact time of dosing on the day of the 
visit, 1 day prior to the visit and 2 days prior to the visit will be recorded in the eCRF by 
having the subject return a medication card on which this information is recorded. 
Is 
Blood samples for pharmacokinetic analysis of ambrisentan will be collected at the time 
points indicated in Table 2.  The actual date and time of each blood sample collection 
will be recorded in the GSK-defined eCRF.  The exact time of dosing on the day of the 
visit, 1 day prior to the visit and 2 days prior to the visit will be recorded in the eCRF by 
having the subject return a patient diary card on which this information is recorded. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
67 
 
Section 6.4.5 
Heading 
Was: 
Change from baseline plasma brain natriuretic peptide (NT-Pro BNP) at Week 24 
Is: 
Change from baseline plasma N-terminal pro-B type natriuretic peptide (NT-Pro BNP) 
at Week 24 
Section 6.5 – Health Outcomes 
Was: 
In addition to the SF10, specific question will be asked regarding school days as follows: 
1. 
Within the past month, how many days of school were scheduled?  
2. 
How many days of school were missed for any reason? 
3. 
How many days of school were missed because of pulmonary arterial 
hypertension (PAH)? 
Is: 
In addition to the SF10, specific question will be asked regarding school days as follows: 
1. 
Within the past month, how many days of school were scheduled? (at Baseline 
only) 
 
or 
 
Since your baseline visit, how many days of school were scheduled? (at Week 
4 only) 
 
or 
 
Since your last clinic visit, how many days of school were scheduled? (all 
other assessment times) 
2. 
How many scheduled days of school were missed for any reason? 
3. 
Of these, how many days were missed because of symptoms of pulmonary 
arterial hypertension (PAH)? 
Subjects will record the days of school scheduled and missed on a patient diary 
card, which will be returned to the clinic at the scheduled visits. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
68 
 
Rationale: 
To clarify that the number of days missed in question 2 is inclusive of the days missed in 
question 3 and to differentiate between days missed because of clinic visits and days 
missed because of symptoms of the disease. 
Section 8.3.3.2  Secondary Comparisons of Interest 
Efficacy bullet item 6 
Was: 
• 
Change from baseline in plasma brain natriuretic peptide (BNP or N-Terminal pro-
B-type Natriuretic Peptide) concentration at Week 24. 
Is: 
• 
Change from baseline in plasma NT-Pro BNP concentration at Week 24. 
Section 8.3.5.4  Efficacy Analyses 
Item 8 
Was: 
• 
change from baseline in plasma BNP concentration at Week 24 
Is: 
• 
change from baseline in plasma NT-Pro BNP concentration at Week 24 
Table 1 – Time and Events Table 
Change “Patient Global Assessment (SF10)” to “Health Outcomes Assessments” 
Add a foot note for “Health Outcomes Assessments” as follows: “SF 10 and a record of 
school days scheduled and missed.  Two diary cards will be given to the subject at 
Baseline, and one diary card will be given to the subject at Weeks 4, 8, 12, 16, 20 and 
24 on which to record the number of school days scheduled, the number missed for 
any reason, and the number missed because of symptoms of PAH.  One baseline 
diary card will be completed and returned during the visit.  The other baseline diary 
card should be returned at the Week 4 visit.  All other diary cards will be returned 
at the next visit.  Data from all diary cards will be transcribed into the eCRF.” 
To footnote for “Plasma Sample for Population Pharmacokinetic Assessment” add “A 
diary card will be given to the subject at Baseline to record date and time of study 
medication dosing 2 days prior to and 1 day prior to the Week 4 visit and at Weeks 
4, 8, 12, and 20 to record date and time of study medication dosing 2 days prior to 
and 1 day prior to the next visit.  At Week 16, a diary card will be given to the 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
69 
 
subject to record the date and time of study medication dosing 2 days prior to, 1 day 
prior to and on the day of the Week 20 visit.  The diary card given out at Baseline 
should be returned at the Week 4 visit.  All other diary cards will be returned at the 
next visit.  The dates and times of study medication dosing will be transcribed into 
the eCRF.  Subjects will have the option to receive a reminder SMS message on the 
days they should complete the diary card and to remind them of their next visit 
date.” 
Footnote for “Pubertal Development Assessment” 
Was: 
Pubertal development in male and female subjects will be assessed by a paediatric 
endocrinologist using Tanner criteria.  In male subjects, testicular volume will be 
assessed using Prader’s orchidometer.  In addition, blood samples will be obtained to 
measure follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, sex 
hormone binding globulin (SBGH) and inhibin B levels. 
Is: 
Pubertal development in male and female subjects will be using Tanner criteria.  In male 
subjects, testicular volume will be assessed using Prader’s orchidometer.  In addition, 
blood samples will be obtained to measure follicle-stimulating hormone (FSH), 
luteinizing hormone (LH), testosterone, sex hormone binding globulin (SBGH) and 
inhibin B levels. 
Rationale 
To be consistent with the text of the protocol and to clarify the use of patient diary cards. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
70 
 
11.6. 
Appendix 6: Protocol Amendment 02 
Statement of Intent 
The intents of this amendment are to clarify procedural issues to insure a better global 
understanding of intent of the protocol and to correct that it is hepatitis B surface antigen 
that is being assessed as part of the exclusion criteria. 
Amended Sections of the Protocol 
Deletions are noted in Italics 
Insertions are noted in bold face. 
Sponsor Information Page 
Was 
Sponsor Medical Monitor Contact Information: 
 
 FRCS 
Clinical Development Physician 
MDC Clinical Metabolic EU 
GlaxoSminthKline  
Stockley Park 
Sponsor Serious Adverse Events (SAE) Contact Information:  
Regulatory Agency Identifying Number(s):  EudraCT 2010-019547-19 
Is 
Sponsor Medical Monitor and Serious Adverse Events (SAE) Contact Information: 
 
 FRCS 
Clinical Development Physician 
MDC Clinical Metabolic EU 
GlaxoSminthKline  
Stockley Park 
Regulatory Agency Identifying Number(s):  EudraCT 2010-019547-19 
 
 
 
 
 
 
US IND 64,915 
Rationale 
To confirm that for the sites in the US, the study is being conducted under a US IND and 
that the Medical Monitor and SAE contact are the same person. 
PPD
PPD


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
71 
 
Table 1 – Time and Events Table 
Footnote 12 
Was 
12.  Hepatitis B surface antibody and hepatitis C antibody (if hepatitis C antibody 
positive, a hepatitis C RIBA immunoblot assay should be reflexively performed on the 
same sample to confirm the result). 
Is 
12.  Hepatitis B surface antigen and hepatitis C antibody (if hepatitis C antibody positive, 
a hepatitis C RIBA immunoblot assay should be reflexively performed on the same 
sample to confirm the result). 
Rationale 
Antibody was a mistake.  The intent was to assess the hepatitis B surface antigen, and the 
line item in the table to which the footnote applied correctly listed “HBsAg” 
Section 4.3  Exclusion Criteria 
Item 6 
Was 
6.  Subjects with diagnosis of active hepatitis (hepatitis B surface antibody and hepatitis 
C antibody), or clinically significant hepatic enzyme elevation (i.e., ALT, AST or AP 
>3xULN) at Screening. 
Is 
6.  Subjects with diagnosis of active hepatitis (hepatitis B surface antigen and hepatitis C 
antibody), or clinically significant hepatic enzyme elevation (i.e., ALT, AST or AP 
>3xULN) at Screening. 
Rationale 
Antibody was a mistake.  The intent was to assess the hepatitis B surface antigen, and the 
line item in the time and events table correctly listed “HBsAg”. 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
72 
 
11.7. 
Appendix 7: Protocol Amendment 03 
Statement of Intent 
The intents of this amendment are to add oestrogen and remove testosterone from 
laboratory assessments being conducted on female subjects and to align the storage 
conditions requirements in the protocol with those that are printed on the study 
medication package. 
Amended Sections of the Protocol 
Deletions are noted in Italics 
Insertions are noted in bold face. 
In Section 5.1  Investigational Product and Reference Therapy 
Was: 
Study medication will be stored in secure (locked) areas at a temperature between 15° 
and 30°C and dispensed according to the protocol under the supervision of the 
Investigator or his/her designee.   
Is 
Study medication will be stored in secure (locked) areas at a temperature below 30°C and 
dispensed according to the protocol under the supervision of the Investigator or his/her 
designee.   
Table 1 – Time and Events Table 
Footnote 11 
Was 
11. 
Pubertal development in male and female subjects will be assessed using Tanner 
criteria.  In male subjects, testicular volume will be assessed using Prader’s orchidometer.  
In addition, blood samples will be obtained to measure follicle-stimulating hormone 
(FSH), luteinizing hormone (LH), testosterone, sex hormone binding globulin (SBGH) 
and inhibin B levels. 
Is 
11. 
Pubertal development in male and female subjects will be assessed using Tanner 
criteria.  In male subjects, testicular volume will be assessed using Prader’s orchidometer, 
and blood samples will be obtained to measure follicle-stimulating hormone (FSH), 
luteinizing hormone (LH), testosterone, sex hormone binding globulin (SHBG) and 


RM2010/00053/03 
CONFIDENTIAL 
 
 
 
AMB112529 
 
73 
 
inhibin B levels.  In female subjects, blood samples will be obtained to measure FSH, 
LH, oestrogen, SHBG and inhibin B levels. 
In Section 6.2.4  Pubertal Development Assessment 
Was: 
In addition, follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, 
sex hormone binding globulin (SHBG), and inhibin B levels will be assessed at baseline, 
Week 12, and Week 24 or early withdrawal.  
Is: 
In addition, follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone 
(in male subjects only), oestrogen (in female subjects only), sex hormone binding 
globulin (SHBG), and inhibin B levels will be assessed at baseline, Week 12, and Week 
24 or early withdrawal.  

SAP_000.pdf: 
CONFIDENTIAL
GlaxoSmithKline group of companies
AMB112529
1
Division: World Wide Development
Retention Category: GRS019
Information Type: Reporting and Analysis Plan
Title:
Reporting and Analysis Plan for AMB112529:
A randomized, open label study comparing safety and efficacy
parameters for a high and a low dose of ambrisentan (adjusted
for body weight) for the treatment of pulmonary arterial
hypertension in paediatric patients aged 8 years up to 18 years.
Compound Number:
GSK1325760
Effective Date:
22-MAY-2018
Description: This document outlines the safety and efficacy reporting planned for 
protocol AMB112529 by GlaxoSmithKline (GSK).
Identifier/Version Number:  Version 1.0
Subject: GSK1325760, Pulmonary Artery Hypertension; Reporting; Tables, Figures, 
Listings (TFLs)
Author’s Name, Title and Functional Area:
 Managing Director, 
Hartington Statistics and Data Management Ltd. 
Approved by: 
Director,
Clinical Statistics
Date
22-MAY-2018
Copyright 2018 the GlaxoSmithKline group of companies. All rights reserved.  
Unauthorised copying or use of this information is prohibited.
PPD
PPD


CONFIDENTIAL
AMB112529
2
TABLE OF CONTENTS
PAGE
ABBREVIATIONS ...........................................................................................................5
1.
INTRODUCTION......................................................................................................7
2.
STUDY OBJECTIVE(S) AND ENDPOINT(S) ...........................................................7
2.1.
Study Objective(s) ........................................................................................7
2.1.1.
Primary Objective ..........................................................................7
2.1.2.
Secondary Objectives....................................................................7
2.2.
Study Endpoint(s) .........................................................................................7
2.2.1.
Primary Endpoints .........................................................................7
2.2.2.
Secondary Endpoints.....................................................................7
2.2.2.1.
Pharmacokinetics .........................................................7
2.2.2.2.
Efficacy.........................................................................7
2.2.2.3.
Exploratory ...................................................................8
2.2.2.4.
Other ............................................................................8
2.3.
Statistical Hypotheses...................................................................................8
2.4.
Pharmacokinetic (PK) and PK/Pharmacodynamic (PD) hypotheses .............8
3.
STUDY DESIGN ......................................................................................................8
3.1.
Randomisation..............................................................................................8
4.
PLANNED ANALYSES ............................................................................................9
4.1.
Interim Analyses ...........................................................................................9
4.2.
Final Analysis ...............................................................................................9
4.2.1.
Changes in the conduct of the study or planned analyses .............9
5.
SAMPLE SIZE CONSIDERATIONS.......................................................................10
6.
ANALYSIS POPULATIONS ...................................................................................10
7.
TREATMENT COMPARISONS..............................................................................10
7.1.
Data Display Treatment and Other Sub-group Descriptors .........................10
8.
GENERAL CONSIDERATIONS FOR DATA ANALYSES.......................................10
8.1.
Examination of Subgroups..........................................................................10
9.
DATA HANDLING CONVENTIONS .......................................................................10
9.1.
Premature Withdrawal and Missing Data ....................................................11
9.1.1.
Missing Efficacy Outcomes Data .................................................11
9.1.2.
Missing AE data...........................................................................11
9.1.3.
Missing Dates (other than for AEs) ..............................................11
9.1.4.
Missing Items on SF-10 ...............................................................12
9.2.
Derived and Transformed Data...................................................................12
9.2.1.
Baseline.......................................................................................12
9.2.2.
Change from baseline and percentage change from 
baseline .......................................................................................13
9.2.3.
WHO FC change from baseline categorisation 1 .........................13
9.2.4.
WHO FC class change from baseline categorisation 2 ................13
9.2.5.
Study Day....................................................................................13


CONFIDENTIAL
AMB112529
3
9.2.6.
Age Calculation............................................................................14
9.2.7.
Duration of Exposure ...................................................................14
9.2.8.
Transformations for Efficacy Outcomes .......................................14
9.2.9.
Treatment Compliance Rates ......................................................14
9.3.
Assessment Windows.................................................................................15
9.4.
Values of Clinical Concern..........................................................................15
9.4.1.
Laboratory Parameters ................................................................15
9.4.2.
Vital Signs....................................................................................17
10. STUDY POPULATION...........................................................................................17
10.1.
Disposition of Subjects................................................................................17
10.2.
Protocol Deviations.....................................................................................17
10.3.
Demographic and Baseline Characteristics.................................................17
10.4.
Medical Conditions .....................................................................................18
10.5.
Prior and Concomitant Medications ............................................................18
10.6.
Treatment Compliance................................................................................19
10.7.
Long-Term Study (AMB 114588) ................................................................19
11. SAFETY ANALYSES .............................................................................................19
11.1.
Extent of Exposure .....................................................................................19
11.2.
Adverse Events...........................................................................................19
11.3.
Adverse Events Leading to Discontinuation of Investigational 
Product and/or Withdrawal from the Study and Other Significant 
Adverse Events...........................................................................................20
11.4.
Deaths and Serious Adverse Events...........................................................20
11.5.
Adverse Events of Special Interest .............................................................20
11.6.
Non-serious Adverse Events.......................................................................21
11.7.
Clinical Laboratory Evaluations...................................................................21
11.8.
Liver Events................................................................................................21
11.9.
Vital Signs...................................................................................................21
11.10. Physical Examination..................................................................................21
11.11. 12-Lead ECG..............................................................................................22
11.12. Endocrinology.............................................................................................22
11.13. Pregnancies (as applicable)........................................................................22
12. EFFICACY ANALYSES..........................................................................................22
12.1.
Exploratory analyses ..................................................................................23
12.2.
Other analyses ...........................................................................................23
13. CLINICAL PHARMACOLOGY DATA ANALYSES..................................................23
13.1.
Pharmacokinetic Analyses..........................................................................23
13.2.
Pharmacodynamic Analyses.......................................................................23
13.3.
Pharmacokinetic/Pharmacodynamic Analyses............................................23
14. BIOMARKER DATA ANALYSIS.............................................................................23
15. PHARMACOGENETIC DATA ANALYSES.............................................................23
16. VIRAL GENOTYPING/PHENOTYPING .................................................................24
17. REFERENCES.......................................................................................................24
18. ATTACHMENTS ....................................................................................................25


CONFIDENTIAL
AMB112529
4
18.1.
Table of Contents for Data Display Specifications.......................................25
18.1.1.
Tables..........................................................................................25
18.1.2.
Listings ........................................................................................31
18.1.3.
Figures ........................................................................................35
18.2.
Data Display Specifications ........................................................................38
19. APPENDICES......................................................................................................145
19.1.
Appendix 1 – IDSL Age Calculation ..........................................................145


CONFIDENTIAL
AMB112529
5
ABBREVIATIONS
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
ATC
Anatomical Therapeutic Chemical
DBF
Database Freeze 
eCRF
Electronic case report form
ECG
electrocardiogram
GSK
GlaxoSmithKline 
IDMC
Independent Data Monitoring Committee
IP
Investigational product
ITT
Intent-to-Treat
MedDRA
Medical Dictionary for Regulatory Activities
6MWD
6 minute walking distance
NT-Pro BNP
N-terminal pro-B-type natriuretic peptide 
PAH
pulmonary arterial hypertension
PD
pharmacodynamic
PK
pharmacokinetic
PT
Preferred Term
RA
Right Atrial
RAP
Reporting and Analysis Plan
RUCAM
Roussel Uclaf Causality Assessment Method
RV
Right Ventricular
SAE
Serious Adverse Event
SAS
Statistical Analysis System 
SD
Standard deviation
SOC
System Organ Class
TAPSE
Tricuspid Annular Plane Systolic Excursion
TFLs
Tables, Figures, Listings 
TRJ
Tricuspid Regurgitant Jet
WHO
World Health Organization


CONFIDENTIAL
AMB112529
6
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companies
Trademarks not owned by the 
GlaxoSmithKline group of companies
AMBRISENTAN
Adcirca
FLOLAN
C RIBA
Letairis
NONMEM
Remodulin
Revatio
Thelin
Tracleer
Ventavis
Viagra


CONFIDENTIAL
AMB112529
7
1.
INTRODUCTION
This Reporting and Analysis Plan (RAP) outlines the safety and efficacy reporting 
planned for protocol AMB112529 for provision to GSK. 
In this RAP, reference is made to the protocol AMB112529 dated 2nd February 2011, and 
subsequent amendments.
2.
STUDY OBJECTIVE(S) AND ENDPOINT(S)
2.1.
Study Objective(s)
2.1.1. Primary Objective
The primary objective is the safety and tolerability of ambrisentan in the paediatric 
pulmonary arterial hypertension (PAH) population.
2.1.2. Secondary Objectives
The secondary objectives are the pharmacokinetics and efficacy of ambrisentan in the 
paediatric pulmonary arterial hypertension (PAH) population.
2.2.
Study Endpoint(s)
2.2.1. Primary Endpoints

Adverse Events.

Serious Adverse Events.

Clinical laboratory parameters.

Physical examination 

Vital Signs.

Pubertal development (change from baseline in endocrinology assessments at 
Weeks12 and 24).
2.2.2. Secondary Endpoints
2.2.2.1.
Pharmacokinetics

Population pharmacokinetic assessment based on one plasma sample per subject 
at Weeks 4 (trough), 8 (0.5 to 4 hours post-dose), 12 (trough), 16 (0.5 to 4 hours 
postdose), 20 (4 to 22 hours post-dose), and 24 (trough).

Pharmacokinetic/pharmacodynamic modelling.
2.2.2.2.
Efficacy

The change from baseline in the 6 minute walking distance (6MWD) test 
evaluated after 24 weeks of therapy.

Mean changes from baseline in the 6MWD test at Weeks 4, 8, 12, 16, and 20.

The time to clinical worsening of PAH.


CONFIDENTIAL
AMB112529
8

The change from baseline in Subject Global Assessment to Week 24 using the 
SF-10 health survey for children.

The change from baseline in World Health Organization (WHO) functional class 
to Week 24.

Change from baseline in plasma N-Terminal pro-B-type Natriuretic Peptide (NT-
Pro BNP) concentration at Week 24.

School days missed due to PAH. (Note that this is not defined as an efficacy 
endpoint in the protocol but has been added to the RAP.) 
2.2.2.3.
Exploratory

The change from baseline in major prognostic factors based on echocardiogram:
pericardial effusion, right atrial (RA) pressure, tricuspid annular plane systolic
excursion (TAPSE), eccentricity index (systolic and diastolic), and right 
ventricular (RV) pressure by tricuspid regurgitant jet (TRJ) velocity to Week 24.
2.2.2.4.
Other

Change from baseline in cardiopulmonary hemodynamics at Week 24 (a sub-
study in subjects enrolled at centres where the collection of hemodynamic data is 
considered part of the standard of care).
2.3.
Statistical Hypotheses
No formal hypothesis is planned.
2.4.
Pharmacokinetic (PK) and PK/Pharmacodynamic (PD) 
hypotheses
Any statistical hypothesis relating to the pharmacokinetic endpoints will be described in a 
separate RAP. The analysis will be the responsibility of the Department of Clinical 
Pharmacology Modeling and Simulation (CPMS), Quantitative Sciences, GSK.
3.
STUDY DESIGN
This study is a 6-month (24-week), randomized, open label evaluation of the safety, 
tolerability and efficacy of a high and low dose ambrisentan (adjusted for body weight) in 
66 subjects (33 per treatment group) aged 8 years up to 18 years with PAH. The study 
will include a screening/baseline period and a treatment period. The treatment period will 
be 24 weeks or until the subject’s clinical condition deteriorates to the point that 
alternative/additional treatment is necessary. Subjects who participate in the study will be 
eligible to enrol into study AMB 114588. 
For further details regarding the study design, please refer to the protocol.
3.1.
Randomisation
All subjects who meet the inclusion and exclusion criteria will be randomized to one of
two dose groups (Low dose or High dose, based on body weight) of
ambrisentan according to a computer-generated randomisation schedule. 


CONFIDENTIAL
AMB112529
9
Body Weight
Low Dose
High Dose
>=50kg
5 mg
10 mg
>=35 and <50 kg
5 mg
7.5 mg
>=20 and <35 kg
2.5 mg
5 mg
To ensure balance with respect to the number of patients assigned to each treatment 
group, the allocation schedule will be generated in blocks. Each subject will be assigned 
to a pack number according to the predefined randomisation list. A central Interactive 
Voice Response System (IVRS) will be used for treatment assignment.
Randomization will be stratified by the age groups 8 years up to 11 years and 12 years up
to 18 years and by aetiology of PAH as follows:-

idiopathic;

heritable [familial];

secondary to connective tissue disease; and

persistent despite surgical repair of atrial septal defects, ventricular septal defects, 
atrio-ventricular septal defects, and persistent patent ductus.
Subjects will be assigned to study treatment in accordance with the randomization
schedule.
4.
PLANNED ANALYSES
4.1.
Interim Analyses
The interim analyses conducted by the Independent Data Monitoring Committee (IDMC) 
are planned for this study.  These analyses are described in a dedicated IDMC RAP.
To facilitate the communication between GSK and regulatory agency, an interim analysis 
was added post the finalization of the study protocol. For data collected up until January 
2018, all safety, tolerability, pharmacokinetics and efficacy data will be reviewed, 
analysed and summarised.
4.2.
Final Analysis
This analysis plan outlines the final analysis that will be performed on the safety and 
efficacy endpoints of this study, once Database Freeze (DBF) has taken place.  
4.2.1. Changes in the conduct of the study or planned analyses
The final analyses were as planned in the protocol except for the following:-

Protocol, Section 8.3.5.4 states summary analysis of the differences between Low 
and High groups will be performed.  However, due to low subject numbers, this is 
not presented in this RAP.  

School days missed due to PAH has been added to the RAP. 


CONFIDENTIAL
AMB112529
10
5.
SAMPLE SIZE CONSIDERATIONS
Due to the low prevalence of the disease in children, sample size was based on feasibility 
rather than formal power calculations. Recruitment of approximately 66 subjects (33 per 
treatment group with no prespecified number in each age group/aetiology stratum) is felt 
to be achievable within a reasonable period of time (~ 2 years) minimizing any impact of 
changing practice on the conduct and interpretation of the study.
6.
ANALYSIS POPULATIONS
The Intent-to-Treat (ITT) Population will consist of all randomized subjects who received 
at least 1 dose of study drug. For the ITT population, subjects were considered as 
belonging to their randomized treatment group, regardless of the actual dose of 
ambrisentan received. The ITT population will be used in all efficacy summaries. 
The Safety Population is defined as all randomized subjects who received at least 1 dose 
of study drug. Subjects were considered as belonging to the treatment group according to 
highest dose received. The safety population will be used in all safety summaries.
7.
TREATMENT COMPARISONS
Treatment comparisons will be between low dose and high dose ambrisentan, by way of 
summary tables, figures and listings.
7.1.
Data Display Treatment and Other Sub-group Descriptors
In the study report data displays, the treatment group descriptors will be the following:

  Ambrisentan Low Dose

  Ambrisentan High Dose
8.
GENERAL CONSIDERATIONS FOR DATA ANALYSES
All programming of tables, figures and listings will be performed using Statistical 
Analysis System (SAS) version 8.2 or higher.
8.1.
Examination of Subgroups
Selected safety and efficacy outputs will be produced by age strata (8-11, 12-18 years).
Selected outputs will also be produced for patients enrolled at centres in Japan to support 
registration activities.
9.
DATA HANDLING CONVENTIONS
All data displays will be presented according to the GSK’s Integrated Data Standards 
Library (IDSL) statistical display principles. The file extension used for landscape tables 
and listings will be L10, with point size of 10, line size of 108 and 43 lines per page.  


CONFIDENTIAL
AMB112529
11
Where data are sparse, empty tables may be produced with the “Data too sparse for table 
to be produced” or “No Data to Report” or similar.
All data collected on the electronic case report form (eCRF) will be listed. Data collected 
outside of the eCRFs (eg. labs, SF10) will also be listed. All listings will be presented by 
treatment group, centre identification and subject identification number.
9.1.
Premature Withdrawal and Missing Data
Subjects who withdraw from the study prior to Week 24 will not be replaced and all 
information obtained from them will be included in the summaries.
9.1.1. Missing Efficacy Outcomes Data 
No imputation will be made for any missing numerical data, unless otherwise specified.
Missing data will generally not be considered in the calculation of percentages (i.e., the 
denominator will not include subjects who have missing data at a given time point).
9.1.2. Missing AE data 
Where a start date for an adverse event (AE) is partial or missing, the following 
imputation rules will be applied: 

If day portion is missing, set day to 1.

If month portion is missing, set month to January.

If the date is completely missing, or if the date imputed using the above rules is prior 
to the first dose date, set the date to first dose date.
Where an end date for an AE is partial or missing, the following imputation rules will be 
applied.  These will only be applied to AEs that are resolved; if they are not resolved then 
nothing will be imputed. 

If day portion is missing, set day to the last day of the month.

If month portion is missing, set month to December. 

If the date is completely missing, or if the date imputed using the above rules is after 
the treatment end date, set the date to the treatment end date or if the treatment end 
date is missing then set to date of discontinuation. 
No further imputation will be performed for missing data.
9.1.3. Missing Dates (other than for AEs)
For any data type that collects partial dates, impute missing day as 01 and missing month 
as January.  If date is completely missing then date should remain missing. 
Where the start date of study medication is missing, the date of randomisation will be 
used.  Where end date of study medication is partial or missing, the last complete non-
missing date of dosing will be used as the last date for determining duration of exposure.


CONFIDENTIAL
AMB112529
12
9.1.4. Missing Items on SF-10
The SF-10 will be scored in accordance with the developer’s guidelines. Out-of-range 
values are converted to missing values and no algorithm is used to estimate missing 
values.  The Physical and Psychosocial summary scores are not calculated if any 
component scores are missing. 
9.2.
Derived and Transformed Data
All listings will include all subjects that have the relevant data for each listing.
The number of subjects (N) in each treatment group and overall for the population being 
summarised, will be displayed in each table unless specified otherwise. 
For continuous data, the following summary statistics will be presented: n, mean, 
standard deviation (SD), median, upper and lower quartiles, minimum and maximum.  
Mean and median values will be reported to one decimal place greater than the original 
data they were collected from while the SD will be reported to two decimal places greater 
than the original data however, if this results in a value of 0.00 being presented then a 
zero (0) will be presented.  Minimum and maximum values will be reported with the 
same precision as they were collected.
All text fields must be left justified.  Numeric or numeric with some text specification 
(e.g., not done, unknown, <4.5, …) must be right justified.
The format for dates will be DDMMMYYYY.
All tables and listings will have the protocol number and population in the top left-hand 
corner and the page number in the form of page x of n will be presented in the top right-
hand corner.  In the bottom left-hand corner of tables and listings the name of the person 
who created the output followed by a colon, the output filepath and the date and time of 
the production of the output, in the form DDMMMYYYY HH:MM, will be displayed.  
If a count in a table summary is zero (0) then a percentage will not be presented. 
To determine whether an adverse event is on-treatment and a medication is prior or 
concomitant, imputation of missing or partial start and stop dates is required (see RAP 
Section 9.1.2 and Section 9.1.3). Imputed dates will not be listed and adverse event 
duration will not be calculated if the start date or stop date had to be imputed.
9.2.1. Baseline
Baseline values are those collected prior to the first dose.  Therefore if a subject has no 
data for a parameter on Day 1 (prior to first dose) then the data from their last pre-
treatment assessment will be used.


CONFIDENTIAL
AMB112529
13
9.2.2.
Change from baseline and percentage change from baseline
For untransformed data change from baseline at Week X will be calculated as Week X 
value minus baseline value. The percentage change from baseline at Week X will be 
calculated as: 100 (Week X value – baseline value) / baseline value.
For log-transformed data (see Section 9.2.8), ratio to baseline expressed as percentage 
change will be calculated by taking the mean change on the log scale, exponentiating, 
subtracting 1 and multiplying by 100.
(Exp(mean of (Log x - Log baseline)) -1)*100
9.2.3.
WHO FC change from baseline categorisation 1
Note that based on the study inclusion criteria subjects must have a WHO FC of II or III 
at baseline.  Change from baseline at Week X will be calculated as Week X value minus 
baseline value, thus categories may be -2, -1, 0, +1, +2. 
Post Baseline WHO FC
I
II
III
IV
Baseline WHO 
FC
II
-1
0
+1
+2
III
-2
-1
0
+1
9.2.4.
WHO FC class change from baseline categorisation 2
Improved = -1 or -2 in Change from Baseline Categorisation
No change = 0 in Change from Baseline Categorisation
Deteriorated = +1 or +2 in Change from Baseline Categorisation
9.2.5. Study Day
Study Day 1 is defined as the day of the first dose of study drug.
Relative Day to start of study medication for an Event is defined as:
Date of event - Date of first study medication + 1, if the event is on or after the first dose 
date.
Date of event - Date of first study medication, if the event is prior to the first dose date.


CONFIDENTIAL
AMB112529
14
Relative Day to end of medication for an Event is defined as:
Date of event - Date of last study medication  + 1, if the event is on or after the last dose 
date.
Date of event - Date of last study medication, if the event is prior to the last dose date.
9.2.6. Age Calculation
Age in years at baseline will be derived as a whole number according to the IDSL 
standard algorithm (see Appendix 1).
9.2.7. Duration of Exposure
Duration of exposure to study drug will be calculated in days as (Treatment stop date –
Treatment start date) + 1. 
9.2.8.
Transformations for Efficacy Outcomes
A log transformation will be applied to NT-proBNP data.
Summaries of the relative changes from baseline based on analysis of log-transformed 
data will include the geometric mean and coefficient of variation (calculated as below 
based on the logged values) and the geometric mean of the ratio of the value of the 
endpoint at the time point of interest to the baseline value (see Section 9.2.2) .
Geometric mean = exp(µ)
Coefficient of variation = 100 x √ [exp(σ2) – 1]
9.2.9.
Treatment Compliance Rates
Compliance to study medication is recorded at each visit in one of the following 
categorical groups:-

0% compliant (subject did not take any doses)

>0% and < 80% compliant (subject missed a number of doses)

>=80% and <=120%, (number of doses taken was within compliance range)

>120% compliant (number of doses taken exceeds compliance limits)
At the subject level compliance rate is calculated as 
100*(the number of visits at which the subject was compliant (i.e. ≥80% and ≤120%) / 
(the sum of all study visits for the subject).  
At a treatment group level compliance rate is calculated as 
100*(the total number of visits at which all subjects in that group were compliant (i.e. ≥ 
80% and ≤ 120%)) / (the sum of all study visits for all subjects in that group).


CONFIDENTIAL
AMB112529
15
9.3.
Assessment Windows
All data will be reported for the whole study period.
Unscheduled assessments will not be slotted to a particular time point, but will remain as 
unscheduled unless otherwise specified.
Time points relating to nominal visits will be used in tables, figures and listings.
Time to clinical worsening of PAH and time to liver event will be calculated using the 
date of assessment. 
9.4.
Values of Clinical Concern
9.4.1. Laboratory Parameters
The following values of potential clinical concern will be considered:
Values of potential 
clinical concern 
values will be 
defined for 
laboratory 
parameters as 
follows:Parameter
Code
Units 
Low 
Concern 
Value (SI 
units)
High 
Concern 
Value (SI 
units)
Worse case 
direction
Hematology
Hemoglobin
HGB
G/L
Males:    
< 98
Females: 
< 91
Males:  > 
180.0
Females:
> 161.0
Low
Hematocrit
HCT 
%
(1)
Males:    
< 32.0
(<0.32)
Females:
<29.0
(<0.29)
Males:    
> 54.0
(>0.54)
Females:
> 50.6
(>0.506)
Low
Platelets
PLATE
10^9/L
(same as 
GI/L)
< 100
> 500
Low
Chemistry


CONFIDENTIAL
AMB112529
16
Values of potential 
clinical concern 
values will be 
defined for 
laboratory 
parameters as 
follows:Parameter
Code
Units 
Low 
Concern 
Value (SI 
units)
High 
Concern 
Value (SI 
units)
Worse case 
direction
Total bilirubin
BILTOT
UMOL/
L
None
>= 34.2
High
AST
ASAT
IU/L
None
>= 3 x 
ULN
High
ALT
ALAT
IU/L
None
>= 3 x 
ULN
High
GGT
GGT
IU/L
None
>= 3 x 
ULN
High
Creatinine
CREAT
UMOL/
L
None
>= 176.8
High


CONFIDENTIAL
AMB112529
17
9.4.2. Vital Signs 
The following criteria will be used to determine whether a subject’s vital signs (blood 
pressure and heart rate) lie outside a pre-determined range of clinical concern:
Parameter
Code
Units 
Low Concern 
Value
High Concern Value
Heart Rate
PUL
Bpm
< 50
> 120
Systolic
SYS
mm Hg
< 80
> 160 mm Hg 
> 30 mm Hg change from 
Baseline
Diastolic
DIA
mm Hg
< 40
> 110 mm Hg
> 20 mm Hg change from 
Baseline
Body weight
WT
Kg
<  20
10.
STUDY POPULATION
Study population data will be presented for the Intent-to-Treat Population unless 
otherwise specified.
10.1. Disposition of Subjects
The number of subjects eligible for each of the analysis populations will be summarised 
by treatment group and overall, and by country and centre.  
The number of subjects completing/withdrawing from the study along with the reasons 
for withdrawal will be summarised by treatment group and overall.
10.2. Protocol Deviations
The number of subjects with important protocol deviations will be summarised by 
treatment group and overall.
A summary of subjects who did not satisfy all inclusion and exclusion criteria will be 
provided by treatment group.
The protocol deviations will be reviewed by the clinical team after the database release 
and prior to the database freeze, to determine which ones are considered to be important.
10.3. Demographic and Baseline Characteristics
The number and percentage of subjects in each category for categorical variables or 
summary statistics for continuous variables will be summarised by treatment group and 


CONFIDENTIAL
AMB112529
18
overall. These include age, age strata, sex, child-bearing potential, ethnicity and 
geographic ancestry, aetiology of PAH strata, duration of PAH, PAH therapy use, WHO 
FC score and 6 minute walk distance.
10.4.
Medical Conditions
The number and percentage of subjects with past or current medical conditions will be 
summarised by treatment group and overall, for any condition and by condition 
classification.
10.5.
Prior and Concomitant Medications
The GSK drug dictionary will be used to code drug names.
Prior medications are those that started and stopped prior to the date of first study 
treatment.  Ongoing medications at baseline are those started before first dose date of 
study drug, which were continued during the treatment phase.
Concomitant medications are defined as:-

Medications that start prior to or on the date of first study treatment and that 
stopped prior to the date of last study treatment,

Medications that start prior to or on the date of first study treatment and continued
after the date of last study treatment,

Medications that start after the date of first study treatment and that stopped prior 
to the date of the last study treatment,

Medications that start after the date of first study treatment and continued after the 
date of last study treatment.
Any medications that started after the last study treatment are classed as post-treatment 
medications. 
Note that it will be assumed that the medication has been taken by the medication start 
and stop dates recorded in the eCRF.
The number and percentage of subjects with concomitant medications will be 
summarised by Anatomical Therapeutic Chemical (ATC) Classification System code and 
preferred term, by treatment group and overall.  
The number and percentage of subjects with ongoing (at baseline) and concomitant PAH 
therapy at Week 24 will be summarised by preferred term, by treatment group and 
overall. The ATC codes from the GSKDrug dictionary for the groupings of PAH therapy 
will be agreed with the Clinical Safety Group and provided in a separate file.  This 
includes:

PDE5i

Prostanoid


CONFIDENTIAL
AMB112529
19
10.6. Treatment Compliance
At each visit, treatment compliance will be recorded as 0%, >0% - <80%, =>80% -
<=120% and >120%. 
The number and percentage of subjects in each compliance category will be summarised 
at each visit by treatment group and overall.
10.7. Long-Term Study (AMB 114588)
The number and percentage of subjects continuing in study AMB 114588 will be 
summarised by treatment group and overall.  
11.
SAFETY ANALYSES
Safety data will be presented for the Safety Population unless otherwise specified.
11.1. Extent of Exposure
The number of days of exposure to study drug will be summarised by treatment group 
and overall.
This number of days of exposure will be categorised in 30 day intervals as follows: <=30 
days, 31-60 days, 61-90 days etc.  
The number and percentage of subjects in each of these categories will be summarised by 
treatment group and overall. 
11.2. Adverse Events
All AEs will be categorised into Preferred Term (PT) and associated System Organ Class 
(SOC) using the Medical Dictionary for Regulatory Activities (MedDRA) coding 
dictionary.
Only treatment-emergent adverse events (TEAEs) will be included in summary tables.
TEAEs are defined as those events that start on or after first dose date of study treatment.
Any subject with at least one reported TEAE will be classified as a subject with:

A TEAE,

A TEAE leading to study treatment discontinuation (definitive or temporary),

A TEAE leading to study withdrawal,

At least one serious TEAE.
The numbers and percentages of subjects with at least one reported TEAE will be 
summarised by treatment group and overall according to:


CONFIDENTIAL
AMB112529
20

PT,

SOC and PT,

SOC and PT by intensity,

SOC and PT by relationship to study treatment,

PT by action taken with investigational product (IP).
Recurring TEAEs (i.e. successive TEAEs classified with the same PT) for a given subject 
will only be counted once and only their most severe intensity will be tabulated.
The cumulative incidence of each TEAE will also be summarised by SOC and PT and the 
following categories:  <2 weeks, <4 weeks, <8 weeks, <12 weeks, <16 weeks, <20 weeks 
and <24 weeks. 
TEAEs will be listed by SOC and PT, by treatment with the number of subjects who 
experienced the event and their subject numbers presented.  A more detailed listing will 
also be produced for all subjects who experienced an AE.  
11.3. Adverse Events Leading to Discontinuation of Investigational 
Product and/or Withdrawal from the Study and Other 
Significant Adverse Events
The numbers and percentages of subjects with at least one reported TEAE leading to 
discontinuation of the investigational product or withdrawal from the study will be 
summarised by SOC and PT for each treatment group and overall.
11.4. Deaths and Serious Adverse Events
Summary tables detailed in Section 11.2 and Section 11.3 (with the exception of 
cumulative incidence) will be repeated for serious TEAEs.
Summary tables will also be presented for serious TEAEs by PT and outcome for each 
treatment group and overall.
A summary of serious TEAEs displaying the number of subjects and occurrences will 
also be presented.
In addition, the number of subjects with fatal TEAEs and fatal TEAEs related to IP will 
be summarised by SOC and PT for each treatment group and overall.
11.5. Adverse Events of Special Interest
Summary tables detailed in Section 11.2 and Section 11.3 (with the exception of tables by 
maximum intensity/grade, action taken and relation to IP) will be repeated for AEs of 
special interest.  MedDRA preferred terms and codes for AEs of special interest will be 
agreed with Clinical Safety Group and provided in a separate file.
The adverse events of special interest are:

Anaemia

Hepatoxicity


CONFIDENTIAL
AMB112529
21

Hypersensitivity

Hypotension

Male infertility

Oedema/fluid retention
11.6. Non-serious Adverse Events
A summary of the most common (>=5%) non-serious TEAEs displaying the number of 
subjects and occurrences will also be presented.
11.7. Clinical Laboratory Evaluations
Absolute values and changes from baseline of laboratory data will be summarised for 
each visit, by treatment group and overall.
Separate tables will be presented for haematology data, clinical chemistry data and 
endocrine data (females only).
The number and percentages of subjects with laboratory values above and below 
reference ranges for potential clinical concern described in Section 9.4.1 will be 
summarised for each visit, by treatment group and overall
11.8.
Liver Events
The number and percentage of subjects reporting a liver event will be summarised:
overall, during and post study treatment.
The following will be listed by treatment group, for subjects with liver events:-

liver chemistry result involved in the event.

Time from first and last dose to start of event 

Patient specific information for liver events 

Medical conditions.

Liver biopsy details.

Liver imaging details.
11.9.
Vital Signs
Absolute values and changes from baseline of vital signs data will be summarised for 
each visit, by treatment group and overall.
The number and percentages of subjects with vital signs values or change from baseline 
values above and below reference ranges for potential clinical concern described in 
Section 9.4.2 will be summarised for each visit, by treatment group and overall. 
11.10.
Physical Examination
Physical examination at each visit will be summarised by treatment group and overall.


CONFIDENTIAL
AMB112529
22
11.11.
12-Lead ECG
The number and percentages of subjects with electrocardiogram (ECG) abnormalities 
(clinically significant and not clinically significant) will be summarised for each visit, by 
treatment group and overall.
11.12.
Endocrinology
The following will be summarised for each visit (as appropriate) by treatment group and 
overall.

Female breast development and pubic hair development.

Male testicular volume, genital development and pubic hair development.

Change from baseline in male testicular volume.

Change from baseline in plasma endocrine parameters (Follicle Stimulating 
Hormone, Luteinizing Hormone, Sex Hormone Binding Globulin, Total 
Testosterone and Inhibin B) by gender.
The above tables will also be summarised by pubertal status at baseline defined as 
follows:
Male:
Pre-pubertal: testicular volume < 4 ml, Post-pubertal: testicular volume ≥ 4 ml.
Female: Pre-pubertal: Stage 1 breast development, Post-pubertal: Stage ≥ 2 breast 
development.
11.13.
Pregnancies (as applicable)
A listing of pregnancy events will be provided, as necessary. 
12.
EFFICACY ANALYSES
Efficacy data will be presented for the Intent-to-Treat Population unless otherwise 
specified.
The following will be summarised for observed case data for each visit (as appropriate) 
by treatment group and overall.

The absolute value, change from baseline and % change from baseline in the 6 
minute walking distance (6MWD) test, overall and by oxygen use.

The walking duration for subjects who walked less than six minutes.

The use of oxygen during the 6MWD test.

The time to clinical worsening of PAH.

The criteria for clinical worsening of PAH.

WHO Functional Class and change from baseline in WHO Functional Class.

The absolute value and percent change from baseline, using log-transformed data,
in N-terminal pro-B-type natriuretic peptide (NT-Pro BNP) concentration.

The absolute value and change from baseline in the number of school days, 
missed school days and missed school days due to PAH.


CONFIDENTIAL
AMB112529
23

The absolute value and change from baseline in Subject Global Assessment as 
measured by the SF-10 health survey for children and summarised for the 
physical summary score (PHS-10) and the psychosocial summary score (PSS-10).
Further table will be produced summarizing change in WHO FC scores categorized in 
terms of “-2, -1, 0, +1, +2” and in terms of “Improved, No Change, Deteriorated” (see 
Section 9.2.3 and Section 9.2.4). 
12.1. Exploratory analyses
The following will be summarised for each visit, by treatment group and overall.

The absolute value and change from baseline in exploratory echocardiogram:-
pericardial effusion, right atrial pressure, tricuspid annular plane systolic 
excursion, eccentricity index (systolic and diastolic), tricuspid regurgitant jet 
velocity and right ventricular pressure.
12.2. Other analyses
The following will be summarised for each visit, by treatment group and overall.

The absolute value and change from baseline in cardiopulmonary hemodynamics  
(at centres where the collection of hemodynamic data is considered part of the 
standard of care):- heart rate, mean arterial blood pressure, mean pulmonary 
arterial pressure, mean right atrial pressure, left ventricular end diastolic pressure 
or pulmonary capillary wedge pressure, pulmonary vascular resistance, cardiac 
output, cardiac index (calculated value), arterial oxygen saturation and mixed 
venous oxygen saturation.
13.
CLINICAL PHARMACOLOGY DATA ANALYSES
13.1. Pharmacokinetic Analyses
Not applicable.
13.2. Pharmacodynamic Analyses
Not applicable.
13.3. Pharmacokinetic/Pharmacodynamic Analyses
Not applicable.
14.
BIOMARKER DATA ANALYSIS
Not applicable.
15.
PHARMACOGENETIC DATA ANALYSES
Not applicable.


CONFIDENTIAL
AMB112529
24
16.
VIRAL GENOTYPING/PHENOTYPING
Not applicable.
17.
REFERENCES
Not Applicable.


CONFIDENTIAL
AMB112529
25
18.
ATTACHMENTS
18.1.
Table of Contents for Data Display Specifications
18.1.1.
Tables
Table numbering for the Japanese subgroup will be add 001 at the end of the table number.  Thus, Table 1.1 will become 1.1001.
Table numbering for the Age Strata subgroup will be add 002 at the end of the table number.  Thus, Table 1.5 will become 1.5002.
Population Tables
Table
Number
Title
Population
Template
Table
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
1.1
Summary of Subject Disposition
Intent-to-
Treat
1.1
X
Interim, SAC
1.2
Summary of Study Populations
Randomised
1.2
Interim, SAC
1.3
Summary of Subjects by Country and Centre
Intent-to-
Treat
1.3
Interim, SAC
1.4
Summary of Inclusion/Exclusion Criteria Deviations
Intent-to-
Treat
1.4
Interim, SAC
1.5
Summary of Demographic and Baseline Characteristics
Intent-to-
Treat
1.5
X
X
Interim, SAC
1.6
Summary of Past Medical Conditions
Intent-to-
Treat
1.6
X
Interim, SAC
1.7
Summary of Current Medical Conditions
Intent-to-
Treat
1.6
X
Interim, SAC
1.8
Summary of Concomitant Medications
Intent-to-
Treat
1.8
X
Interim, SAC
1.9
Summary of Ongoing Background PAH Therapy at Baseline 
By Drug Class and Preferred Term
Intent-to-
Treat
1.9
X
Interim, SAC
1.10
Summary of Ongoing Background PAH Therapy at Week 24 
By Drug Class and Preferred Term
Intent-to-
Treat
1.9
X
Interim, SAC
1.11
Summary of Subjects who continue in the long term 
study (AMB 114588)
Intent-to-
Treat
1.11
Interim, SAC


CONFIDENTIAL
AMB112529
26
Table
Number
Title
Population
Template
Table
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
1.12
Summary of Compliance to Investigational Product since 
last visit
Intent-to-
Treat
1.12
Interim, SAC
1.13
Summary of Investigational Product Compliance Overall
Intent-to-
Treat
1.13
Interim, SAC
1.14
Summary of Important Protocol Deviation
Intent-to-
Treat
1.14
Interim, SAC
Efficacy Tables
Table
Number
Title
Population
Template
Table
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
2.1
Summary of 6 Minute Walking Distance (meters)
Intent-to-
Treat
2.1
X
X
Interim, SAC
2.2
Summary of Change from Baseline in 6 Minute Walking 
Distance (meters)
Intent-to-
Treat
2.1
X
X
Interim, SAC
2.3
Summary of Percent Change from Baseline in 6 Minute 
Walking Distance (meters)
Intent-to-
Treat
2.1
X
X
Interim, SAC
2.4
Summary of Walking Duration (minutes) for subjects who 
walked less than six minutes
Intent-to-
Treat
2.4
X
X
Interim, SAC
2.5
Summary of use of Oxygen during 6 Minute Walking 
exercise (L/min)
Intent-to-
Treat
2.5
X
X
Interim, SAC
2.6
Summary of Time to Clinical Worsening of PAH (days)
Intent-to-
Treat
2.6
X
Interim, SAC
2.7
Summary of Clinical Worsening of PAH
Intent-to-
Treat
2.7
Interim, SAC
2.8
Summary of WHO Functional Class
Intent-to-
Treat
2.8
X
X
Interim, SAC
2.9
Summary of Change from Baseline in WHO Functional 
Class
Intent-to-
Treat
2.8
X
X
Interim, SAC


CONFIDENTIAL
AMB112529
27
Table
Number
Title
Population
Template
Table
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
2.10
Summary of WHO Functional Class Shifts from Baseline 
by Visit
Intent-to-
Treat
2.10
X
X
Interim, SAC
2.11
Summary of WHO Functional Class Change from Baseline 
Categorisation
Intent-to-
Treat
2.11
X
X
Interim, SAC
2.12
Summary of Plasma NT-Pro BNP concentration (ng/L)
Intent-to-
Treat
2.12
X
X
Interim, SAC
2.13
Summary of Ratio to Baseline in Plasma NT-Pro BNP 
concentration (%)
Intent-to-
Treat
2.12
X
X
Interim, SAC
2.14
Summary of Exploratory Echocardiogram
Intent-to-
Treat
2.14
X
X
Interim, SAC
2.15
Summary of Change from Baseline in Exploratory 
Echocardiogram
Intent-to-
Treat
2.15
X
X
Interim, SAC
2.16
Summary of Cardiopulmonary Hemodynamics
Intent-to-
Treat
2.16
X
Interim, SAC
2.17
Summary of Change from Baseline in Cardiopulmonary 
Hemodynamics
Intent-to-
Treat
2.16
X
Interim, SAC
2.18
Summary of Number of Subjects with School Days within 
the Past Month
Intent-to-
Treat
2.18
X
X
Interim, SAC
2.19
Summary Statistics of School Days within the past 
month
Intent-to-
Treat
2.19
X
X
Interim, SAC
2.20
Summary Statistics of Change from Baseline in School 
Days within the Past month
Intent-to-
Treat
2.19
X
X
Interim, SAC
2.21
Summary of Subject Global Assessment (SF10 Health 
Survey for Children) 
Intent-to-
Treat
2.21
X
X
Interim, SAC
2.22
Summary of Change from Baseline in Subject Global 
Assessment (SF10 Health Survey for Children)
Intent-to-
Treat
2.21
X
X
Interim, SAC
2.23
Summary of SF10 Health Survey – Number and Percentage 
of Subjects with Particular Item Responses
Intent-to-
Treat
2.23
X
X
Interim, SAC


CONFIDENTIAL
AMB112529
28
Safety Tables
Table
Number
Title
Population
Template
Table
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
3.1
Summary of Exposure to Investigational Product
Safety
3.1
X
X
Interim, SAC
3.2
Summary of Treatment-Emergent Adverse Events
Safety
3.2
X
X
Interim, SAC
3.3
Summary of Treatment-Emergent Adverse Events by 
Preferred Term
Safety
3.3
X
Interim, SAC
3.4
Summary of Treatment-Emergent Adverse Events by 
Maximum Intensity
Safety
3.4
X
Interim, SAC
3.5
Summary of Treatment-Emergent Adverse Events by Action 
Taken with IP
Safety
3.5
Interim, SAC
3.6
Summary of Treatment-Emergent Adverse Events leading 
to Permanent Discontinuation of IP or Withdrawal from 
the Study
Safety
3.2
X
Interim, SAC
3.7
Summary of Treatment-Emergent Adverse Events related 
to IP
Safety
3.2
X
X
Interim, SAC
3.8
Summary of Cumulative Incidence of Treatment-Emergent 
Adverse Events by Time to First Occurrence
Safety
3.8
Interim, SAC
3.9
Summary of Serious Treatment-Emergent Adverse Events
Safety
3.2
X
Interim, SAC
3.10
Summary of Serious Treatment-Emergent Adverse Events –
Number of Subjects and Occurrences
Safety
3.10
Interim, SAC
3.11
Summary of Serious Treatment-Emergent Adverse Events 
by Outcome
Safety
3.11
Interim, SAC
3.12
Summary of Serious Treatment-Emergent Adverse Events 
by Action Taken with IP
Safety
3.5
Interim, SAC
3.13
Summary of Serious Treatment-Emergent Adverse Events 
leading to Permanent Discontinuation of IP or 
Withdrawal from the Study
Safety
3.2
Interim, SAC
3.14
Summary of Serious Treatment-Emergent Adverse Events 
related to IP
Safety
3.2
Interim, SAC
3.15
Summary of Fatal Serious Treatment-Emergent Adverse 
Events 
Safety
3.2
Interim, SAC
3.16
Summary of Fatal Serious Treatment-Emergent Adverse 
Events related to IP
Safety
3.2
Interim, SAC


CONFIDENTIAL
AMB112529
29
Table
Number
Title
Population
Template
Table
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
3.17
Summary of Treatment-Emergent Adverse Events of 
Special Interest
Safety
3.2
X
Interim, SAC
3.18
Summary of Treatment-Emergent Adverse Events of 
Special Interest leading to Permanent Discontinuation 
of IP or Withdrawal from the Study
Safety
3.2
Interim, SAC
3.19
Summary of Cumulative Incidence of Treatment-Emergent 
Adverse Events of Special Interest by Time to First 
Occurrence
Safety
3.8
Interim, SAC
3.20
Summary of Most Common (>5%) Non-Serious Treatment-
Emergent Adverse Events – Number of Subjects and 
Occurrences
Safety
3.10
Interim, SAC
3.21
Summary of Haematology Data
Safety
3.21
X
Interim, SAC
3.22
Summary of Change from Baseline in Haematology Data
Safety
3.21
X
Interim, SAC
3.23
Summary of Haematology Data of Potential Clinical 
Concern
Safety
3.23
X
Interim, SAC
3.24
Summary of Clinical Chemistry Data
Safety
3.21
X
Interim, SAC
3.25
Summary of Change from Baseline in Clinical Chemistry
Data
Safety
3.21
X
Interim, SAC
3.26
Summary of Clinical Chemistry Data of Potential 
Clinical Concern
Safety
3.23
X
Interim, SAC
3.27
Summary of Endocrinology Laboratory Data (females 
only)
Safety
3.21
X
Interim, SAC
3.28
Summary of Change from Baseline in Endocrinology 
Laboratory Data (females only)
Safety
3.21
X
Interim, SAC
3.29
Summary of Liver Events Assessment
Safety
3.29
Interim, SAC
3.30
Summary of Vital Signs
Safety
3.30
X
Interim, SAC
3.31
Summary of Change from Baseline in Vital Signs
Safety
3.30
X
Interim, SAC
3.32
Summary of Vital Signs Data of Potential Clinical 
Concern
Safety
3.32
X
Interim, SAC


CONFIDENTIAL
AMB112529
30
Table
Number
Title
Population
Template
Table
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
3.33
Summary of Change from Baseline in Vital Signs Data of 
Potential Clinical Concern
Safety
3.32
X
Interim, SAC
3.34
Summary of Physical Examination by Visit
Safety
3.34
X
Interim, SAC
3.35
Summary of 12-lead ECG
Safety
3.35
X
Interim, SAC
3.36
Summary of Endocrinology assessments by Visit – Female
Safety
3.36
X
Interim, SAC
3.37
Summary of Endocrinology assessments by Visit – Male
Safety
3.37
X
Interim, SAC
3.38
Summary of Pubertal Development Shifts from Baseline -
Female
Safety
3.38
X
Interim, SAC
3.39
Summary of Pubertal Development Shifts from Baseline -
Male
Safety
3.39
X
Interim, SAC
3.40
Summary of Testicular Volume Change from Baseline –
Male
Safety
3.40
X
Interim, SAC
3.41
Summary of Change from Baseline in Plasma Endocrine 
Parameters – Female
Safety
3.41
X
Interim, SAC
3.42
Summary of Change from Baseline in Plasma Endocrine 
Parameters – Male
Safety
3.42
X
Interim, SAC


CONFIDENTIAL
AMB112529
31
18.1.2.
Listings
Population Listings
Listing
Number
Title
Population
Template
Listing
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
1.1
Listing of Randomised and Actual Treatments
Intent-to-
Treat
1.1
Interim, SAC
1.2
Listing of Reasons for Study Withdrawal
Intent-to-
Treat
1.2
Interim, SAC
1.3
Listing of Subjects with Inclusion/Exclusion Criteria 
Deviations
Intent-to-
Treat
1.3
Interim, SAC
1.4
Listing of Demographic Characteristics
Intent-to-
Treat
1.4
Interim, SAC
1.5
Listing of Race
Intent-to-
Treat
1.5
Interim, SAC
1.6
Listing of Disease History
Intent-to-
Treat
1.6
Interim, SAC
1.7
Listing of Medical Conditions
Intent-to-
Treat
1.7
Interim, SAC
1.8
Listing of Medications
Intent-to-
Treat
1.8
Interim, SAC
1.9
Listing of PAH Therapy
Intent-to-
Treat
1.9
Interim, SAC
1.10
Relationship between ATC Level 1, Ingredient and 
Verbatim Text
Intent-to-
Treat
1.10
Interim, SAC
1.11
Listing of Protocol Deviation
Intent-to-
Treat
1.11
Interim, SAC


CONFIDENTIAL
AMB112529
32
Efficacy Listings
Listing
Number
Title
Population
Template
Listing
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
2.1
Listing of 6 Minute Walk Distance Data
Intent-to-
Treat
2.1
Interim, SAC
2.2
Listing of Clinical Worsening of PAH
Intent-to-
Treat
2.2
Interim, SAC
2.3
Listing of WHO Functional Class Data
Intent-to-
Treat
2.3
Interim, SAC
2.4
Listing of Plasma NT-Pro BNP Concentration (ng/L)
Intent-to-
Treat
2.4
Interim, SAC
2.5
Listing of Exploratory Echocardiogram
Intent-to-
Treat
2.5
Interim, SAC
2.6
Listing of Cardiopulmonary Hemodynamics
Intent-to-
Treat
2.6
Interim, SAC
2.7
Listing of School Days
Intent-to-
Treat
2.7
Interim, SAC
2.8
Listing of Subject Global Assessment (SF10 Health 
Survey for Children)
Intent-to-
Treat
2.8
Interim, SAC
Safety Listings
Listing
Number
Title
Population
Template
Listing
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
3.1
Listing of Exposure and Compliance to Investigational 
Product
Safety
3.1
Interim, SAC
3.2
Listing of All Adverse Events
Safety
3.2
Interim, SAC
3.3
Listing of Relationship between Adverse Event System 
Organ Class, Preferred Term and Verbatim Text
Safety
3.3
Interim, SAC
3.4
Listing of Subject Numbers for Specified Adverse 
Events
Safety
3.4
Interim, SAC
3.5
Listing of Serious Adverse Events
Safety
3.2
Interim, SAC


CONFIDENTIAL
AMB112529
33
Listing
Number
Title
Population
Template
Listing
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
3.6
Listing of Fatal Serious Adverse Events
Safety
3.2
Interim, SAC
3.7
Listing of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment or Withdrawal from 
Study 
Safety
3.2
Interim, SAC
3.8
Listing of Haematology
Safety
3.8
Interim, SAC
3.9
Listing of Haematology Data for Subjects with 
Abnormalities of Potential Clinical Concern
Safety
3.9
Interim, SAC
3.10
Listing of Clinical Chemistry
Safety
3.8
Interim, SAC
3.11
Listing of Clinical Chemistry Data for Subjects with 
Abnormalities of Potential Clinical Concern
Safety
3.9
Interim, SAC
3.12
Listing of Endocrinology Laboratory Data - Females 
only
Safety
3.8
Interim, SAC
3.13
Listing of Liver Event Results and Time of Event 
Relative to Treatment
Safety
3.13
Interim, SAC
3.14
Listing of patient specific information for liver 
events
Safety
3.14
Interim, SAC
3.15
Listing of Medical Conditions for Subjects with Liver 
Events on Treatment
Safety
3.15
Interim, SAC
3.16
Listing of Liver Biopsy Details
Safety
3.16
Interim, SAC
3.17
Listing of Liver Imaging Details
Safety
3.17
Interim, SAC
3.18
Listing of Vital Signs
Safety
3.18
Interim, SAC
3.19
Listing of Vital Signs Data for Subjects with 
Abnormalities of Potential Clinical Concern
Safety
3.9
Interim, SAC
3.20
Listing of Physical Examination
Safety
3.20
Interim, SAC
3.21
Listing of 12-Lead ECG Findings
Safety
3.21
Interim, SAC
3.22
Listing of Endocrinology Assessments
Safety
3.22
Interim, SAC


CONFIDENTIAL
AMB112529
34
Listing
Number
Title
Population
Template
Listing
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
3.23
Listing of Pregnancy Results
Safety
3.23
Interim, SAC


CONFIDENTIAL
AMB112529
35
18.1.3.
Figures
Population Figures
Figure
Number
Title
Population
Template
Figure
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
1.1
Summary of Subject Accrual
Intent-to-
Treat
1.1
Interim, SAC
Efficacy Figures
Figure
Number
Title
Population
Template
Figure
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
2.1
Box plots of 6 Minute Walking Distance (meters) by Week
Intent-to-
Treat
3.4
Interim, SAC
2.2
Box plots of Change from Baseline in 6 Minute Walking 
Distance (meters) by Week
Intent-to-
Treat
3.4
Interim, SAC
2.3
Kaplan-Meier Survival Curves with 95% Confidence Bands 
of Time to First Clinical Worsening of PAH
Intent-to-
Treat
3.1
Interim, SAC
2.6
Box plots of Plasma NT-Pro BNP concentration by Week
Intent-to-
Treat
3.4
Interim, SAC
2.7
Box plots of Change from Baseline in Plasma NT-Pro BNP 
concentration by Week
Intent-to-
Treat
3.4
Interim, SAC
2.8
Box plots of Exploratory Echocardiogram Data by Week
Intent-to-
Treat
3.4
X
(Line
plots of 
Explorato
ry 
Echocardi
ogram 
Data by 
Subject)
see 
Interim, SAC


CONFIDENTIAL
AMB112529
36
Figure
Number
Title
Population
Template
Figure
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
template 
3.11)
2.9
Box plots of Change from Baseline in Exploratory 
Echocardiogram Data by Week
Intent-to-
Treat
3.5
Interim, SAC
Safety Figures
Figure
Number
Title
Population
Template
Figure
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
3.1
Kaplan-Meier Survival Curves with 95% Confidence Bands 
of Time to First Treatment-Emergent Adverse Event 
Safety
3.1
Interim, SAC
3.2
Kaplan-Meier Survival Curves with 95% Confidence Bands 
of Time to First Serious Adverse Event
Safety
3.1
Interim, SAC
3.3
Bar Chart of Treatment-Emergent Adverse Events Occurring 
in Two or More Subjects in any Treatment Group 
Safety
3.3
Interim, SAC
3.4
Box plots of Haematology Data by Week (Selected 
Parameters)
Safety
3.4
Interim, SAC
3.5
Box plots of Change from Baseline in Haematology Data by 
Week (Selected Parameters)
Safety
3.4
Interim, SAC
3.6
Box plots of Chemistry Data by Week (Selected 
Parameters)
Safety
3.4
Interim, SAC
3.7
Box plots of Change from Baseline in Chemistry Data by 
Week (Selected Parameters)
Safety
3.4
Interim, SAC
3.8
Patient Profiles of Liver Function Tests 
Safety
3.8
Interim, SAC


CONFIDENTIAL
AMB112529
37
Figure
Number
Title
Population
Template
Figure
Japanese 
subgroup 
analysis
Age 
strata 
subgroup 
analysis
Deliverable
3.9
Box plots of Vital Signs Data by Week
Safety
3.4
Interim, SAC
3.10
Box plots of Change from Baseline in Vital Signs Data by 
Week
Safety
3.4
Interim, SAC
3.11
Line plots of Endocrinology Assessments by subject
Safety
3.11
Interim, SAC


CONFIDENTIAL
AMB112529
38
18.2.
Data Display Specifications
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 1.1:  Summary of Subject Disposition
Ambrisentan
Low Dose
(N=XXX)
Ambrisentan
High Dose
(N=XXX)
Total
(N=XXX)
Subject status
  Completed
    XX (%)
    XX (%)
    XX (%)
  Withdrawn
    XX (%)
    XX (%)
    XX (%)
  Died
Primary reason for study withdrawal *
  Adverse event
    XX (%)
    XX (%)
    XX (%)
  Lack of Efficacy
    XX (%)
    XX (%)
    XX (%)
  Protocol Deviation
    XX (%)
    XX (%)
    XX (%)
  Subject reached protocol defined stopping criteria
    XX (%)
    XX (%)
    XX (%)
  Study closed/terminated
    XX (%)
    XX (%)
    XX (%)
  Lost to Follow-up
    XX (%)
    XX (%)
    XX (%)
  Investigator discretion
    XX (%)
    XX (%)
    XX (%)
  Withdrew consent
    XX (%)
    XX (%)
    XX (%)
Note:  * Percentages are based on the number of subjects in the treatment group.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Denominator for each primary reason for withdrawal is number of subjects in the Intent-to-Treat population 
per treatment group.
PPD


CONFIDENTIAL
AMB112529
39
Protocol: AMB112529                                                                                                Page 1 of n
Population: Randomised
Table 1.2:  Summary of Study Populations
Ambrisentan
Low Dose
(N=XXX)
Ambrisentan
High Dose
(N=XXX)
Total
(N=XXX)
Randomised
   XXX  
   XXX  
   XXX 
Safety Population
   XXX (%)
   XXX (%)
   XXX (%)
Intention-to-Treat population
   XXX (%)
   XXX (%)
   XXX (%)
Note:  The Safety Population is defined as all randomized subjects who received at least 1 dose of study drug. 
Subjects are considered as belonging to the treatment group according to highest dose received. 
   
The Intention-to-Treat (ITT) Population is defined as all randomized subjects who received at least 1 dose
of study drug. Subjects are considered as belonging to their randomized treatment group, regardless of the
actual dose of ambrisentan received. 
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: See notes above relating to denominators for percentages.
PPD


CONFIDENTIAL
AMB112529
40
Protocol: AMB112529                                                                                                Page 1 of n  
Population: Intent-to-treat                                                                                 
Table 1.3: Summary of Subjects by Country and Centre
Country
Centre ID
Ambrisentan
Low Dose
(N=XXX)
Ambrisentan
High Dose
(N=XXX)
Total
(N=XXX)
XXXXXXXXX
All
    XX (%)  
    XX (%)
    XX (%)
XXXXXX
    XX (%)  
    XX (%)
    XX (%)
XXXXXXXXX
All
    XX (%)  
    XX (%)
    XX (%)
XXXXXX
    XX (%)  
    XX (%)
    XX (%)
XXXXXXXXX
All
    XX (%)
    XX (%)
    XX (%)
XXXXXX
    XX (%)  
    XX (%)
    XX (%)
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
41
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 1.4:  Summary of Inclusion/Exclusion Criteria Deviations
Ambrisentan
Low Dose
(N=XXX)
Ambrisentan
High Dose
(N=XXX)
Total
(N=XXX)
Any criteria deviations
    XX (%)
    XX (%)
    XX (%)
Inclusion
  I1
    XX (%)
    XX (%)
    XX (%)
  I2
    XX (%)
    XX (%)
    XX (%)
  Etc..
Exclusion
  E1
    XX (%)
    XX (%)
    XX (%)
  E2
    XX (%)
    XX (%)
    XX (%)
  Etc..
Note:  Please refer to numbering of inclusion and exclusion criteria in protocol.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Only present criteria where there is at least one (total) deviation.  “Any criteria deviations” is the 
number of subjects who had at least one deviation.
PPD


CONFIDENTIAL
AMB112529
42
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 1.5:  Summary of Demographic and Baseline Characteristics
Ambrisentan
Low Dose
(N=XXX)
Ambrisentan
High Dose
(N=XXX)
Total
(N=XXX)
Age (yrs)
  n
     XXX    
     XXX
     XXX
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Age (yrs)
  n
      XXX 
      XXX
      XX (%)
  <8 years
      XX (%)
      XX (%)
      XX (%)
  8 – 11 years
      XX (%)
      XX (%)
      XX (%)
  12 - <18 years 
      XX (%)
      XX (%)
      XX (%)
  >=18 years
      XX (%)
      XX (%)
      XX (%)
Sex
  n
      XXX 
      XXX
      XX (%)
  Female
      XX (%)
      XX (%)
     XX (%)
  Male
      XX (%)
      XX (%)
      XX (%)
Note:  * A subject may be represented in more than one geographic ancestry group.
         Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
         
PPD


CONFIDENTIAL
AMB112529
43
Protocol: AMB112529                                                                                                Page 2 of n
Population: Intent-to-Treat
Table 1.5:  Summary of Demographic and Baseline Characteristics
Ambrisentan
Low Dose
(N=XXX)
Ambrisentan
High Dose
(N=XXX)
Total
(N=XXX)
Child Bearing Potential (Females only)
  n
     XXX
     XXX
     XXX
  Pre-menarcheal
      XX (%)
      XX (%)
      XX (%)
  Sterile (of child bearing age)
      XX (%)
      XX (%)
      XX (%)
  Potentially able to bear children
      XX (%)
      XX (%)
      XX (%)
Ethnicity
  n
     XXX
     XXX
     XXX
  Hispanic/Latino
      XX (%)
      XX (%)
      XX (%)
  Not Hispanic/Latino
      XX (%)
      XX (%)
      XX (%)
Geographic Ancestry
  n
     XXX
     XXX
     XXX
  African American/African Heritage
      XX (%)
      XX (%)
      XX (%)
  American Indian or Alaskan Native
      XX (%)
      XX (%)
      XX (%)
  Asian - Central/South Asian Heritage
      XX (%)
      XX (%)
      XX (%)
  Asian - East Asian Heritage
      XX (%)
      XX (%)
      XX (%)
  Asian - Japanese Heritage
      XX (%)
      XX (%)
      XX (%)
  Asian - South East Asian Heritage
      XX (%)
      XX (%)
      XX (%)
  Native Hawaiian or Other Pacific Islander
      XX (%)
      XX (%)
      XX (%)
  White - Arabic/North African Heritage
      XX (%)
      XX (%)
      XX (%)
  White - White/Caucasian/European Heritage
      XX (%)
      XX (%)
      XX (%)
Note:  * A subject may be represented in more than one geographic ancestry group.
         Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
         
PPD


CONFIDENTIAL
AMB112529
44
Protocol: AMB112529                                                                                                Page 3 of n
Population: Intent-to-Treat
Table 1.5:  Summary of Demographic and Baseline Characteristics
Ambrisentan
Low Dose
(N=XXX)
Ambrisentan
High Dose
(N=XXX)
Total
(N=XXX)
Weight (kg)
  n
     XXX    
     XXX
     XXX
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Weight (kg)
  n
      XXX 
      XXX
      XX (%)
  <20 kg
      XX (%)
      XX (%)
      XX (%)
  20 – <35 kg
      XX (%)
      XX (%)
      XX (%)
  35 - <50 kg 
      XX (%)
      XX (%)
      XX (%)
  >=50 kg
      XX (%)
      XX (%)
      XX (%)
Aetiology of PAH Randomised Strata
  n
      XXX 
      XXX
      XX (%)
  Idiopathic (IPAH)
      XX (%)
      XX (%)
      XX (%)
  Familial (FPAH)
      XX (%)
      XX (%)
      XX (%)
  Persistent PAH despite surgical repair
      XX (%)
      XX (%)
      XX (%)
  Secondary to connective tissue disease
      XX (%)
      XX (%)
      XX (%)
Note:  * A subject may be represented in more than one geographic ancestry group.
         Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
         
PPD


CONFIDENTIAL
AMB112529
45
Protocol: AMB112529                                                                                                Page 4 of n
Population: Intent-to-Treat
Table 1.5:  Summary of Demographic and Baseline Characteristics
Ambrisentan
Low Dose
(N=XXX)
Ambrisentan
High Dose
(N=XXX)
Total
(N=XXX)
Duration of PAH (days)
  n
     XXX    
     XXX
     XXX
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
PAH Therapy Use
  n
      XXX 
      XXX
      XX (%)
  Ongoing PAH therapy at baseline
      XX (%)
      XX (%)
      XX (%)
  Prior PAH therapy, not ongoing at baseline
      XX (%)
      XX (%)
      XX (%)
  No PAH therapy recorded
      XX (%)
      XX (%)
      XX (%)
Note:  * A subject may be represented in more than one geographic ancestry group.
         Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
         
PPD


CONFIDENTIAL
AMB112529
46
Protocol: AMB112529                                                                                                Page 5 of n
Population: Intent-to-Treat
Table 1.5:  Summary of Demographic and Baseline Characteristics
Ambrisentan
Low Dose
(N=XXX)
Ambrisentan
High Dose
(N=XXX)
Total
(N=XXX)
WHO Functional Class
  N
      XXX 
      XXX
      XX (%)
  Class II
      XX (%)
      XX (%)
      XX (%)
  Class III
      XX (%)
      XX (%)
      XX (%)
6 minute walk data (m)
  N
     XXX    
     XXX
     XXX
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Note:  * A subject may be represented in more than one geographic ancestry group.
         Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
         
PPD


CONFIDENTIAL
AMB112529
47
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 1.6:  Summary of Past Medical Conditions
Classification
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Any condition
    XX (%)
    XX (%)
    XX (%)
Classification 1
  Any condition
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 1
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 2
    XX (%)
    XX (%)
    XX (%)
etc
Classification 2
  Any condition
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 1
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 2
    XX (%)
    XX (%)
    XX (%)
etc
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: “Any condition” relates to the number and percentage of subjects who had at least one condition.  Subjects 
may be counted more than once across classifications.
PPD


CONFIDENTIAL
AMB112529
48
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 1.8:  Summary of Concomitant Medications
ATC Level 1
  Preferred Term
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Any medication
    XX (%)
    XX (%)
    XX (%)
Endocrine & Metabolic
  Any medication
    XX (%)
    XX (%)
    XX (%)
  Fluticasone propionate
    XX (%)
    XX (%)
    XX (%)
  Beclomethasone dipropionate
    XX (%)
    XX (%)
    XX (%)
Anti-infectives & immunologicals
  Any medication
    XX (%)
    XX (%)
    XX (%)
  Amoxycillin
    XX (%)
    XX (%)
    XX (%)
  Amoxycillin trihydrate
    XX (%)
    XX (%)
    XX (%)
  Clamoxyl
    XX (%)
    XX (%)
    XX (%)
  Cefaclor
    XX (%)
    XX (%)
    XX (%)
  Cefproxil
    XX (%)
    XX (%)
    XX (%)
Etc..
Note: A medication may be included in more than one ATC level category and appear more than once.
      Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
      High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Medications will be sorted in descending order of total incidence across treatment groups for the ATC level 
1 and in descending order of total incidence for the preferred term within each ATC level. If the total incidence for any two 
or more preferred terms is equal, they will be presented in alphabetical order.  
PPD


CONFIDENTIAL
AMB112529
49
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 1.9:  Summary of Ongoing Background PAH Therapy at Baseline
By Drug Class and Preferred Term 
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
PAH Therapy
(N=XXX)
(N=XXX)
(N=XXX)
Any medication
    XX (%)
    XX (%)
    XX (%)
PDE5i (monotherapy)
  Any medication
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 1
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 1
    XX (%)
    XX (%)
    XX (%)
Etc..
Prostanoid (monotherapy)
  Any medication
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 1
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 1
    XX (%)
    XX (%)
    XX (%)
Etc..
PDE5i and prostanoid in combination
  Any medication
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 1 + Preferred Term 2
    XX (%)
    XX (%)
    XX (%)
  Preferred Term 3 + Preferred Term 4
    XX (%)
    XX (%)
    XX (%)
Etc.. 
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
50
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 1.11:  Summary of Subjects who continue in the long term study (AMB114588)
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
AMB 114588
(N=XXX)
(N=XXX)
(N=XXX)
Yes
    XX (%)
    XX (%)
    XX (%)
No
    XX (%)
    XX (%)
    XX (%)
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
51
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 1.12:  Summary of Compliance to Investigational Product since last visit
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Planned Relative Time
Compliance assessment
(N=XXX)
(N=XXX)
(N=XXX)
Week 2
   n
   XXX
   XXX
   XXX
   0% compliant
    XX (%)
    XX (%)
   XX (%)
   >0% and < 80%
    XX (%)
    XX (%)
    XX (%)
   >= 80% and <= 120%
    XX (%)
    XX (%)
    XX (%)
   >120% compliant
    XX (%)
    XX (%)
    XX (%)
Week 4
   n
   XXX
   XXX
   XXX
   0% compliant
    XX (%)
    XX (%)
   XX (%)
   >0% and < 80%
    XX (%)
    XX (%)
    XX (%)
   >= 80% and <= 120%
    XX (%)
    XX (%)
    XX (%)
   >120% compliant
    XX (%)
    XX (%)
    XX (%)
Etc..
Etc..
Note:  EW = Early Withdrawal.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present for Weeks 2, 4, 8, 12, 16, 20, 24 and EW.
PPD


CONFIDENTIAL
AMB112529
52
Protocol: AMB112529                                                                                                Page 1 of n  
Population: Intent-to-treat                                                                                 
                            Table  1.13: Summary of Investigational Product Compliance Overall
Ambrisentan
Lose Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Overall % of visits at which subject is compliant
  XX 
  XX 
  XX 
  n
  XX
  XX
  XX
  Mean
  XX.X   
  XX.X   
  XX.X   
  SD
  XX.XX  
  XX.XX  
  XX.XX  
  Q1
  XX.X   
  XX.X   
  XX.X   
  Median
  XX.X   
  XX.X   
  XX.X   
  Q3
  XX.X   
  XX.X   
  XX.X   
  Min.
  XX
  XX
  XX
  Max.
  XX
  XX
  XX
Note: Q1 = 1st quartile, Q3 = 3rd quartile.
      Compliant visits are those at which subjects are ≥80% and ≤120% compliant. Compliance is determined
      by the site.
      At a subject level compliance = 100*(the number of visits at which the subject was compliant)/(the sum
      of all study visits for the subject). At a treatment group level the overall compliance = 100*(the
      total number of visits at which all subjects in that group were compliant)/(the sum of all study 
      visits for all subjects in that group).
      Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
      High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
53
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 1.14:  Summary of Important Protocol Deviation
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Protocol Deviation Category
(N=XXX)
(N=XXX)
(N=XXX)
Any Deviation
    XX (%)
    XX (%)
    XX (%)
Eligibility criteria not met
    XX (%)
    XX (%)
    XX (%)
Not withdrawn after developing withdrawal criteria
    XX (%)
    XX (%)
    XX (%)
Prohibited medication or device
    XX (%)
    XX (%)
    XX (%)
Visit window
    XX (%)
    XX (%)
    XX (%)
Informed consent procedure
    XX (%)
    XX (%)
    XX (%)
Administer/dispense study medication
    XX (%)
    XX (%)
    XX (%)
Failure to report SAE, Pregnancy, or liver function abnormalities per protocol
    XX (%)
    XX (%)
    XX (%)
Study blind/ unblind procedures
    XX (%)
    XX (%)
    XX (%)
Study treatment supply procedures
    XX (%)
    XX (%)
    XX (%)
Biological specimen sample procedures
    XX (%)
    XX (%)
    XX (%)
Assessment procedures
    XX (%)
    XX (%)
    XX (%)
Diary Card procedures
    XX (%)
    XX (%)
    XX (%)
Equipment procedures
    XX (%)
    XX (%)
    XX (%)
Randomization procedures
    XX (%)
   XX (%)
    XX (%)
Other
    XX (%)
    XX (%)
    XX (%)
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
54
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.1:  Summary of 6 Minute Walking Distance (meters)
Treatment
Planned 
Relative Time
n
Mean
SD
Q1
Median
Q3
Min.
Max.
Ambrisentan 
Low Dose
Baseline*
Overall
With oxygen use
Without oxygen use
XXX
XXX
XXX
XX.X
XX.X
XX.X
XX.XX
XX.XX
XX.XX
XX.X
XX.X
XX.X
XX.X
XX.X
XX.X
XX.X
XX.X
XX.X
XX
XX
XX
XX
XX
XX
(N=XXX)
Week 4
Overall
With oxygen use
Without oxygen use
XXX
XXX
XXX
XX.X
XX.X
XX.X
XX.XX
XX.XX
XX.XX
XX.X
XX.X
XX.X
XX.X
XX.X
XX.X
XX.X
XX.X
XX.X
XX
XX
XX
XX
XX
XX
Etc..
Week 24
EW
Ambrisentan 
High Dose
Etc..
(N=XXX)
Total
Etc..
(N=XXX)
Note: * Baseline is the last value recorded prior to start of study treatment.
  
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
EW = Early Withdrawal.
EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
55
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.4:  Summary of Walking Duration (minutes) for subjects who walked less than six minutes
Treatment
Number of subjects who 
attempted the 6 minute 
walk
Planned 
Relative Time
n
Mean
SD
Q1
Median
Q3
Min.
Max.
Ambrisentan 
Low Dose
Baseline*
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 4
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Ambrisentan 
High Dose
Baseline*
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 4
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Total
Etc..
(N=XXX)
Note: * Baseline is the last value recorded prior to start of study treatment.
  
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       % out of the number of subjects who attempted the 6 minute walk.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
56
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.5:  Summary of use of Oxygen during 6 Minute Walking exercise (L/min)
Treatment
Number of subjects 
who attempted the 6 
minute walk
Planned 
Relative Time
n
Mean
SD
Q1
Median
Q3
Min.
Max.
Ambrisentan 
Low Dose
Baseline*
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 4
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Ambrisentan 
High Dose
Baseline*
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 4
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XX (%)
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Total
Etc..
(N=XXX)
Note: * Baseline is the last value recorded prior to start of study treatment.
  
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       % out of the number of subjects who attempted the 6 minute walk.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
57
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.6:  Summary of Time to the first Clinical Worsening of PAH (days)
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Note:  Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
58
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.7:  Summary of Clinical Worsening of PAH
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Subjects with at least one criteria
XX (%) 
XX (%)
XX (%)
Death (all cause) or placed on active list for lung transplant
XX (%) 
XX (%)
XX (%)
Hospitalisation for worsening of PAH
XX (%) 
XX (%)
XX (%)
Addition/increased dose of other targeted PAH therapetic agents and/or atrial 
septostomy
XX (%) 
XX (%)
XX (%)
PAH related deterioration
XX (%) 
XX (%)
XX (%)
PAH related deterioration:-
Increase from baseline in WHO functional class
XX (%) 
XX (%)
XX (%)
Deterioration in exercise testing 
XX (%) 
XX (%)
XX (%)
Clinical signs or symptoms of right sided heart failure
XX (%) 
XX (%)
XX (%)
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
59
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.8:  Summary of WHO Functional Class
Treatment
Planned 
Relative Time
n
Mean
SD
Q1
Median
Q3
Min.
Max.
Ambrisentan 
Low Dose
Baseline*
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 4
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Ambrisentan 
High Dose
Baseline*
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 4
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XX 
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Total
Etc..
(N=XXX)
Note:  * Baseline is the last value recorded prior to start of study treatment.
       There are 4 grades of WHO FC based on symptom severity (Class I=none, Class IV=most severe).
       Grades mapped to numeric scale 1-4 (i.e. Class IV=4).
  
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Baseline and Weeks 4, 8, 12, 16, 20, 24 and EW.
PPD


CONFIDENTIAL
AMB112529
60
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.10:  Summary of WHO Functional Class Shifts from Baseline by Visit
Treatment
Planned 
Relative 
Time
WHO
Functional 
Class
Baseline 
WHO Functional Class
II
III
Ambrisentan Low Dose (N=XXX)
Week 4
I
  XX (%)
XX (%)
II
  XX (%)
XX (%)
III
    XX (%)
    XX (%)
IV
    XX (%)
    XX (%)
Unknown/
Not Recorded
   XX  
    XX  
Week 8
I
  XX (%)
XX (%)
II
  XX (%)
XX (%)
III
    XX (%)
    XX (%)
IV
    XX (%)
    XX (%)
Unknown/
Not Recorded
    XX  
    XX  
Etc..
Note:  Baseline is the last value recorded prior to start of study treatment.
      There are 4 grades of WHO FC based on symptom severity (Class I=none, Class IV=most severe).
  
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Weeks 4, 8, 12, 16, 20, 24 and EW, for each treatment group and overall.
PPD


CONFIDENTIAL
AMB112529
61
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.11:  Summary of WHO Functional Class Change from Baseline Categorisation
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Planned Relative Time
WHO Category
(N=XXX)
(N=XXX)
(N=XXX)
Week 4
n
   XXX 
   XXX 
   XXX 
Improved
    XX (%)
    XX (%)
    XX (%)
No Change
    XX (%)
    XX (%)
    XX (%)
Deteriorated
    XX (%)
    XX (%)
    XX (%)
-2
    XX (%)
    XX (%)
    XX (%)
-1
    XX (%)
    XX (%)
    XX (%)
0
    XX (%)
    XX (%)
    XX (%)
+1
    XX (%)
    XX (%)
    XX (%)
+2
    XX (%)
    XX (%)
    XX (%)
Etc..
Note: Baseline is the last value recorded prior to start of study treatment
      There are 4 grades of WHO FC based on symptom severity (Class I=none, Class IV=most severe).
      Grades mapped to numeric scale 1-4 (i.e. Class IV=4).
      Change categorisation (based on -2, -1, 0, +1, +2);  No Change (0), Improved (-1,-2),
      Deterioration (+1,+2).
           There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
      EW = Early Withdrawal.
      Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
      High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present Weeks 4, 8, 12, 16, 20, 24 and EW, for each treatment group and overall.
PPD


CONFIDENTIAL
AMB112529
62
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.12:  Summary of plasma NT-Pro BNP concentration (ng/L)
Treatment
Planned 
Relative Time
n
Geometric
Mean
SD
[logs]
Q1
Median
Q3
Min.
Max.
Ambrisentan 
Low Dose
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 12
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Ambrisentan 
High Dose
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 12
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Total
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 12
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
63
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.14:  Summary of Exploratory Echocardiogram
Planned 
Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Pericardial
N
   XXX    
   XXX    
   XXX    
Effusion
Absent
    XX (%)
    XX (%)
    XX (%)
Trace: separation of pericardial layers in both systole and 
diastole
    XX (%)
    XX (%)
    XX (%)
Small: diastolic separation equals 1cm
    XX (%)
    XX (%)
    XX (%)
Moderate: diastolic separation of 1 to 2cm
    XX (%)
    XX (%)
    XX (%)
Large: diastolic separation equals 2cm
    XX (%)
    XX (%)
    XX (%)
Mean right
N
    XXX    
    XXX    
    XXX    
Atrial
Mean
     XX.X
     XX.X
     XX.X
Pressure
SD
     XX.XX
     XX.XX
     XX.XX
(mmHg)
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Tricuspid
N
    XXX    
    XXX    
    XXX    
Annular
Mean
     XX.X
     XX.X
     XX.X
Plane
SD
     XX.XX
     XX.XX
     XX.XX
Systolic
Q1
     XX.X
     XX.X
     XX.X
Excursion 
Median
     XX.X
     XX.X
     XX.X
(cm)
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal. Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Baseline, Week 12, Week 24 and EW.
PPD


CONFIDENTIAL
AMB112529
64
Protocol: AMB112529                                                                                                Page 2 of n
Population: Intent-to-Treat
Table 2.14:  Summary of Exploratory Echocardiogram
Planned 
Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Eccentricity
N
    XXX    
    XXX    
    XXX    
Index
Mean
     XX.X
     XX.X
     XX.X
Systolic
SD
     XX.XX
     XX.XX
     XX.XX
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Eccentricity
N
    XXX    
    XXX    
    XXX    
Index
Mean
     XX.X
     XX.X
     XX.X
Diastolic
SD
     XX.XX
     XX.XX
     XX.XX
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
      EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Baseline, Week 12, Week 24 and EW.
PPD


CONFIDENTIAL
AMB112529
65
Protocol: AMB112529                                                                                                Page 3 of n
Population: Intent-to-Treat
Table 2.14:  Summary of Exploratory Echocardiogram
Planned 
Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Tricuspid
N
    XXX    
    XXX    
    XXX    
Regurgitant
Mean
     XX.X
     XX.X
     XX.X
Jet Velocity
SD
     XX.XX
     XX.XX
     XX.XX
(m/s)
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Right
N
    XXX    
    XXX    
    XXX    
Ventricular
Mean
     XX.X
     XX.X
     XX.X
Pressure
SD
     XX.XX
     XX.XX
     XX.XX
(mmHg)
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Baseline, Week 12, Week 24 and EW.
PPD


CONFIDENTIAL
AMB112529
66
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.15:  Summary of Change from Baseline in Exploratory Echocardiogram
Planned 
Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Week 12
(N=XXX)
(N=XXX)
(N=XXX)
Pericardial
n
   XXX    
   XXX    
   XXX    
Effusion
No Change
  Absent
    XX (%)
     XX (%)
    XX (%)
     XX (%)
    XX (%)
     XX (%)
Improved
    XX (%)
    XX (%)
    XX (%)
Worsened
    XX (%)
    XX (%)
    XX (%)
Mean right
n
    XXX    
    XXX    
    XXX    
Atrial
Mean
     XX.X
     XX.X
     XX.X
Pressure
SD
     XX.XX
     XX.XX
     XX.XX
(mmHg)
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Tricuspid
n
    XXX    
    XXX    
    XXX    
Annular
Mean
     XX.X
     XX.X
     XX.X
Plane
SD
     XX.XX
     XX.XX
     XX.XX
Systolic
Q1
     XX.X
     XX.X
     XX.X
Excursion 
Median
     XX.X
     XX.X
     XX.X
(cm)
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Note:  Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal. Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Week 12, Week 24 and EW.
PPD


CONFIDENTIAL
AMB112529
67
Protocol: AMB112529                                                                                                Page 2 of n
Population: Intent-to-Treat
Table 2.15:  Summary of Change from Baseline in Exploratory Echocardiogram
Planned 
Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Week 12
(N=XXX)
(N=XXX)
(N=XXX)
Eccentricity
n
    XXX    
    XXX    
    XXX    
Index
Mean
     XX.X
     XX.X
     XX.X
Systolic
SD
     XX.XX
     XX.XX
     XX.XX
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Eccentricity
N
    XXX    
    XXX    
    XXX    
Index
Mean
     XX.X
     XX.X
     XX.X
Diastolic
SD
     XX.XX
     XX.XX
     XX.XX
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Note:  Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Week 12, Week 24 and EW.
PPD


CONFIDENTIAL
AMB112529
68
Protocol: AMB112529                                                                                                Page 3 of n
Population: Intent-to-Treat
Table 2.15:  Summary of Change from Baseline in Exploratory Echocardiogram
Planned 
Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Week 12
(N=XXX)
(N=XXX)
(N=XXX)
Tricuspid
N
    XXX    
    XXX    
    XXX    
Regurgitant
Mean
     XX.X
     XX.X
     XX.X
Jet Velocity
SD
     XX.XX
     XX.XX
     XX.XX
(m/s)
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Right
N
    XXX    
    XXX    
    XXX    
Ventricular
Mean
     XX.X
     XX.X
     XX.X
Pressure
SD
     XX.XX
     XX.XX
     XX.XX
(mmHg)
Q1
     XX.X
     XX.X
     XX.X
Median
     XX.X
     XX.X
     XX.X
Q3
     XX.X
     XX.X
     XX.X
Min.
     XX
     XX
     XX
Max.
     XX
     XX
     XX
Note:  Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Week 12, Week 24 and EW.
PPD


CONFIDENTIAL
AMB112529
69
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.16:  Summary of Cardiopulmonary Hemodynamics
Parameter
Treatment
Planned 
Relative Time
n
Mean
SD
Q1
Median
Q3
Min.
Max.
<Parameter (units)>
Ambrisentan 
Low Dose
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Ambrisentan 
High Dose
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Total
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Include heart rate, mean arterial blood pressure, mean pulmonary arterial pressure, mean right atrial 
pressure, left ventricular end diastolic pressure or pulmonary capillary wedge pressure, pulmonary vascular resistance, 
cardiac output, cardiac index (calculated value), arterial oxygen saturation and mixed venous oxygen
saturation.
PPD


CONFIDENTIAL
AMB112529
70
Protocol: AMB112529                                                                                                Page 1 of n  
Population: Intent-to-treat                                                                                
                                               
Table  2.18: Summary of Number of Subjects with School Days within the Past Month
Planned Relative Time
Low Dose
High Dose
Total
Baseline*
(N=XX)
(N=XX)
(N=XX)
Subjects with scheduled days
xx     (xx%)
xx     (xx%)
xx     (xx%)
Subjects with at least one scheduled day missed
xx     (xx%)
xx     (xx%)
xx     (xx%)
Number of scheduled days missed /
xx/xxx (xx%)
xx/xxx (xx%)
xx/xxx (xx%)
Number of scheduled days
Subjects with at least one scheduled day missed due to PAH
xx     (xx%)
xx     (xx%)
xx     (xx%)
Number of scheduled days missed due to PAH /
xx     (xx%)
xx     (xx%)
xx     (xx%)
Number of scheduled days
xx/xxx (xx%)
xx/xxx (xx%)
xx/xxx (xx%)
Note:  * Baseline is the last value recorded prior to start of study treatment.
       This summary excludes subjects with 0 scheduled days of school for the given period.
There were no subjects with follow up visits (of the 3 subjects who did not participate in 
       study AMB11488, one died, one was lost to follow-up and the other withdrew consent).
       EW = Early Withdrawal.  
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present Baseline, Weeks 4, 8, 12, 16, 20, 24 and EW.
PPD


CONFIDENTIAL
AMB112529
71
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.19:  Summary Statistics of School Days within the Past month
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Number
n
     XXX    
     XXX    
     XXX    
of scheduled days
Mean
      XX.X
      XX.X
      XX.X
SD
      XX.XX
      XX.XX
      XX.XX
Q1
      XX.X
      XX.X
      XX.X
Median
      XX.X
      XX.X
      XX.X
Q3
      XX.X
      XX.X
      XX.X
Min.
      XX
      XX
      XX
Max.
      XX
      XX
      XX
Number
N
     XXX    
     XXX    
     XXX    
of missed days
Mean
      XX.X
      XX.X
      XX.X
SD
      XX.XX
      XX.XX
      XX.XX
Q1
      XX.X
      XX.X
      XX.X
Median
      XX.X
      XX.X
      XX.X
Q3
      XX.X
      XX.X
      XX.X
Min.
      XX
      XX
      XX
Max.
      XX
      XX
      XX
Number
N
     XXX    
     XXX    
     XXX    
of missed days
Mean
      XX.X
      XX.X
      XX.X
due to PAH
SD
      XX.XX
      XX.XX
      XX.XX
Q1
     XX.X
      XX.X
      XX.X
Median
      XX.X
      XX.X
      XX.X
Q3
      XX.X
      XX.X
      XX.X
Min.
      XX
      XX
      XX
Max.
      XX
      XX
      XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
       This summary excludes subjects with 0 scheduled days of school for the given period.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.  Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Baseline, Weeks 4, 8, 12, 16, 20, 24 and EW.
PPD


CONFIDENTIAL
AMB112529
72
Protocol: AMB112529                                                                                                Page 2 of n
Population: Intent-to-Treat
Table 2.19:  Summary Statistics of School Days within the Past month
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Proportion of days
n
     XXX    
     XXX    
     XXX    
missed (%)
Mean
      XX.X
      XX.X
      XX.X
SD
      XX.XX
      XX.XX
      XX.XX
Q1
      XX.X
      XX.X
      XX.X
Median
      XX.X
      XX.X
      XX.X
Q3
      XX.X
      XX.X
      XX.X
Min.
      XX
      XX
      XX
Max.
      XX
      XX
      XX
Proportion of days
N
     XXX    
     XXX    
     XXX    
missed due to PAH(%)
Mean
      XX.X
      XX.X
      XX.X
SD
      XX.XX
      XX.XX
      XX.XX
Q1
      XX.X
      XX.X
      XX.X
Median
      XX.X
      XX.X
      XX.X
Q3
      XX.X
      XX.X
      XX.X
Min.
      XX
      XX
      XX
Max.
      XX
      XX
      XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
      This summary excludes subjects with 0 scheduled days of school for the given period.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal. Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present Baseline, Weeks 4, 8, 12, 16, 20, 24 and EW.
PPD


CONFIDENTIAL
AMB112529
73
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.21:  Summary of Subject Global Assessment (SF10 Health Survey for Children)
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Physical Health Summary
n
     XXX    
     XXX    
     XXX    
Mean
      XX.X
      XX.X
      XX.X
SD
      XX.XX
      XX.XX
      XX.XX
Q1
      XX.X
      XX.X
      XX.X
Median
      XX.X
      XX.X
      XX.X
Q3
      XX.X
      XX.X
      XX.X
Min.
      XX
      XX
      XX
Max.
      XX
      XX
      XX
Psychosocial Summary
N
     XXX    
     XXX    
     XXX    
Mean
      XX.X
      XX.X
      XX.X
SD
      XX.XX
      XX.XX
      XX.XX
Q1
      XX.X
      XX.X
      XX.X
Median
      XX.X
      XX.X
      XX.X
Q3
      XX.X
      XX.X
      XX.X
Min.
      XX
      XX
      XX
Max.
      XX
      XX
      XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present Baseline, Weeks 4, 8, 12, 16, 20, 24 and EW.
PPD


CONFIDENTIAL
AMB112529
74
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Table 2.23:  Summary of SF10 Health Survey – Number and Percentage of Subjects with Particular Item Responses
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Completed SF-10 ^
    XX (%) 
    XX (%) 
    XX (%) 
In general, would you say your child’s health is
  n
    XX
    XX
    XX
  Excellent
    XX (%) 
    XX (%) 
    XX (%) 
  Very Good
    XX (%)
    XX (%)
    XX (%)
  Good
    XX (%)
    XX (%)
    XX (%)
  Fair
    XX (%)
    XX (%)
    XX (%)
  Poor
    XX (%)
    XX (%)
    XX (%)
During the past 4 weeks, has your child been limited doing 
things that take some energy such as riding a bike or skating 
due to HEALTH problems?
  n
    XX
    XX
    XX
  Yes, limited a lot
    XX (%) 
    XX (%) 
    XX (%) 
  Yes, limited some
    XX (%)
    XX (%)
    XX (%)
  Yes, limited a little
    XX (%)
    XX (%)
    XX (%)
  No, not limited
    XX (%)
    XX (%)
    XX (%)
During the past 4 weeks, has your child been limited during 
bending, lifting or stooping due to HEALTH problems?
  n
    XX
    XX
    XX
  Yes, limited a lot
    XX (%) 
    XX (%) 
    XX (%) 
  Yes, limited some
    XX (%)
    XX (%)
    XX (%)
  Yes, limited a little
    XX (%)
    XX (%)
    XX (%)
  No, not limited
    XX (%)
    XX (%)
    XX (%)
etc...
Note:  * Baseline is the last value recorded prior to start of study treatment.
       ^ Completed at least one of the 10 items of SF-10
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present Baseline, Weeks 4, 8, 12, 16, 20, 24 and EW.
PPD


CONFIDENTIAL
AMB112529
75
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.1:  Summary of Exposure to Investigational Product
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
(N=XXX)
(N=XXX)
(N=XXX)
Number of days
n
     XXX    
   XXX    
   XXX    
of exposure
Mean
      XX.X
    XX.X
    XX.X
SD
      XX.XX
    XX.XX
    XX.XX
Q1
      XX.X
    XX.X
    XX.X
Median
      XX.X
    XX.X
    XX.X
Q3
      XX.X
    XX.X
    XX.X
Min.
      XX
    XX
    XX
Max.
      XX
    XX
   XX
Interval of days
n
   XXX
   XXX
   XXX
of exposure
<=30 days
    XX (%)
    XX (%)
    XX (%)
31 to 60 days
    XX (%)
    XX (%)
    XX (%)
61 to 90 days
    XX (%)
    XX (%)
    XX (%)
Etc..
    XX (%)
    XX (%)
    XX (%)
Note: For each patient, exposure (days) = date of last dose of study drug – first dose date + 1 day.
     Q1 = 1st quartile, Q3 = 3rd quartile.
      Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
      High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
76
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.2:  Summary of Treatment-Emergent Adverse Events
System Organ Class
  Preferred term
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Any event
    XX (%)
    XX (%)
    XX (%)
Gastrointestinal disorders
  Any event
    XX (%)
    XX (%)
    XX (%)
  Dyspepsia
    XX (%)
    XX (%)
    XX (%)
  Nausea
    XX (%)
    XX (%)
    XX (%)
Nervous system disorders
  Any event
    XX (%)
    XX (%)
    XX (%)
  Headache
    XX (%)
    XX (%)
    XX (%)
  Dizziness
    XX (%)
    XX (%)
    XX (%)
  Somnolence
    XX (%)
    XX (%)
    XX (%)
  Tremor
    XX (%)
    XX (%)
    XX (%)
  Sedation
    XX (%)
    XX (%)
    XX (%)
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Events will be sorted in descending order of total incidence across treatment groups for the System Organ 
Class and in descending order of total incidence for the preferred term within each System Organ Class. If the total incidence 
for any two or more preferred terms is equal, they will be presented in alphabetical order.
PPD


CONFIDENTIAL
AMB112529
77
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.3:  Summary of Treatment-Emergent Adverse Events by Preferred Term
  Preferred term
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Any event
    XX (%)
    XX (%)
    XX (%)
  Dyspepsia
    XX (%)
    XX (%)
    XX (%)
  Nausea
    XX (%)
    XX (%)
    XX (%)
  Headache
    XX (%)
    XX (%)
    XX (%)
  Dizziness
    XX (%)
    XX (%)
    XX (%)
  Somnolence
    XX (%)
    XX (%)
    XX (%)
  Tremor
    XX (%)
    XX (%)
    XX (%)
  Sedation
    XX (%)
    XX (%)
    XX (%)
Etc..
Note: Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
      High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Events will be sorted in descending order of total incidence across treatment groups for the preferred 
term.  If the total incidence for any two or more preferred terms is equal, they will be presented in alphabetical order.
PPD


CONFIDENTIAL
AMB112529
78
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.4:  Summary of Treatment-Emergent Adverse Events by Maximum Intensity
Ambrisentan Low Dose
(N=XXX)
Ambrisentan High Dose
(N=XXX)
System Organ Class
  Preferred Term
Mild
Moderate
Severe
Mild
Moderate
Severe
Any Event
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
Cardiovascular disorders
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
  Any Event
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
  Hypertension
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
  Syncope
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
  Aneurysms
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
  Hypotension
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
  Etc..
  
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Repeat display for Total group on following page.  Subjects who experience the same event several times, 
with different intensities/grades, will only be counted with the maximum intensity/grade. For example, a subject who had three 
headaches, two severe and one mild, is counted only once, under the preferred term "Headache" in the "Severe" column of the 
table. Likewise, each subject is counted only once, at the maximum severity/grade, within each SOC even though they may have 
several different PT events at different intensities/grades within that SOC. Events will be sorted in descending order of 
total incidence across treatment groups for the System Organ Class and in descending order of total incidence for the 
preferred term within each System Organ Class. If the total incidence for any two or more preferred terms is equal, they will 
be presented in alphabetical order.
PPD


CONFIDENTIAL
AMB112529
79
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.5:  Summary of Treatment-Emergent Adverse Events by Action Taken with IP
System Organ Class
  Preferred term
    Action Taken
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Any event
    XX (%)
    XX (%)
    XX (%)
<System Organ Class 1>
<Any event>
    XX (%)
    XX (%)
    XX (%)
  IP withdrawn
    XX (%)
    XX (%)
    XX (%)
  Dose interrupted
    XX (%)
    XX (%)
    XX (%)
  Dose reduced
    XX (%)
    XX (%)
    XX (%)
  Dose not changed
    XX (%)
    XX (%)
    XX (%)
  Dose increased
    XX (%)
    XX (%)
    XX (%)
  Not applicable
    XX (%)
    XX (%)
    XX (%)
<Preferred Term 1>
    XX (%)
    XX (%)
    XX (%)
  IP withdrawn
    XX (%)
    XX (%)
    XX (%)
  Dose interrupted
    XX (%)
    XX (%)
    XX (%)
  Dose reduced
    XX (%)
   XX (%)
    XX (%)
  Dose not changed
    XX (%)
    XX (%)
    XX (%)
  Dose increased
    XX (%)
    XX (%)
    XX (%)
  Not applicable
    XX (%)
    XX (%)
    XX (%)
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Subjects who experience the same event several times, with different Action Taken, will only be counted 
once for the overall and Preferred Term category, but more than once in the Action Taken categories. Events will be sorted in 
descending order of total incidence across treatment groups for the preferred term.  If the total incidence for any two or 
more preferred terms is equal, they will be presented in alphabetical order.
PPD


CONFIDENTIAL
AMB112529
80
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.8:  Summary of Cumulative Incidence of Treatment-Emergent Adverse Events by Time to First Occurrence
Treatment: Ambrisentan Low Dose (N=XXX)
Time Since Start of Study Medication
System Organ Class
  Preferred term
<2 Wks
<4 Wks
<8 Wks
<12 Wks
<16 Wks
<20 Wks
<24 Wks
Overall
Any event
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
Gastrointestinal 
disorders
  Any event
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  Dyspepsia
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  Nausea
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
Nervous system 
disorders
  Any event
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  Headache
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  Dizziness
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  Somnolence
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  Tremor
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  Sedation
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
  XX (%)
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Events will be sorted in descending order of total incidence across treatment groups for the preferred 
term.  If the total incidence for any two or more preferred terms is equal, they will be presented in alphabetical order. 
Repeat for Ambrisentan High Dose and Total groups.
PPD


CONFIDENTIAL
AMB112529
81
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.10:  Summary of Serious Treatment-Emergent Adverse Events – Number of Subjects and Occurrences
____________________________________________________________________________________________________________
                                                                                                  Fatalities
                                                                         Occurrences              Causally  
                                                                         Causally                 Related   
                                       Subjects   Subjects               Related to               to        
System Organ Class         Treatment   Affected,  Exposed,  Occurrences  Treatment,  Fatalities,  Treatment,
Preferred Term             Group       Number     Number    All, Number  Number*     Number       Number*   
____________________________________________________________________________________________________________
CARDIAC DISORDERS                                                                                           
Atrial fibrillation        Ambrisentan    x          x         x            x           x            x      
Low Dose      
                           Ambrisentan    x          x         x            x           x            x      
                           High Dose                                                                              
                           Total          x          x         x            x           x            x      
Bradyarrhythmia            Ambrisentan    x          x         x            x           x            x      
Low Dose
                           Ambrisentan    x          x         x            x           x            x      
                           High Dose                                                                              
                           Total          x          x         x            x           x            x      
etc
  
Note: * Drug-related as determined by the investigator.                                                     
PPD


CONFIDENTIAL
AMB112529
82
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.11:  Summary of Serious Treatment-Emergent Adverse Events by Outcome
System Organ Class
  Preferred term
  Outcome
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Any event
    XX (%)
    XX (%)
    XX (%)
<System Organ Class 1>
<Any event>
    XX (%)
    XX (%)
    XX (%)
  Recovered/Resolved
    XX (%)
    XX (%)
    XX (%)
  Recovering/Resolving
    XX (%)
    XX (%)
    XX (%)
  Recovered/Resolved with sequelae
    XX (%)
    XX (%)
    XX (%)
  Not Recovered/ Not Resolved
    XX (%)
    XX (%)
    XX (%)
<Preferred Term 1>
    XX (%)
    XX (%)
    XX (%)
  Recovered/Resolved
    XX (%)
    XX (%)
    XX (%)
  Recovering/Resolving
    XX (%)
    XX (%)
    XX (%)
  Recovered/Resolved with sequelae
    XX (%)
    XX (%)
    XX (%)
  Not Recovered/ Not Resolved
    XX (%)
    XX (%)
    XX (%)
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Subjects who experience the same event several times, with different Outcome, will only be counted once for 
the overall and Preferred Term category, but more than once in the Outcome categories. Events will be sorted in descending 
order of total incidence across treatment groups for the preferred term.  If the total incidence for any two or more preferred 
terms is equal, they will be presented in alphabetical order.
PPD


CONFIDENTIAL
AMB112529
83
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.21:  Summary of Haematology Data
Parameter: <Parameter (units)>
Treatment
Planned 
Relative Time
N
Mean
SD
Q1
Median
Q3
Min.
Max.
Ambrisentan 
Low Dose
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 2
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 4
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Ambrisentan 
High Dose
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 2
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 4
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Total
Etc..
(N=XXX)
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal. Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
84
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.23:  Summary of Haematology Data of Potential Clinical Concern
Parameter: <Parameter (units) [Reference range = xx.x to xx.x ]>
Planned 
Relative Time
Category
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Baseline*
N
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 2
N
   XXX
   XXX
   XXX
> reference range high
    XX (%)
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 4
N
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 8
N
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 12
N
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       For 'Any time post-baseline':-
       Subjects with both Normal and Low values are counted once under their worst case (Low).                       
       Subjects with both Normal and High values are counted once under their worst case (High).             
       Subjects with both High and Low values are counted under both categories.                             
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
85
Protocol: AMB112529                                                                                                Page 2 of n
Population: Safety
Table 3.23:  Summary of Haematology Data of Potential Clinical Concern
Parameter: <Parameter (units) [Reference range = xx.x to xx.x ]>
Planned 
Relative Time
Category
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Week 16
N
  XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 20
N
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 24
n
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
EW
n
   XXX
   XXX
   XXX
> reference range high
    XX (%)
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Any time
post-baseline
n
   XXX
   XXX
   XXX
> reference range high
    XX (%)
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       For 'Any time post-baseline':-
       Subjects with both Normal and Low values are counted once under their worst case (Low).                       
       Subjects with both Normal and High values are counted once under their worst case (High).             
       Subjects with both High and Low values are counted under both categories.                             
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
86
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.29:  Summary of Liver Events Assessment
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
(N=XXX)
(N=XXX)
(N=XXX)
Subjects reporting a significant liver chemistry result *
XX  (XX%)
XX  (XX%)
XX  (XX%)
Subjects with event occurring while receiving study treatment
XX  (XX%)
XX  (XX%)
XX  (XX%)
Subjects with event occurring after stopping study treatment
XX  (XX%)
XX  (XX%)
XX  (XX%)
Note:  * A significant liver chemistry result is any result which meets the stopping criteria defined in the protocol.
Detailed information on liver events assessment can be found in related listings.
Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
      High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).  
PPD


CONFIDENTIAL
AMB112529
87
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.30  Summary of Vital Signs
Parameter
Treatment
Planned 
Relative Time
n
Mean
SD
Q1
Median
Q3
Min.
Max.
<Parameter (units)>
Ambrisentan 
Low Dose
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 2
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 4
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Ambrisentan 
High Dose
Baseline*
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
(N=XXX)
Week 2
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 4
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 8
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 12
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 16
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 20
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Week 24
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
EW 
XXX
XX.X
XX.XX
XX.X
XX.X
XX.X
XX
XX
Total
Etc..
(N=XXX)
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal. Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Include Height, Weight, Systolic BP, Diastolic BP, Heart Rate, BSA and BMI.
PPD


CONFIDENTIAL
AMB112529
88
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.32:  Summary of Vital Signs Data of Potential Clinical Concern
Parameter: <Parameter (units) [Reference range = xx.x to xx.x ]>
Planned 
Relative Time
Category
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Baseline*
n
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 2
n
   XXX
   XXX
   XXX
> reference range high
    XX (%)
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 4
n
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 8
n
   XXX
   XXX
  XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 12
n
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       For 'Any time post-baseline':-
       Subjects with both Normal and Low values are counted once under their worst case (Low).                       
       Subjects with both Normal and High values are counted once under their worst case (High).             
       Subjects with both High and Low values are counted under both categories.                             
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Include Systolic BP, Diastolic BP and Heart Rate
PPD


CONFIDENTIAL
AMB112529
89
Protocol: AMB112529                                                                                                Page 2 of n
Population: Safety
Table 3.32:  Summary of Vital Signs Data of Potential Clinical Concern
Parameter: <Parameter (units) [Reference range = xx.x to xx.x ]>
Planned 
Relative Time
Category
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Week 16
n
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 20
n
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Week 24
n
   XXX
   XXX
   XXX
> reference range high
    XX (%) 
   XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
EW
n
   XXX
   XXX
   XXX
> reference range high
    XX (%)
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Any time
Post-baseline
n
   XXX
   XXX
   XXX
> reference range high
    XX (%)
    XX (%) 
    XX (%) 
< reference range low
    XX (%)
    XX (%)
    XX (%)
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       For 'Any time post-baseline':-
       Subjects with both Normal and Low values are counted once under their worst case (Low).                       
       Subjects with both Normal and High values are counted once under their worst case (High).             
       Subjects with both High and Low values are counted under both categories.                             
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Include Systolic BP, Diastolic BP and Heart Rate
PPD


CONFIDENTIAL
AMB112529
90
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.34:  Summary of Physical Examination by Visit
Planned Relative Time: Baseline
Low Dose
(N=XXX)
High Dose
(N=XXX)
Total
(N=XXX)
Ascites
  Absent
      XX (%)
      XX (%)
      XX (%)
  Present
      XX (%)
      XX (%)
      XX (%)
Peripheral Oedema
  Absent
      XX (%)
      XX (%)
      XX (%)
  Present
      XX (%)
      XX (%)
      XX (%)
Saturated Oxygen (units)
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
     XX.XX
      XX.XX
  Median
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
91
Protocol: AMB112529                                                                                                Page 2 of n
Population: Safety
Table 3.34:  Summary of Physical Examination by Visit
Planned Relative Time: Week 12
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Ascites
  n
     XX
     XX
     XX
  Absent
      XX (%)
      XX (%)
      XX (%)
  Present:Improved
      XX (%)
      XX (%)
      XX (%)
  Present:Unchanged 
      XX (%)
      XX (%)
      XX (%)
  Present:Worsened 
      XX (%)
      XX (%)
      XX (%)
Peripheral Oedema 
  n
      XX
     XX
     XX
  Absent
      XX (%)
      XX (%)
      XX (%)
  Present:Improved
      XX (%)
      XX (%)
      XX (%)
  Abnormal:Worsened 
      XX (%)
      XX (%)
      XX (%)
  Abnormal:Unchanged
      XX (%)
     XX (%)
      XX (%)
Saturated Oxygen (units)
  n
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present for Week 12, Week 24 and EW.
PPD


CONFIDENTIAL
AMB112529
92
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.35:  Summary of 12-lead ECG
Planned 
Relative Time
Category
Ambrisentan 
Low Dose
(N=XXX)
Ambrisentan 
High Dose
(N=XXX)
Total
(N=XXX)
Baseline*
n
   XXX
   XXX
   XXX
Normal
    XX (%) 
    XX (%) 
    XX (%) 
Abnormal, not clinically significant
    XX (%)
    XX (%)
    XX (%)
Abnormal, clinically significant
    XX (%)
    XX (%)
    XX (%)
Week 12
n
   XXX
   XXX
   XXX
Normal
    XX (%) 
    XX (%) 
    XX (%) 
Abnormal, not clinically significant
    XX (%)
    XX (%)
    XX (%)
Abnormal, clinically significant
    XX (%)
    XX (%)
    XX (%)
Week 24
n
   XXX
   XXX
  XXX
Normal
    XX (%) 
    XX (%) 
    XX (%) 
Abnormal, not clinically significant
    XX (%)
    XX (%)
    XX (%)
Abnormal, clinically significant
    XX (%)
    XX (%)
    XX (%)
EW
n
   XXX
   XXX
   XXX
Normal
    XX (%) 
    XX (%) 
    XX (%) 
Abnormal, not clinically significant
    XX (%)
    XX (%)
    XX (%)
Abnormal, clinically significant
    XX (%)
    XX (%)
    XX (%)
Any time post-baseline
n
   XXX
   XXX
   XXX
Normal
    XX (%) 
    XX (%) 
    XX (%) 
Abnormal, not clinically significant
    XX (%)
    XX (%)
    XX (%)
Abnormal, clinically significant
    XX (%)
    XX (%)
    XX (%)
Note:  * Baseline is the last value recorded prior to start of study treatment.
There were no subjects with post-last dose follow up visits. Of the 3 subjects who did not
  
participate in study AMB115488, one died, one was lost to follow-up and the other was investigator discretion.
       EW = Early Withdrawal.
       For 'Any time post-baseline' if a subject had more than one ECG result, the worst case will
       be chosen for a conservative approach.  
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
PPD


CONFIDENTIAL
AMB112529
93
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.36:  Summary of Endocrinology assessments – Female
Overall
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Female breast development
   n
   XXX
   XXX
   XXX
   Pre-adolescent
    XX (%)
    XX (%)
    XX (%)
   Breast bud stage
    XX (%)
    XX (%)
    XX (%)
   Etc..
    XX (%)
    XX (%)
    XX (%)
Female pubic hair development 
   n
   XXX
   XXX
   XXX
   Pre-adolescent
    XX (%)
    XX (%)
    XX (%)
   Sparse growth
    XX (%)
    XX (%)
    XX (%)
  Etc.. 
    XX (%)
    XX (%)
    XX (%)
Note:  * Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Pre-pubertal: Stage 1 breast development, Post-pubertal: Stage ≥ 2 breast development.
Programming notes: Present for Baseline, Week 12, Week 24 and EW, Overall and by Pubertal Status (Pre-pubertal, Post 
Pubertal).
PPD


CONFIDENTIAL
AMB112529
94
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.37:  Summary of Endocrinology assessments – Male
Overall
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Right Testicular volume 
(units)
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Left Testicular volume 
(units)
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
     XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Note:  * Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal. 
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Pre-pubertal: testicular volume < 4 ml, Post-pubertal: testicular volume ≥ 4 ml
Programming notes: Present for Baseline, Week 12, Week 24 and EW, Overall and by Pubertal Status (Pre-pubertal, Post 
Pubertal).
PPD


CONFIDENTIAL
AMB112529
95
Protocol: AMB112529                                                                                                Page 2 of n
Population: Safety
Table 3.37:  Summary of Endocrinology assessments – Male
Overall
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
Baseline*
(N=XXX)
(N=XXX)
(N=XXX)
Male genital development
   N
   XXX
   XXX
   XXX
   Pre-adolescent
    XX (%)
    XX (%)
    XX (%)
   Etc..
    XX (%)
    XX (%)
    XX (%)
Male pubic hair development
   N
   XXX
   XXX
   XXX
   Pre-adolescent
    XX (%)
    XX (%)
    XX (%)
   Sparse growth
    XX (%)
    XX (%)
    XX (%)
   Etc. 
    XX (%)
    XX (%)
    XX (%)
Note:  * Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal.
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Pre-pubertal: testicular volume < 4 ml, Post-pubertal: testicular volume ≥ 4 ml
Programming notes: Present for Baseline, Week 12, Week 24 and EW, Overall and by Pubertal Status (Pre-pubertal, Post 
Pubertal).
PPD


CONFIDENTIAL
AMB112529
96
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.38:  Summary of Pubertal Development Shifts from Baseline – Female
Overall
Female Breast Development
Treatment
Planned 
Relative 
Time
Code
Baseline Code
1
2
3
4
5
Ambrisentan Low Dose (N=XXX)
Week 12
1
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
2
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
3
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
4
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
5
XX (%) 
XX (%) 
XX (%) 
XX (%) 
XX  
Unknown/
Not Recorded
XX  
XX  
XX  
XX  
XX  
Week 24
1
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
2
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
3
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
4
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
5
XX (%) 
XX (%) 
XX (%) 
XX (%) 
XX  
Unknown/
Not Recorded
XX  
XX  
XX  
XX  
XX  
Etc..
Note:  Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal. 
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Pre-pubertal: Stage 1 breast development, Post-pubertal: Stage ≥ 2 breast development.
Programming notes: Present for Female Breast Development and Female Pubic Hair Development, for each treatment group, overall
and by Pubertal Status (Pre-pubertal, Post Pubertal), at week 12, 24 and EW. Put coding below on first page on listing:-
       Female Breast Development:-
       1=Pre-adolescent; elevation of papilla only, 2=etc…
       Female Pubic Hair Development:-
       1=Pre-adolescent; vellus over pubes not developed over anterior abdominal wall, 2=etc…
PPD


CONFIDENTIAL
AMB112529
97
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.39:  Summary of Pubertal Development Shifts from Baseline - Male
Overall
Male Genital Development
Treatment
Planned 
Relative 
Time
Code
Baseline Code
1
2
3
4
5
Ambrisentan Low Dose (N=XXX)
Week 12
1
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
2
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
3
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
4
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
5
XX (%) 
XX (%) 
XX (%) 
XX (%) 
XX 
Unknown/
Not Recorded
XX  
XX  
XX  
XX  
XX  
Week 24
1
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
2
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
3
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
4
XX (%)
XX (%)
XX (%)
XX (%)
XX (%)
5
XX (%) 
XX (%) 
XX (%) 
XX (%) 
XX  
Unknown/
Not Recorded
XX  
XX  
XX  
XX  
XX  
Etc..
Note:  Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal. 
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Pre-pubertal: testicular volume < 4 ml, Post-pubertal: testicular volume ≥ 4 ml
Programming notes: Present for Male Genital Development and Male Pubic Hair Development, for each treatment group, overall and 
by Pubertal Status (Pre-pubertal, Post Pubertal),at week 12, 24 and EW. Put coding below on first page on listing:-
       Male Genital Development:-
       1=Pre-adolescent; testes, scrotum and penis same size and proportion, 2=etc…
       Male Pubic Hair Development:-
       1=Pre-adolescent; velus over pubes no further developed than over abdominal wall, 2=etc…
PPD


CONFIDENTIAL
AMB112529
98
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.40:  Summary of Testicular Volume Change from Baseline - Male
Overall
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
(N=XXX)
(N=XXX)
(N=XXX)
Week 12
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Week 24
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Etc..
Note:  Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal. 
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Pre-pubertal: testicular volume < 4 ml, Post-pubertal: testicular volume ≥ 4 ml
Programming notes: Present overall and by Pubertal Status (Pre-pubertal, Post Pubertal), at week 12, 24 and EW.
PPD


CONFIDENTIAL
AMB112529
99
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.41:  Summary of Change from Baseline in Plasma Endocrine Parameters – Female
Overall
Parameter: <Parameter (units)>
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
(N=XXX)
(N=XXX)
(N=XXX)
Week 12
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Week 24
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Etc..
Note:  Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal. 
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Pre-pubertal: Stage 1 breast development, Post-pubertal: Stage ≥ 2 breast development.
Programming notes: Present overall and by Pubertal Status (Pre-pubertal, Post Pubertal), at week 12, 24 and EW, for Follicle 
Stimulating Hormone, Luteinizing Hormone, Sex Hormone Binding Globulin, Total Testosterone and Inhibin B. 
PPD


CONFIDENTIAL
AMB112529
100
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Table 3.41:  Summary of Change from Baseline in Plasma Endocrine Parameters – Male
Overall
Parameter: <Parameter (units)>
Planned Relative Time
Ambrisentan 
Low Dose
Ambrisentan 
High Dose
Total
(N=XXX)
(N=XXX)
(N=XXX)
Week 12
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Week 24
  N
     XXX    
     XXX    
     XXX    
  Mean
      XX.X
      XX.X
      XX.X
  SD
      XX.XX
      XX.XX
      XX.XX
  Q1
      XX.X
      XX.X
      XX.X
  Median
      XX.X
      XX.X
      XX.X
  Q3
      XX.X
      XX.X
      XX.X
  Min.
      XX
      XX
      XX
  Max.
      XX
      XX
      XX
Etc..
Note:  Baseline is the last value recorded prior to start of study treatment.
       EW = Early Withdrawal. 
       Q1 = 1st quartile, Q3 = 3rd quartile.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Pre-pubertal: testicular volume < 4 ml, Post-pubertal: testicular volume ≥ 4 ml
Programming notes: Present overall and by Pubertal Status (Pre-pubertal, Post Pubertal), at week 12, 24 and EW, for Follicle 
Stimulating Hormone, Luteinizing Hormone, Sex Hormone Binding Globulin, Total Testosterone and Inhibin B. 
PPD


CONFIDENTIAL
AMB112529
101
Protocol: AMB112529                                                                                                Page 1 of n  
Population: Intent-to-treat                                                                                 
Listing 1.1:
Listing of Randomised and Actual Treatments
Country: Argentina
Centre ID: XXXXXX
                                                                                    
Centre 
ID/
Subject 
ID
Randomisation
Number / Date
Randomisation
Strata
Actual
Strata
Randomised /
Actual Treatment
Treatment
Start Date
Deviation
[1]
XXXXXX
XXXXXX /
DDMMMYYYY
Aetiology - IPAH /
Age 12-18
IPAH /
Age 12-18
Low dose /
Low dose
DDMMMYYY
XXXXXX
XXXXXX /
DDMMMYYYY
Aetiology – HPAH /
Age 12-18
HPAH /
Age 12-18
Low dose /
Low dose
DDMMMYYY
Note: 1 = Indicates subjects who have a deviation between their randomised and actual strata or treatment.
      IPAH, idiopathic PAH; HPAH, heritable [familial] PAH; PAH-CTD, secondary to connective tissue disease;
      PAH-CHD,persistent despite surgical repair of atrial/ventricular/atrio-ventricular septal defects, and
      persistent patent ductus. 
Programming notes: Sort by Country, Centre ID, Subject ID. 


CONFIDENTIAL
AMB112529
102
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 1.2:  Listing of Reasons for Study Withdrawal
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Date of 
Withdrawal
Study
Day
Reason for 
Withdrawal
XXXXXX/ 
XXXXXX
DDMMMYYYY
XX
XXXXXXXXXXXXX
XXXXXX/ 
XXXXXX
DDMMMYYYY
XX
XXXXXXXXXXXXX
XXXXXX/ 
XXXXXX
DDMMMYYYY
XX
XXXXXXXXXXXXX
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID.
PPD


CONFIDENTIAL
AMB112529
103
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 1.3:  Listing of Subjects with Inclusion/Exclusion Criteria Deviations
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Type
Criterion
XXXXXX/ 
XXXXXX
Inclusion
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Exclusion
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
104
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 1.4:  Listing of Demographic Characteristics
Treatment: Ambrisentan Low Dose
  
Centre ID/
Subject ID
Partial
Date of Birth
Age (years)*
Sex
Child Bearing 
Potential
Ethnicity
XXXXXX/ 
XXXXXX
YYYY
XX
Female
Pre-menarcheal
Hispanic/Latino
Etc..
Note:  Age is based on full date of birth.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
105
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 1.5:  Listing of Race
Treatment: Ambrisentan Low Dose
  
Centre ID/
Subject ID
Race
XXXXXX/ 
XXXXXX
Asian – East Asian Heritage
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
106
Protocol: AMB112529                                                                                                Page 1 of n  
Population: Intent-to-treat                                                                                 
Listing  1.6:  Listing of Disease History
Treatment: Ambrisentan Low Dose
Duration
Centre ID /
Date of
of PAH
Baseline
Subject ID
Diagnosis
Sub category
Diagnosis
(yrs)
WHO FC
XXXXXX /
Idiopathic PAH
DDMMMYYYY
X.X
I
XXXXXX
XXXXXX /
XXXXXX
Persistent PAH despite surgical 
repair
Atrio-ventricular septal 
defects
DDMMMYYYY
X.X
II
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
107
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 1.7:  Listing of Medical Conditions
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age (y)/
Sex/
Classification
Preferred Term
Condition
Status
XXXXXX/ 
XXXXXX
XX/
XXXXXX
Hepatobiliary disorders
XXXXXXXXXXXXXXX
HEPATITIS A
Current
Psychiatric disorders
XXXXXXXXXXXXXXXX
PARANOIA COMBINED WITH MANIA.
Past
XXXXXX/ 
XXXXXX
XX/
XXXXXX
Eye disorders
XXXXXXXXXXXXXXXX
ASTIGMATISM
Current
XXXXXX/ 
XXXXXX
XX/
XXXXXX
Metabolism and nutrition 
disorders
XXXXXXXXXXXX
RICKETS
Current
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
108
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 1.8:  Listing of Medications
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
ATC Level 1/ 
Ingredient/
Verbatim Text
Unit
Dose/    
Units/ 
Freq/    
Route
Date 
Started/
Study Day
Date 
Stopped/
Study Day
XXXXXX/ 
XXXXXX
Endocrine & metabolic/ 
Fluticasone propionate/
FLIXOTIDE #
2/ 
MG/
2XD/
IH
15
Endocrine & metabolic/ 
Fluticasone propionate/
FLIXOTIDE #
4/ 
MG/
2XD/
IH
21
Ongoing
Etc..
Etc..
Note:  * Prior, # Concomitant, $ Post-treatment.
       PAH Therapies are not included within this listing, for PAH Therapy please see Listing 1.7
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD
PPD
PPD


CONFIDENTIAL
AMB112529
109
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 1.9:  Listing of PAH Therapy
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Drug Class/
ATC Level 1/
Ingredient/
Verbatim Text/
Total 
Daily
Dose/    
Units
Date 
Started/
Study Day
Date 
Stopped/
Study Day
Reason the 
medication 
discontinued or 
changed?
XXXXXX/ 
XXXXXX
XXXXXXXXXXXXXXXXX/
XXXXXXXXXXXXXXXXXXXXXXXXX/ 
XXXXXXXXXXXXXXXXX/
XXXXXXXXXXX #@
X/ 
XX
DDMMMYYYY/
XX
DDMMMYYYY
XXXXXXXXXXXXXXX
XXXXXX/ 
XXXXXX
XXXXXXXXXXXXXXXXX/
XXXXXXXXXXXXXXXXXXXXXXXXX/ 
XXXXXXXXXXXXXXXXX/
XXXXXXXXXXX #
X/ 
XX
DDMMMYYYY/
XX
Ongoing
XXXXXXXXXXXXXX
Etc..
Etc..
Note:  * Prior, # Concomitant, $ Post-treatment.
       @ Ongoing background PAH therapy at baseline
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
110
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 1.10:  Relationship between ATC Level 1, Ingredient and Verbatim Text
ATC Level 1
Ingredient
Verbatim Text
Endocrine & metabolic
Fluticasone Propionate
FLIXOTIDE
Prednisolone
PREDNISOLONE
Drugs acting via the nervous 
system
Paracetamol
PANADOL 
CHILDREN'S PANADOL 1-5YERS
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Sort by ATC level 1treatment group, Ingredient. 
PPD


CONFIDENTIAL
AMB112529
111
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 1.11:  Listing of Protocol Deviation
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Important 
Protocol
Deviations
Protocol Deviation Category
Protocol Deviation 
Description
Protocol 
Deviation 
Date/
Study Day
Visit Phase
Action taken
XXXXXX/ 
XXXXXX
Y
Biological specimen sample procedures
XXXXXXXXXXXXXXXXXXXX
XXX *
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXXXXX
XXXXXXXXXXX
X
XXXXXX/ 
XXXXXX
N
Other: XXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXX
XXX
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXXXXX
XXXXXXXXXXX
X
Etc..
Etc..
Note:  * Important Deviation
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
112
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 2.1:  Listing of 6 Minute Walk Distance Data
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Visit
Visit 
Date/
Study Day
Distance Walked (m)
Did subject 
walk less 
than 6 
minutes?/
Reason for 
stopping 
prematurely
Duration 
walked 
(seconds)
Did subject 
use 
supplemental 
oxygen
Oxygen 
flow 
rate 
(L/min)
Actual
Change
from 
Baseline
Percentage
Change 
from 
Baseline
XXXXXX/ 
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXX
Y/
XXXXXXXXXXXX
XXX
Y
XXXX
XXXXXXX
DDMMMYYYY/
XX
XXX
XXX
XXX
Y/
XXXXXXXXXXXX
XXX
Y
XXXX
XXXXXXX
DDMMMYYYY/
XX
XXX
XXX
XXX
N
N
XXXXXXX
DDMMMYYYY/
XX
XXX
XXX
XXX
N
N
Etc..
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
113
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 2.2:  Listing of Clinical Worsening of PAH
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Event Date/
Study Day
Clinical worsening criteria
XXXXXX/ 
XXXXXX
DDMMMYYYY/
XX
Hospitalisation for worsening of PAH
DDMMMYYYY/
XX
PAH related deterioration: Clinical signs or symptoms of right sided heart failure
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
114
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 2.3:  Listing of WHO Functional Class Data
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Visit
Visit 
Date/
Study Day
WHO pulmonary 
hypertension 
functional 
classification
Actual 
*
Change 
from 
Baseline
Change 
Categorisation
XXXXXX/ 
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
Class II
2
XXXXXXX
DDMMMYYYY/
XX
Class II
2
0
NC
XXXXXXX
DDMMMYYYY/
XX
Class IV
4
2
Det
XXXXXXX
DDMMMYYYY/
XX
Class I
1
-1
Imp
Etc..
Etc..
Note:  There are 4 grades for WHO FC based on severity of symptoms (Class I = none, Class IV = most severe).
       * Grades mapped to numeric scale 1-4 (i.e. Class IV = 4). 
       Change categorisation (based on -2, -1, 0, +1, +2); NC=No Change (0), Imp=Improved (-1,-2),
       Det=Deterioration (+1,+2).
      Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
115
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 2.4:  Listing of Plasma NT-Pro BNP Concentration (ng/L)
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Visit
Visit 
Date/
Study Day
Visit Value
Change from Baseline
Raw 
Log
Raw
Log*
XXXXXX/ 
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXX.X
X.XX
XXXXXXX
DDMMMYYYY/
XX
XXX.X
X.XX
XXX.X
X.XX
XXXXXXX
DDMMMYYYY/
XX
XXX.X
X.XX
XXX.X
X.XX
XXXXXXX
DDMMMYYYY/
XX
XXX.X
X.XX
XXX.X
X.XX
Etc..
Etc..
Note:  * Log (change from baseline) = Log (Visit) – Log (Baseline).
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
116
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 2.5:  Listing of Exploratory Echocardiogram
Treatment: Ambrisentan Low Dose
Centre 
ID/
Subject 
ID
Visit
Visit 
Date/
Study Day
Pericardial 
effusion/
Change from 
Baseline
Mean right 
atrial 
pressure 
(mmHg)/
Change from 
Baseline
Tricuspid 
annular plane 
systolic 
excursion (cm)/
Change from 
Baseline
Systolic 
Eccentricity 
Index/
Change from 
Baseline
Diastolic 
Eccentricity 
Index/
Change from 
Baseline
Tricuspid 
regurgitant 
jet (m/s)/
Change from 
Baseline
Right 
Ventricular 
Pressure 
(mmHg)/
Change from 
Baseline
XXXXXX/ 
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
Absent
XXX
XXX
XXX
XXX
XXX
XXX
XXXXXXX
DDMMMYYYY/
XX
Trace/
Worsened
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXXXXXX
DDMMMYYYY/
XX
Small/
Worsened
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXXXXXX
DDMMMYYYY/
XX
Trace/
Worsened
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
Etc..
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
117
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 2.6:  Listing of Cardiopulmonary Hemodynamics
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Visit
Right Heart 
Catheterization 
Date /
Study Day
Heart 
Rate(bpm)/
Change from 
Baseline
Mean Pulmonary
Arterial
Pressure (mmHg)/
Change from 
Baseline
Mean Right
Atrial
Pressure (mmHg)/
Change from 
Baseline
Pulmonary
Capillary Wedge
Pressure (mmHg)/
Change from 
Baseline
XXXXXX/ 
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXX
XXX
XXX
XXX
XXXXXXX
DDMMMYYYY/
XX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXXXXXX
DDMMMYYYY/
XX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXXXXXX
DDMMMYYYY/
XX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
Etc..
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
118
Protocol: AMB112529                                                                                                Page 2 of n
Population: Intent-to-Treat
Listing 2.6:  Listing of Cardiopulmonary Hemodynamics
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Visit
Right Heart 
Catheterization 
Date /
Study Day
Method used to 
Calculate 
Cardiac Output/
Oxygen 
Consumption
Cardiac Output 
(Litres/minute)/
Change from 
Baseline
Cardiac index 
(L/min/meters/
square)/
Change from 
Baseline
Pulmonary Vascular 
Resistance 
(mmHg/L/min)/
Change from 
Baseline
XXXXXX/ 
XXXXXX
XXXXXXX
DDMMMYYYY/
HH:MM/
XX
XXXXXXXXXXXX/
XXXXXXXXXXX
XXX
XXX
XXX
XXXXXXX
DDMMMYYYY/
HH:MM/
XX
XXXXXXXXXXXX/
XXXXXXXXXXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXXXXXX
DDMMMYYYY/
HH:MM/
XX
XXXXXXXXXXXX/
XXXXXXXXXXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXXXXXX
DDMMMYYYY/
HH:MM/
XX
XXXXXXXXXXXX/
XXXXXXXXXXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
Etc..
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
119
Protocol: AMB112529                                                                                                Page 3 of n
Population: Intent-to-Treat
Listing 2.6:  Listing of Cardiopulmonary Hemodynamics
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Visit
Right Heart 
Catheterization 
Date /
Study Day
Left Ventricle 
End Diastolic 
Pressure (mmHg)/
Change from 
Baseline
Arterial 
Oxygen 
Saturation 
Percentage/
Change from 
Baseline
Venous 
Oxygen 
Saturation/
Change from 
Baseline
Mean Arterial 
Pressure (mmHg)/
Change from 
Baseline
XXXXXX/ 
XXXXXX
XXXXXXX
DDMMMYYYY/
HH:MM/
XX
XXX
XXX
XXX
XXX
XXXXXXX
DDMMMYYYY/
HH:MM/
XX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXXXXXX
DDMMMYYYY/
HH:MM/
XX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXXXXXX
DDMMMYYYY/
HH:MM/
XX
XXX/
XXX
XXX/
XXX
XXX/
XXX
XXX/
XXX
Etc..
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
120
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 2.7:  Listing of School Days
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age(y)/
Sex/
Race
Visit
Visit Date /
Study Day
School Days 
Scheduled */
Change from 
Baseline
School Days 
missed/
Change from 
Baseline
School Days  
missed due 
to PAH/
Change from 
Baseline
Proportion of 
days missed 
(%)/
Change from 
Baseline
Proportion of 
days missed due 
to PAH (%)/
Change from 
Baseline
XXXXXX/
XXXXXX
XX/
Male/
XXXXXX
Baseline
DDMMMYYYY/
XX
XX
XX
XX
XX
XX
XXXXXXX
DDMMMYYYY/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XXXXXXX
DDMMMYYYY/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XXXXXXX
DDMMMYYYY/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
Etc..
Etc..
Note:  * In past month at Baseline; since baseline visit at Week 4; and since the patient’s last clinic visit (all other     
       assessments).
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
121
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Listing 2.8:  Listing of Subject Global Assessment (SF10 Health Survey for Children)
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Visit
Visit Date 
/
Study Day
1.Childs 
General 
Health
2a.Limited 
Riding and 
Skating
2b.Limited 
Bending
3.Physical 
Problems 
Limit 
Schoolwork
4.Emotional 
Problems 
Limit 
Schoolwork
5.Bodily pain
XXXXXX/
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
Etc..
Etc..
Note:  The Physical Summary Score (aggregate of item responses 1, 2a, 2b, 3 and 5) and Psychosocial Summary Score (aggregate         
      of item responses 4, 6, 7, 8 and 9) were calculated by QualityMetrics Health Outcomes software.  
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
122
Protocol: AMB112529                                                                                                Page 2 of n
Population: Intent-to-Treat
Listing 2.8:  Listing of Subject Global Assessment (SF10 Health Survey for Children)
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Visit
Visit Date 
/
Study Day
6.Satisfied with 
friendships
7.Satisfied with 
life overall
8.Time 
bothered or 
upset
9.General 
behaviour
Physical 
Health 
Summary/
Change 
from 
Baseline
Psychosocial 
Summary/
Change from 
Baseline
XXXXXX/
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XX/
XX
XX/
XX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XX/
XX
XX/
XX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XX/
XX
XX/
XX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XXXXXXXX
XX/
XX
XX/
XX
Etc..
Etc..
Note:  The Physical Summary Score (aggregate of item responses 1, 2a, 2b, 3 and 5) and Psychosocial Summary Score (aggregate         
       of item responses 4, 6, 7, 8 and 9) were calculated by QualityMetrics Health Outcomes software.  
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
123
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.1:  Listing of Exposure and Compliance to Investigational Product
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
IP
Start
Date
IP
Stop
Date
Duration
(Days)
% of
compliant 
visits
Visit
Visit Date/
Study Day
Compliance since 
the last visit
XXXXXX/ 
XXXXXX
DDMMMYYYY
DDMMMYYYY
XX
100
XXXXXXXXX
DDMMMYYYY/
XX
XXXXXXXXX
DDMMMYYYY/
XX
>=80% and <=120%
XXXXXXXXX
DDMMMYYYY/
XX
>=80% and <=120%
XXXXXXXXX
DDMMMYYYY/
XX
>=80% and <=120%
XXXXXXXXX
DDMMMYYYY/
XX
>=80% and <=120%
XXXXXXXXX
DDMMMYYYY/
XX
>=80% and <=120%
XXXXXXXXX
DDMMMYYYY/
XX
>=80% and <=120%
Etc..
Note:  Compliant visits are those at which subjects are >=80% and <=120% compliant.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
124
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.2:  Listing of All Adverse Events
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age (y)/
Sex/
Race/
Weight (kg)
Preferred Term/
Verbatim Text
Outcome/
Onset Date/
Resolution 
Date/
Frequency
Time Since 
First Dose/
Last Dose/
Duration (days)
Maximum 
Intensity/
Serious/ 
Withdrawal
Action 
Taken/
Relation to 
Study Drug
XXXXXX/ 
XXXXXX
XX/
XXXXXX/
XXXXXX/
XX
XXXXXXXXXXX/
XXXXXXXXXXX *
XXXXXXXXX/
DDMMMYYYY/
DDMMMYYYY/
XXXXXXXXX
XX/
XX/
XX
XXXX/
XXX/
XXX
XXXXXXXX/
XX
XXXXXXXXXXX/
XXXXXXXXXXX #
XXXXXXXXX/
DDMMMYYYY/
DDMMMYYYY/
XXXXXXXXX
XX/
XX/
XX
XXXX/
XXX/
XXX
XXXXXXXX/
XX
XXXXXX/
XXXXXX
XX/
XXXXXX/
XXXXXX/
XX
XXXXXXXXXXX/
XXXXXXXXXXX $
XXXXXXXXX/
DDMMMYYYY/
DDMMMYYYY/
XXXXXXXXX
XX/
XX/
XX
XXXX/
XXX/
XXX
XXXXXXXX/
XX
Etc..
Note:  * Prior, # Treatment-emergent, $ Post-treatment.
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID and 
Onset date.
PPD


CONFIDENTIAL
AMB112529
125
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.3:  Listing of Relationship between Adverse Event System Organ Class, Preferred Term and Verbatim Text
System Order Class
Preferred Term
Verbatim Text
Blood and lymphatic system 
disorder
Lymphadenopathy
Enlarged lymph node
Cardiac disorder
Palpitations
Heart palpitation
Tachycardia nos
Tachycardia
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Continue for all combinations.  Sort in order of SOC, PT, and verbatim text.
PPD


CONFIDENTIAL
AMB112529
126
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.4:  Listing of Subject Numbers for Specified Adverse Events
Treatment: Ambrisentan Low Dose
System Organ Class
  Preferred term
No. with 
Event
Centre ID/Subject ID
Gastrointestinal disorders
  Dyspepsia
  9
XXXXXX/XXXXXX, XXXXXX/XXXXXX,
XXXXXX/XXXXXX, XXXXXX/XXXXXX,
XXXXXX/XXXXXX, XXXXXX/XXXXXX,
XXXXXX/XXXXXX, XXXXXX/XXXXXX,
XXXXXX/XXXXXX, 
  Nausea
  1
XXXXXX/XXXXXX
  Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Present each treatment group. Sort by treatment group, SOC, PT. 
PPD


CONFIDENTIAL
AMB112529
127
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.8:  Listing of Haematology
Central Laboratory
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age(y)/
Sex/
Race/
Baseline
Weight(kg) Lab test (units)
Planned
Relative
Time
Date
Study
Day
Converted Data
Flag *
NR CC BL
Value
Normal Range
XXXXXX/ 
XXXXXX
XX/
<Parameter (units)>
Screening
DDMMMYYYY
XX    
XXX 
XXX – XXX 
XXXXXX/
Baseline
DDMMMYYYY
XX    
XXX 
XXX – XXX
XXXXXX/
Week 2
DDMMMYYYY
XX    
XXX 
XXX – XXX
H  H   H
XX
Week 4
DDMMMYYYY
XX    
XXX 
XXX – XXX
H      H  
Week 8
DDMMMYYYY
XX    
XXX 
XXX – XXX
Week 12
DDMMMYYYY
XX    
XXX 
XXX – XXX
Week 16
DDMMMYYYY
XX    
XXX 
XXX – XXX
Week 20
DDMMMYYYY
XX    
XXX
XXX – XXX
L  L   L
EW
DDMMMYYYY
XX    
XXX 
XXX – XXX
Follow-Up
DDMMMYYYY
XX    
XXX 
XXX - XXX
L
<Parameter (units)>
Etc..
Etc..
Note:  * NR for Normal Range flag, CC for Clinical Concern flag; BL for Change from Baseline 
       H=Above range, L=Below range
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. Continue for all parameters.
PPD


CONFIDENTIAL
AMB112529
128
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.9  Listing of Haematology Data for Subjects with Abnormalities of Potential Clinical Concern
Central Laboratory
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age(y)/
Sex/
Race/
Baseline
Weight(kg) Lab test (units)
Planned
Relative
Time
Date
Study
Day
Converted Data
Flag *
NR CC BL
Value
Normal 
Range
Low
Concern
High
Concern
XXXXXX/ 
XXXXXX
XX/
<Parameter (units)>
Screening
DDMMMYYYY
XX    XXX 
XXX – XXX 
XXX 
XXX 
XXXXXX/
Baseline
DDMMMYYYY
XX    XXX 
XXX – XXX
XXX 
XXX 
XXXXXX/
Week 2
DDMMMYYYY
XX    XXX 
XXX – XXX
XXX 
XXX 
H  H   H
XX
Week 4
DDMMMYYYY
XX    XXX 
XXX – XXX
XXX 
XXX 
H      H  
Week 8
DDMMMYYYY
XX    XXX 
XXX – XXX
XXX 
XXX 
Week 12
DDMMMYYYY
XX    XXX 
XXX – XXX
XXX 
XXX 
Week 16
DDMMMYYYY
XX    XXX
XXX – XXX
XXX 
XXX 
Week 20
DDMMMYYYY
XX    XXX
XXX – XXX
XXX
XXX
L  L   L
EW
DDMMMYYYY
XX    XXX 
XXX – XXX
XXX 
XXX 
Follow-Up
DDMMMYYYY
XX    XXX 
XXX - XXX
XXX 
XXX 
L
<Parameter (units)>
Etc..
Etc..
Note:  * NR for Normal Range flag, CC for Clinical Concern flag; BL for Change from Baseline 
       H=Above range, L=Below range
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
      High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. Continue for all parameters.
PPD


CONFIDENTIAL
AMB112529
129
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.13:  Listing of Liver Event Results and Time of Event Relative to Treatment
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age (y)/
Sex/
Race/
Event Date/
Study Day
Days from 
first dose to 
start of 
event
Days from 
last dose to 
start of 
event
Event that reached or exceeded protocol 
defined criteria
XXXXXX/
XXXXXX
XX/
DDMMMYYYY/
X
X
ALT (alanine aminotransferase)
XXXXXX/
XX
XXXXXX/
XX
Etc..
    
    
    
    
  
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
130
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.14:  Listing of patient specific information for liver events
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age 
(y)/
Sex/
Race/
Event that 
reached or 
exceeded 
protocol 
defined 
criteria
Event 
Date/
Study Day
Days 
from 
last 
dose 
to 
start 
of 
event Assessment
Result
XXXXXX/
XXXXXX
XX/
XXXXXXXXXXXXX DDMMMYYYY/ X
Subject become pregnant?
No
XXXXXX/
XX
Was a biopsy taken?
Yes
XXXXXX/
Any unconventional medications
No
XX
Fasting or significant dietary change
No
Is this event serious?
Yes
Evaluation interval
During the 
treatment period
Does the subject consume alcohol?
Yes
Average number of units of alcohol consumed per 
week
XX
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
131
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.15: Listing of Medical Conditions for Subjects with Liver Events on Treatment
Treatment
Centre 
ID/
Subject 
ID
Age (y)/
Sex/
Race/
Classification
Condition
Status
Ambrisentan 
Low Dose
XXXXXX/
XXXXXX
XX/
XXXXXXX/
XXXXXX
Hepatobiliary
HEPATITIS A
Current
Psychiatric
PARANOIA COMBINED WITH MANIA.
Past
XXXXXX/
XXXXXX
XX/
XXXXXXX/
XXXXXX
Eye
ASTIGMATISM
Current
Ambrisentan 
High Dose
XXXXXX/
XXXXXX
XX/
XXXXXXX/
XXXXXX
Metabolism and 
nutrition
RICKETS
Current


CONFIDENTIAL
AMB112529
132
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.16:  Listing of Liver Biopsy Details
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age 
(y)/
Sex/
Race/
Event that 
reached or 
exceeded 
protocol 
defined 
criteria
Biopsy 
Date/
Study Day
Biopsy 
Size
(mm)
Liver biopsy test
Liver biopsy result
XXXXXX/
XXXXXX
XX/
XXXXXXXXXXXXX DDMMMYYYY/ X
Bile ducts
Other: Bile ducts blocked
XXXXXX/
XX
Final diagnosis
Alcoholic hepatic cirrhosis
XXXXXX/
Description of liver 
cells/hepatocytes
Normal
XX
Liver cell/hepatocyte 
inclusion/vacuole
No inclusions
Hepatocyte/liver cell nuclear abnorm
None
Etc..
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID.
PPD


CONFIDENTIAL
AMB112529
133
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.17:  Listing of Liver Imaging Details
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age 
(y)/
Sex/
Race/
Event that 
reached or 
exceeded 
protocol 
defined 
criteria
Imaging 
Date/
Study Day
Liver 
imaging 
method
Are images 
technically 
adequate?
Liver imaging test
Liver imaging result
XXXXXX/
XXXXXX
XX/
XXXXXXXXXXXXX DDMMMYYYY/ X
XX
Liver Size
Hypertrophy (or 
enlarged)
XXXXXX/
XX
Liver Texture
Normal
XXXXXX/
Liver fatty infiltrate grade
Not applicable – No 
fatty infiltration
XX
Ascites present
None present
Focal hepatic lesions character
Not applicable – no 
hepatic lesions
Gallstones or gallbladder lesions
None
Biliary ductal lesions
None
Portal/Hepatic vein abnormalities
None
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group and Centre/Subject ID. Sort by treatment group, Centre ID, Subject ID. 
PPD


CONFIDENTIAL
AMB112529
134
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.18:  Listing of Vital Signs
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age(y)/
Sex/
Race
Visit
Visit 
Date/
Study Day
Systolic
Blood 
Pressure
(mmHg)/
Change 
from 
Baseline
Diastolic
Blood 
Pressure 
(mmHg)/
Change 
from 
Baseline
Heart
Rate
(bpm)/ 
Change 
from 
Baseline
Height
(units)/
Change 
from 
Baseline
Weight
(units)/
Change 
from 
Baseline
BMI
(units)/
Change 
from 
Baseline
BSA 
(units)/
Change 
from 
Baseline
XXXXXX/
XXXXXX
XX/
XXXXXX/
XXXXXXX
DDMMMYYYY/
XX
XX
XX
XX 
XX
XX
XX 
XX 
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XXXXXXX
DDMMMYYYY/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
XX/
XX
Etc..
Etc..
Note: H=Above clinical concern, L=Below clinical concern, 
      Change from Baseline HC=Above clinical concern, LC=Below clinical concern 
      Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
      High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
135
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.20:  Listing of Physical Examination
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age(y)/
Sex/
Race
Visit
Visit 
Date/
Study Day
Liver
Size
Jugular
Venous 
Pressure
Ascites
Peripheral 
Oedema
Saturated 
Oxygen
(units)
XXXXXX/
XXXXXX
XX/
XXXXXX/
XXXXXXX
DDMMMYYYY/
XX
XXXXXX
XXXXXXXX
XXXXXXX
XXXXXXX
XX.XXX
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXX
XXXXXXXX (I)
XXXXXXX
XXXXXXX
XX.XXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXX
XXXXXXXX
XXXXXXX (W)
XXXXXXX
XX.XXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXX
XXXXXXXX (U)
XXXXXXX
XXXXXXX
XX.XXX
Etc..
Note:  I=Improved, W=Worsened, U=Unchanged
       Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
136
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.21:  Listing of 12-Lead ECG Findings
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age(y)/
Sex/
Race
Visit
Visit Date/
Study Day
Result
XXXXXX/
XXXXXX
XX/
XXXXXX/
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXXXXXXX
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXXXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXXXXXXX
Etc..
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
137
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.22:  Listing of Endocrinology Assessments
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age(y)/
Sex/
Race
Visit
Endocrinology 
Assessment 
Date/
Study Day
Assessment Type
Assessment 
Result
XXXXXX/
XXXXXX
XX/
Male/
XXXXXXX
DDMMMYYYY/
XX
Testicular volume
Right/Left (units)
XXX / XXX
XXXXXX
Male genital 
development 
XXXXXXXXXX
XXX
Male pubic hair 
development 
XXXXXXXXXX
XXX
XXXXXXX
DDMMMYYYY/
XX
Testicular volume 
Right/Left (units)
XXX / XXX
Male genital 
development 
XXXXXXXXXX
XXX
Male pubic hair 
development 
XXXXXXXXXX
XXX
Etc..
XXXXXX/
XXXXXX
XX/
Female/
XXXXXXX
DDMMMYYYY/
XX
Female breast 
development
XXXXXXXXXX
XXX
XXXXXX
Female pubic hair 
development
XXXXXXXXXX
XXX
Etc..
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
138
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Listing 3.23:  Listing of Pregnancy Results
Treatment: Ambrisentan Low Dose
Centre ID/
Subject ID
Age(y)/
Race
Visit
Visit Date/
Study Day
Result
Subject became 
pregnant?
XXXXXX/
XXXXXX
XX/
XXXXXX/
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXXXXXXX
No
XXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXXXXXXX
XXXXXXX
DDMMMYYYY/
XX
XXXXXXXXXXXXX
Etc..
Etc..
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
 
Programming notes: Present each treatment group, Centre/Subject ID and time-point. Sort by treatment group, Centre ID, Subject 
ID and time-point. 
PPD


CONFIDENTIAL
AMB112529
139
Protocol: AMB112529                                                                                                Page 1 of n
Population: Intent-to-Treat
Figure 1.1:  Summary of Subject Accrual
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Change Labels: X -> Ambrisentan Low Dose, Y -> Ambrisentan High Dose.
PPD


CONFIDENTIAL
AMB112529
140
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Figure 3.1:  Kaplan-Meier Survival Curves with 95% Confidence Bands of Time to First Treatment-Emergent Adverse Event
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Change Labels: Drug A -> Ambrisentan Low Dose, Drug B -> Ambrisentan High Dose. Also present combined group. Annotate to display number of events in each 
group also.
PPD


CONFIDENTIAL
AMB112529
141
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Figure 3.3:  Bar Chart of Treatment-Emergent Adverse Events Occurring in Two or More Subjects in any Treatment Group
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Change Labels: DrugA -> Ambrisentan Low Dose, DrugB -> Ambrisentan High Dose.  Also present combined group. 
Continue for each preferred term.
PPD


CONFIDENTIAL
AMB112529
142
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
         
Figure 3.4: Box plots of Haematology Data by Week (Selected Parameters)
Parameter = <Parameter (units)>
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Change Labels: Drug A -> Ambrisentan Low Dose, Drug B -> Ambrisentan High Dose.  Also present combined group. Label vertical axes with parameter name and 
units. Label horizontal axis with appropriate week structure. Repeat for each parameter. Haematology parameters (haemoglobin, hematocrit, platelets), Chemistry parameters (Total 
bilirubin, AST, ALT, GGT, Creatinine). Use log scale for Plasma NT-Pro BNP (Figure 2.6 and Figure 2.7).
PPD


CONFIDENTIAL
AMB112529
143
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Figure 3.8:  Patient Profiles of Liver Function Tests
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Change Labels: Drug A -> Ambrisentan Low Dose, Drug B -> Ambrisentan High Dose. Also present combined 
group. Present parameters ALT, AST, Alk. Phos, Total Bilirubin. Present one patient per page only, not grid of 4 patients.
PPD
PPD
PPD
PPD
PPD


CONFIDENTIAL
AMB112529
144
Protocol: AMB112529                                                                                                Page 1 of n
Population: Safety
Figure 3.11:  Line plots of Endocrinology Assessments by Subject
Note:  Low dose, 2.5 mg (body weight >=20 kg and <35 kg);  5 mg (>= 35 kg).
       High dose, 5 mg (body weight >=20 kg and <35 kg); 7.5 mg (>=35 kg and <50 kg); 10 mg (>= 50 kg).
Programming notes: Only one patient on a page, with a grid of plots on each page for each parameter. For Figure 3.11, plot 
female breast development and pubic hair development; male testicular volume, genital development and pubic hair development 
and change from baseline in male testicular volume (left and right separately). For Figure 2.8 (Japanese subset) plot 
echocardiogram parameters. For coded data, plot the numeric code and present codes on first page of the plot.
P
PP
PP
P
PPD


CONFIDENTIAL
AMB112529
145
19.
APPENDICES
19.1. Appendix 1 – IDSL Age Calculation
IDSL standard/GSK standard of the derivation of AGE:
AGE = intck(‘year’,DEMO.BIRTHDT, AGEREFDT) –
            (month(AGEREFDT) < month(DEMO.BIRTHDT) or       
               (month(AGEREFDT)=month(DEMO.BIRTHDT) and 
                    day(AGEREFDT) <  day(DEMO.BIRTHDT)
               ));
For this study, it was decided that the AGE is calculated based on the date of the baseline visit ie.
AGEREFDT = Date of record with VISITNUM=20 in the VISIT dataset.
BIRTHDT = derived by DM in DEMO dataset which contains imputed date for
date of birth (ie. 30JUNYYYY) .